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ZUSAMMENFASSUNG 
Die idiopatische pulmonale Fibrose (IPF) ist eine schwerwiegende, chronische interstitielle 
Lungenerkrankung (ILD). IPF ist gekennzeichnet durch eine progressive Äthiopathologie, einer 
Beeinträchtigung und Hyperplasie des Epithels sowie, einer extensiven Anlagerung von extra-
zellulärer Matrix (ECM) im Lungeninterstitium. Diese pathologischen Prozesse, die primär von 
einem anomalen Umbau des Gewebes gesteuert werden, resultieren in einem beeinträchtigten 
Gasaustausch, der zum Tod führt. Der dynamische Prozess des Gewebeumbaus ist auf einen 
aktiven und wandlungsfähigen Fibroblastenphänotyp angewiesen. Dieser Fibroblastenphänotyp 
besitzt eine besonders ausgeprägte Fähigkeit, in stromales Gewebe einzuwandern. Die Zielsetzung 
der vorliegenden Studie umfasste die umfangreiche Charakterisierung dieses aktivierten, invasiven 
Fibroblastenphänotyps und die Identifizierung zugrundeliegender potenzieller Regulatoren. 
Hierfür wurden zunächst kollagenbasierte, phänotypische Assays der dreidimensionalen (3D) 
Fibroblasteninvasion entwickelt (Burgstaller, Oehrle et al., 2013). Unter Verwendung dieser 
neuartigen Assays wurde der invasive Fibroblastenphänotyp auf morphologischer und molekularer 
Ebene charakterisiert. Für mesenchymale Zellen, die physiologisch in der 3D Struktur der Lunge 
angesiedelt sind, sind adaptive und reziproke Interaktionen zwischen Zellen und der sie 
umgebenden ECM weithin anerkannt und spiegeln sich in der Zellmorphologie wider. Demgemäß 
wurde ein signifikanter Unterschied der zellulären Morphologie zwischen Fibroblasten, die in 2D 
und 3D Zellkultursystemen kultiviert wurden, identifiziert. Um den invasiven 
Fibroblastenphänotyp auf molekularer Ebene zu charakterisieren, wurden transkriptom-weite 
Signaturen der Fibroblasteninvasion generiert (microarrays) unter der Verwendung einer murinen 
Fibroblastenzelllinie (MLg) (Oehrle, Burgstaller et al. 2015 – in press). Die resultierenden Gen-
expressionsprofile der invasiven und nicht-invasiven Fibroblasten setzen sich deutlich voneinander 
ab: 1049 Gene waren unterschiedlich reguliert (>1,5-fach). Eine in silico Analyse der 
Transkriptomsignatur der Invasion deckte eine Anreicherung der funktionalen Cluster „invasion of 
cells“, „IPF“ und „metastasis“ auf. Anschließend wurden die Invasionsassays mit dem profibro-
tischen Zytokin transforming growth factor (TGF) β1 implementiert, was das Invasionsvermögen 
der MLg Zellen erhöhte. Daraufhin, wurde eine Transkriptionsanalyse der TGFβ1-induzierten 
Fibroblasteninvasion durchgeführt. In der sich überschneidenden Signatur der nicht induzierten 
und TGFβ1-induzierten Invasion wurde der Inhibitor der Wingless/Integrase-1 (Wnt) Signalwege, 
secreted frizzled-related protein (Sfrp) 1, als negativer Regulator für Fibroblasteninvasion 
identifiziert. Stimulierung mit TGFβ1 erniedrigte signifikant die Expression von Sfrp1 und die 
spezifische Inhibierung von Sfrp1 durch ein Diarylsulfon-Sulfonamid Derivat erhöhte die 3D 
Invasion ohne die 2D Motilität zu beeinflussen. Primäre humane Fibroblasten (phF) von ILD 
Patienten exprimierten geringe Sfrp1 Spiegel, was invers mit deren Invasionskapazität korrelierte. 
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SUMMARY 
Idiopathic pulmonary fibrosis (IPF) is a severe, chronic interstitial lung disease (ILD). IPF is 
characterized by a progressive ethiopathology, damage and hyperplasia of the epithelium as well 
as extensive deposition of extracellular matrix (ECM) within the lung interstitium. These 
pathological processes, which are primarily driven by aberrant tissue remodeling, ultimately result 
in impaired gas exchange and death by asphyxiation. The dynamic process of tissue remodeling 
depends on an activated, versatile fibroblast phenotype. This fibroblast phenotype exhibits an 
exceptional and distinct capacity to invade stromal tissue.  
The objective of the current study was to comprehensively characterize this activated, invasive 
fibroblast phenotype and to identify potential underlying regulators. For this purpose, three 
dimensional (3D) collagen-based phenotypic assays of fibroblast invasion were established 
(published in Burgstaller, Oehrle et al., 2013). Using these novel assays, the invading fibroblast 
phenotype was characterized on morphological and molecular levels. For mesenchymal cells, 
physiologically residing in the 3D structure of the lung interstitium, adaptive and reciprocal 
interactions between cells and surrounding ECM are well recognized and are reflected in the cell 
morphology. Accordingly, significant differences of cellular morphology between fibroblasts 
cultured in 2D and 3D cell culture systems were identified. To characterize the invading fibroblast 
phenotype on molecular level, transcriptome-wide signatures of fibroblast invasion were generated 
(microarrays) using a murine lung fibroblast cell line (MLg) (Oehrle, Burgstaller et al. 2015 – in 
press). The resulting gene expression profiles of invading and non-invading fibroblasts were 
highly distinct: 1049 genes were differentially regulated (>1.5-fold). In silico analysis of this 
invasion transcriptome signature revealed a significant enrichment for the functional clusters 
“invasion of cells”, “IPF”, and “metastasis”. Subsequently, the invasion assays were implemented 
with the profibrotic cytokine, transforming growth factor (TGF) β1, which increased the invasion 
capacity of MLg cells. Transcriptome analysis of the TGFβ1-induced fibroblast invasion was then 
performed. Within overlapping signatures of baseline and TGFβ1-induced invasion, the 
Wingless/Integrase-1 (Wnt) signaling pathway inhibitor, secreted frizzled-related protein (Sfrp) 1, 
was identified as a negative regulator of fibroblast invasion. Sfrp1 expression was significantly 
lowered upon TGFβ1 stimulation and specific chemical inhibition of Sfrp1 by a diarylsulfone 
sulfonamide derivate increased 3D invasion, without affecting 2D motility. Furthermore, primary 
human lung fibroblasts derived from ILD patients expressed low Sfrp1 levels, which inversely 
correlated with the invasion capacity. 
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1. INTRODUCTION 
1.1 Interstitial lung disease (ILD) 
Interstitial lung disease (ILD) or diffuse parenchymal lung disease (DPLD) designates a group of 
lung pathologies that affects the epithelium, endothelium, the basal membrane as well as the 
perivascular and perilymphatic tissues of the lung. ILD is associated with high morbidity and 
mortality rates (Antoniou, Margaritopoulos et al. 2014). The term ILD comprises more than 150 
different subgroups of the same clinical, pathological, physiological, and radiological 
manifestations but varying underlying etiologies and molecular pathophysiologies (Eickelberg and 
Selman 2010). ILDs can be subclassified according to their causes, which include inhaled 
substances (inorganic or organic), drug induced, radiation exposure, connective tissue diseases, 
infections, or idiopathic.   
 
1.2 Idiopathic pulmonary fibrosis (IPF) 
Idiopathic pulmonary fibrosis (IPF) shows, with a median survival of three years, the highest 
mortality among the ILDs (Antoniou, Margaritopoulos et al. 2014). The prevalence of IPF is 
estimated to be 14 - 63 cases per 100,000 in the United States and 1.25 - 23.4 cases per 100,000 in 
Europe, depending on the case definition used (Nalysnyk, Cid-Ruzafa et al. 2012). The prevalence 
rises dramatically with age, as evidenced in the United States, where 0.2% of the population older 
than 75 years is already affected (Wolters, Collard et al. 2014). Men are more frequently affected 
than women and a correlation with patients’ smoking history has been reported. IPF is 
characterized by a progressive ethiopathology, damage, and hyperplasia of the alveolar epithelium, 
extensive deposition of extracellular matrix (ECM), especially collagens, within the lung 
interstitium, and enhanced fibroblast proliferation and activation, which causes the formation of 
fibroblastic foci (Selman, King et al. 2001). These processes lead to disruption of the lung 
architecture, impairment of gas exchange and ultimately death by asphyxiation. IPF clinically 
presents with dry cough, unexplained chronic exertional dyspnea, bibasilar inspiratory crackles, 
and finger clubbing (Raghu, Collard et al. 2011). The clinical course is often influenced by the 
occurrence of acute episodes of respiratory worsening. These acute exacerbations may be initiated 
by viral infection (Wootton, Kim et al. 2011), air pollution (Johannson, Vittinghoff et al. 2014), or 
microaspiration (Lee, Song et al. 2012) and are associated with a high mortality risk.  
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 Diagnosis and treatment strategies of IPF 1.2.1
Referring to the official revised diagnosis guideline of the American Thoracic Society, European 
Respiratory Society, Japanese Respiratory Society and Latin American Thoracic Association, 
diagnosis of IPF without surgical biopsy is accomplished following the major and minor diagnosis 
criteria listed in Table 1.1. Importantly, IPF can only be diagnosed by excluding other causes of 
ILD.  
 
Table 1.1: Diagnosis of IPF in absence of surgical lung biopsy (2000). (Wells 2013) – modified. 
Major diagnosis criteria 
- Exclusion of known causes of ILD (environmental exposure, 
connective tissue diseases and drug toxicities) 
- Evidence of restriction and impaired gas exchange by 
pulmonary function studies 
- HRCT scans show bibasilar reticular abnormalities with 
minimal ground glass opacities 
- BAL and transbronchial lung biopsy do not support 
alternative diagnosis 
 
Minor diagnosis criteria 
- Age > 50 years 
- Insidious onset of otherwise unexplained dyspnea on exertion  
- Duration of illness > 3 months 
Abbreviations: High-resolution computer tomography (HRCT), Bronchoalveolar lavage (BAL) 
 
Despite intense research efforts over the past decades no effective pharmaceutical therapy has 
been discovered to date. Solely Pirfenidone has been approved for the treatment of IPF in Japan in 
2008 and in Europe in 2011 although phase III clinical trials are still ongoing (Potts and 
Yogaratnam 2013). Most recently, efficacy in a phase III clinical trial has been reported for the 
multiple tyrosine kinase inhibitor Nintedanib (formerly known as BIBF 1120) (Richeldi, du Bois et 
al. 2014).  
Ineffective treatment strategies to date are anti-inflammatory immunomodulators (Corticosteroid 
monotherapy, Cyclophosphamide, Azathioprine, Everolimus), anticoagulants (Warfarin, Heparin), 
endothelin receptor antagonists and vasodilators (Bosentan, Ambisentan, Macicentan, Sildenafil), 
and antifibrotics and cytokine/kinase-inhibitors (INFγ1b, Eternacept, Imatinib, CC-930). Further 
treatment strategies currently in phase III clinical trials are summarized in Table 1.2.  
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Nevertheless, to date, the only intervention for IPF that improves survival is lung 
transplantation (Rafii, Juarez et al. 2013).  
 
Table 1.2: Selected ongoing clinical trials for IPF (Rafii, Juarez et al. 2013) – modified. 
Agent/treatment Potential mechanism Clinical trial 
Pirfenidone 
Inhibitor of TGFβ, anti-
inflammatory, antioxidant 
ASCEND (Intermune), USA 
Nintedanib 
Multiple tyrosine kinase 
inhibitor 
INPULSIS 1-2 (Boehringer Ingelheim 
Pharmaceuticals), UK 
GC1008 Anti-TGFβ1-3 antibody 
Genzyme and Cambridge Antibody Technology, 
UK 
STX-100 Anti-αvβ6 integrin Stromedix, USA 
FG-3019 CTGF inhibitor Fibrogen, USA 
Octreotide Somatostatin analogue 
Institut National de la Santé Et de la Recherche 
Médicale, France 
CNTO 888 Anti CCL2 antibody Centocor, USA 
QAX576, 
Tralokinumab 
Anti-IL-13 antibody Novartis, Switzerland, MedImmune LLC 
SAR156597 
Bispecific Anti-IL-13 and 
IL-4 antibody 
Sanofi-Aventis 
Thalidomide 
Inhibitor of TGFβ1 
signaling and VEGF 
expression 
John Hopkins University, USA 
GS-6624 Anti-LOXL2 antibody Gilead Sciences 
BIBF1120 
Angiokinase inhibitor 
targeting FGFR, PDGFR, 
VEGFR 
TOMORROW (Boehringer Ingelheim 
Pharmaceuticals), UK 
Minocycline 
Tetracycline with anti-
inflammatory and anti-
angiogenic properties 
University of California, USA 
Tetrathiomolybdate Antiangiogenic University of Michigan, USA 
Doxycycline MMP inhibitor Indian Institute of Chemical Biology, India 
Losartan Angiotensin II inhibitor National Cancer Institute, USA 
Carbon Monoxide 
Anti-proliferative diatomic 
gas, inhibitor of fibroblast 
ECM deposition 
Brigham and Women’s hospital, USA 
Mesenchymal stem 
cells 
Potential alveolar re-
epithelialization 
The Prince Charles Hospital, Australia 
Abbreviations: Transforming growth factor (TGF), Connective tissue growth factor (CTGF), Chemokine (CC-motif) 
ligand (CCL), Interleukin (IL), Vascular endothelial growth factor (VEGF), Lysyl oxidase-like (LOXL), Fibroblast 
growth factor receptor (FGFR), Platelet-derived growth factor receptor (PDGFR), Matrix Metallo-proteinase (MMP).  
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 Pathologic features of IPF 1.2.2
According to the guidelines, described in Table 1.1, HRCT is an essential tool for the diagnosis of 
IPF. By means of HRCT scans the histopathological feature of IPF can be identified, which is 
termed usual interstitial pneumonia (UIP). UIP is characterized by a spatial and temporal 
heterogeneity where the lung injury pattern in the periphery is highly different from that of the 
center of the pulmonary lobule. The subpleural/paraseptal regions are affected by scarring and 
microscopic honeycombing and intersect abruptly with normal lung tissue. Honeycombs are large 
airspaces lined by bronchiolar epithelium and filled with mucous and inflammatory cells, such as 
neutrophils and macrophages (Cavazza, Rossi et al. 2010). Other characteristic HRCT features of 
UIP are ground glass and reticular opacity. 
Hallmarks of UIP are so called fibroblastic foci which are small interstitial associations of 
myofibroblasts, covered by hyperplastic alveolar epithelial cells or bronchiolar cells. 
Histopathologically, these fibrotic lesions are primarily detected by their expression of alpha 
smooth muscle actin (αSMA) (Figure 1.1). Fibroblastic foci mainly occur at the interface of 
fibrotic and less affected regions. These sites represent manifestations of proliferating spindle-
shaped fibroblasts that frequently arrange parallel to the alveolar surface. Numbers of fibrotic 
lesions predict disease progression, as more fibroblastic foci are found in lungs of patients with a 
rapidly progressive form of IPF (King, Schwarz et al. 2001).  
 
 
Figure 1.1: Histopathological appearance of UIP. 
Immunohistochemical staining for alpha smooth muscle actin (αSMA) of tissue sections from a normal donor lung (left 
panel) and a lung with usual interstitial pneumonia (UIP) pattern (right panel). αSMA-staining (brown) is indicated with 
black solid arrows. While in donor specimens exclusively smooth muscle cells are stained, in UIP fibroblast foci show 
and intense signal for αSMA (solid arrow). Extensive interstitial collagen deposition in UIP is indicated with a (double-
line headed arrow). (Eickelberg and Laurent 2010) – modified. (Reprinted with permission of the American Thoracic 
Society. Copyright © 2014 American Thoracic Society).  
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 IPF pathogenesis 1.2.3
Initially, IPF was considered a disease that resulted from excessive chronic inflammation that 
induces lung injury and thus fibrosis. However, failure of anti-inflammatory therapeutic 
approaches (compare section 1.2) led to a paradigm shift to consider IPF more and more as a 
disease driven by excessive wound healing processes (Gross and Hunninghake 2001). Currently, 
epithelial cells as well as the mesenchyme are considered key components in IPF.  
The pathobiology of IPF can be divided into predisposition, initiation and progression stages 
(Wolters, Collard et al. 2014).  
The predisposition stage is mainly manifested by epithelial cell dysfunction. Familial 
clustering of pulmonary fibrosis suggests the existence of a genetic predisposition. Consequently, 
several mutations have been identified in patients suffering from pulmonary fibrosis. The major 
alteration identified in 2011 in a large genome-wide associated study is the SNP rs35705950, 
which is located 3 kb upstream of the mucin 5B (MUC5B) gene on chromosome 11. This SNP 
occurred in 34% of patients with IPF and induced 37.4 times higher MUC5B expression in IPF 
compared to healthy lungs. However, the molecular consequences of increased MUC5B 
expression remain to be discovered. The second most frequent genetic mutation affects the age-
related genes, telomerase reverse transcriptase (TERT) and telomerase RNA component (TERC). 
TERT and TERC mutations are associated with shortened telomere lengths; a phenomenon that 
has been reported in IPF (Liu, Ullenbruch et al. 2013). The third most prominent group of 
mutations affects the surfactant protein family. A heterozygous mutation (SPC∆exon4) in surfactant 
protein C encoding gene (SFTPC) was identified (Nogee, Dunbar et al. 2001). Other mutations in 
SFTPC affect the BRICHOS domain, which is involved in post-translational processing and has a 
chaperone-like function (Thomas, Lane et al. 2002), (Knight, Presto et al. 2013). In addition, 
mutations in surfactant protein A2 encoding gene (SFTPA2) were detected (Wang, Kuan et al. 
2009). Both mutations induce endoplasmatic reticulum (ER) stress in the lung epithelium. Another 
aspect for the predispositional stage of IPF arose from the fact that the genetic mutations described 
did not directly induce fibrosis in animal models (Lawson, Cheng et al. 2011). (Lee, Reddy et al. 
2009), (Rudolph, Chang et al. 1999). One explanation for this may be the requirement for an 
additional stressor. Besides aging, environmental exposures to dust, pollution and smoke may 
particularly act on a genetically predisposed epithelium (Sueblinvong, Neujahr et al. 2012).  
The prevailing theory of fibrogenesis in IPF suggests that recurring, non-resolving microinjury 
of the alveolar epithelium is the main initiation factor. Epithelial cell dysfunction, caused by ER 
stress that activates the unfolded protein response (Lawson, Cheng et al. 2011), disruption of 
basement membrane, excessive activation of signaling pathways and release of fibrogenic 
mediators induce fibrocyte recruitment (Andersson-Sjoland, de Alba et al. 2008) and plasticity of 
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numerous other cell types. Ultimately, activated fibroblasts infiltrate the lung interstitium to form 
fibroblastic foci and excessively secret ECM components. Together with an aberrant re-
epithelialization, these tissue remodeling processes accumulate in the distorted lung architecture 
and impaired lung function (du Bois 2010), (King, Pardo et al. 2011), observed in IPF.   
Once initiated, IPF progresses unrelentingly. Although the detailed mechanism behind the 
progressive character of the disease is not yet uncovered, it is speculated that the pathologically 
remodeled ECM (Booth, Hadley et al. 2012) and excessive fibroblast proliferation (Nho, Hergert 
et al. 2011) significantly contribute to the disease progression. Furthermore, epigenetic changes 
such as the DNA methylation pattern (Rabinovich, Kapetanaki et al. 2012), (Sanders, 
Ambalavanan et al. 2012) and micro RNA expression changes (Pandit, Milosevic et al. 2011) are 
hypothesized to contribute to IPF progression (Wolters, Collard et al. 2014).  
 
 Molecular mechanisms of IPF 1.2.4
To date, numerous profibrotic mediators have been identified that contribute to fibrogenic changes 
by promoting fibroblast activation, invasion, differentiation and collagen production (Laurent, 
McAnulty et al. 2008). Among the manifold sources for the cytokines that have been reported, the 
epithelium presents one essential secretor for paracrine factors, acting on the mesenchyme. In the 
lung, epithelial and mesenchymal cells reside in close spatial proximity. Moreover in terms of IPF, 
fibroblastic foci are covered by hyperplastic alveolar epithelial cells (compare section 1.2.3). 
Given that fibrotic processes within the lung are believed to be initiated at the epithelium but 
ultimately result in extensive mesenchymal malfunction, it appears likely that there occurs signal 
transduction between both compartments. In addition to epithelial cells, macrophages, 
lymphocytes, smooth muscle cells and endothelial cells have been reported among others as 
potential sources of cytokines in IPF (Laurent, McAnulty et al. 2008). 
Considering the enormous number of cell types postulated to be involved in IPF pathogenesis, 
unsurprisingly the network of the suggested underlying molecular mechanism is very complex. In 
order to identify the most interesting profibrotic mediators, Coker and Laurent proposed a list of 
criteria according to which profibrotic mediators must be present in the diseased lung, show 
profibrotic potential in vitro, and their inhibition should ameliorate fibrosis in animal models 
(Laurent, McAnulty et al. 2008). Mediators that fulfill these criteria comprise the proinflammatory 
cytokines TNFα, interleukin (IL)-1β and -13 (IL-13), the vasoconstrictors endothelin 1 (ET-1), and 
angiotensin II, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF)-1 and 
TGFβ (Laurent, McAnulty et al. 2008). Inhibitors thereof have been tested or currently entered 
clinical trials (compare Table 1.2). 
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One pleiotropic fibrogenic cytokine, widely accepted as the key regulator of fibrosis, is TGFβ1 
(Fernandez and Eickelberg 2012a). Besides its role in fibrogenesis, TGFβ signaling involvement 
has been revealed in embryogenesis (Wu and Hill 2009), tissue homeostasis (Massague 2012), 
immunity (Li, Wan et al. 2006), and cancerogenesis (Massague 2008). In humans, the TGFβ-
superfamily comprises over 30 members that all signal through receptor serine/threonine kinases, 
including three TGFβ isoforms: TGFβ1, 2 and 3 (Massague 2012), (Fernandez and Eickelberg 
2012a). Among these isoforms, TGFβ1 is most highly associated with IPF pathogenesis (Xaubet, 
Marin-Arguedas et al. 2003). A latent form of TGFβ is secreted and subsequently stored in the 
ECM. Activation is accomplished proteolytically by Matrix Metallo-proteinase (MMP) 2 and 9, by 
thrombospondin-1, reactive oxygen species (ROS), or under acidic conditions. Interestingly, tissue 
stiffness was reported as potential TGFβ1 activator in myofibroblasts via integrin-mediated 
contraction (Wipff, Rifkin et al. 2007, Hinz 2009). During canonical TGFβ1 signal transduction 
(Smad dependent), active TGFβ1 binds to a heterotetrameric receptor complex consisting of one 
TGFβ receptor (TGFβR) I and TGFβRII homodimer, respectively. Formation of this active 
complex results in phosphorylation of TGFβRI and TGFβRII which in turn induces 
phosphorylation of the effector proteins Smad2 and 3. Both Smads subsequently bind to the 
coregulator Smad 4 and translocate to the nucleus where they induce target gene expression. 
Activity of the receptor regulated Smads (R-Smad) 2 and 3, is controlled by inhibitory Smads (I-
Smad) e.g. Smad7 (Zi, Chapnick et al. 2012). 
Expression of TGFβ ligand or receptors is highly induced in fibrotic tissue of both, 
experimental fibrosis models (Cabrera, Selman et al. 2013) as well as pulmonary fibrosis patients 
(Coker, Laurent et al. 2001). Importantly, blocking TGFβ1 signaling (Bonniaud, Margetts et al. 
2005) and epithelium-specific deletion of TGFβRII (Li, Krishnaveni et al. 2011) protect against 
pulmonary fibrosis in rodent models. On the other hand, overexpression of TGFβ1 causes 
persistent fibrosis (Sime, Xing et al. 1997). TGFβ acts on the epithelium as well as mesenchyme. 
Specifically, TGFβ1 induces apoptosis (Siegel and Massague 2003) and EMT (Willis and Borok 
2007), (Willis, Liebler et al. 2005), (Kim, Kugler et al. 2006) in the epithelium. In fibroblasts, 
TGFβ1 induces activation, invasion, proliferation (Clark, McCoy et al. 1997), (Leask and 
Abraham 2004), and ECM production (Cutroneo, White et al. 2007). TGFβ1 is further integrated 
in interconnected networks with different signaling pathways. For instance, TGFβ1 induces 
expression and secretion of proinflammatory (TNFα, IL-1β, IL-13) and profibrotic cytokines 
(PDGF) which further intensifies fibrotic changes in the lung. Further significant insights into 
potential IPF causing signaling networks emerged from a system biology approach on IPF lung 
samples. This study revealed the reactivation of developmental signaling pathways within the 
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diseased lung, including in addition to TGFβ1, Sonic Hedgehog, Notch and Wingless/integrase-1 
(Wnt) (Studer and Kaminski 2007), (Selman, Pardo et al. 2008).  
Besides profibrotic mediators, protective factors have been identified, with prostaglandin E2 
(PGE2) being the most eminent one. PGE2 was shown to inhibit fibroblast proliferation and ECM 
synthesis. Stimulation of fibroblasts derived from lung fibrosis patients with profibrotic mediators 
resulted in a reduced expression of PGE2 and attributed to a defect in cyclooxygenase (COX) 
mediated arachidonic acid metabolism (Wilborn, Crofford et al. 1995).  
 
1.3 Lung fibroblast biology 
Fibroblasts represent a group of ubiquitous mesenchymal cells that reside in the stroma of 
numerous tissues. Regarding the adult lung, they are present in the adventitia of vascular structures 
and airways. Fibroblasts are the main ECM-producing cells, fulfilling the function of maintaining 
structural tissue integrity (Hinz, Phan et al. 2012). Thus, they are key players in wound healing 
processes (Pechkovsky, Hackett et al. 2010). Unlike other cell types in the lung, no specific marker 
for fibroblasts has been identified thus far. Therefore, fibroblasts are mainly identified by means of 
their characteristic spindle-shaped morphology. The absence of a pertinent fibroblast marker may 
indicate that fibroblasts are not a distinct homogenous cell population but rather a heterogeneous 
conglomerate of diverse subpopulations (Phan 2008). Identification of phenotypic and functional 
features of these fibroblast subpopulations is currently central in fibroblast research. 
 
 Activated fibroblasts in IPF 1.3.1
The major characteristics of IPF pathology are an aberrant accumulation of fibroblasts, the 
formation of fibroblastic foci in the lung interstitium, and an extensive deposition of ECM. 
Therefore, although alveolar epithelial damage is recognized as the pivotal initiative factor of IPF, 
the majority of pathological changes are ascribed to activated fibroblasts. 
The extensive accumulation of fibroblasts results primarily from increased fibroblast 
proliferation and an acquired resistance to apoptosis. Experimentally, fibroblasts derived from IPF 
lungs show a higher proliferative capacity when cultured on polymerized collagen (Nho, Hergert et 
al. 2011) and resistance to apoptosis when exposed to FAS ligand (Maher, Evans et al. 2010). 
Furthermore, numerous studies provide evidence that activated fibroblasts, or myofibroblasts, 
emerge from different cell types via cellular transition. Hence, various pathological changes, 
including profibrotic cytokines, in particular TGFβ1, may initiate the differentiation of resident 
fibroblasts into activated fibroblasts. Thus, resident fibroblasts represent one major source for 
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activated fibroblasts in IPF (Zhang, Rekhter et al. 1994), (Hung, Linn et al. 2013). Furthermore, 
through the processes of epithelial-mesenchymal transition (EMT) and endothelial-mesenchymal 
transition (EndoMT), type I and type II alveolar epithelial cells (AT I and ATII) and endothelial 
cells loose cell-cell contacts and cell polarity while increasingly expressing mesenchymal markers 
such as fibronectin, αSMA and vimentin (Kalluri and Neilson 2003), (Montorfano, Becerra et al. 
2014). Although extensively studied, doubts about the contribution of EMT to IPF pathology 
recently emerged in the scientific society (reviewed in (Kage and Borok 2012)). While Marmai 
and colleagues provided evidence for in vivo EMT processes in IPF (Marmai, Sutherland et al. 
2011), current lineage tracing studies disputed this observation (Rock, Barkauskas et al. 2011). 
Besides resident fibroblasts, epithelial and endothelial cells, several further cell types were 
reported as potential sources for activated fibroblasts or myofibroblasts in IPF. Thus, infiltrating 
fibrocytes in the fibrotic lung were speculated as one origin for activated fibroblasts (Andersson-
Sjoland, de Alba et al. 2008). In addition, recent studies added pericytes (Patel, West-Mays et al. 
2010), and pleural mesothelial cells (PMC) as pivotal progenitors of activated fibroblasts 
(Mubarak, Montes-Worboys et al. 2012). Accordingly, Hung et al. could show that pericytes, 
which are cells of mesenchymal origin that adhere to blood vessels, feature as precursor of 
activated fibroblast in pulmonary fibrosis (Hung, Linn et al. 2013). PMCs are a dynamic cell type 
that covers the lung as monolayer structure in close proximity to the lung parenchyma (Nasreen, 
Mohammed et al. 2009). Recently, Zolak et al. could proof in vivo a TGFβ1-induced transition of 
PMCs to activated fibroblasts while trafficking into the lung interstitium (Zolak, Jagirdar et al. 
2013).  
The different lung cell types that potentially contribute to the pool of activated fibroblasts in 
the fibrotic lung are summarized in Figure 1.2.  
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Figure 1.2: Cellular transition.  
Lung cell types that contribute to the pool of activated fibroblasts in the fibrotic lung. Alveolar type I (AT I) and alveolar 
type II (AT II) epithelial cells, pleural mesothelial cell (PMC). Figure template from (Fernandez and Eickelberg 2012b).  
 
 
While fibroblastic foci were long thought of as discrete entities, current studies suggest the 
existence of an interconnected fibroblastic reticular structure, termed the fibroblast reticulum 
(Cool, Groshong et al. 2006). Based on the finding of this structure, a new hypothesis for the 
origin and dissemination of the disease was generated. By means of computer-based 3D 
reconstructions of serial sections from surgical lung biopsy specimens of patients diagnosed with 
UIP, Cool and colleagues identified the subpleural region of the lung as the point of origin of the 
disease. This suggests that the pathological process is initiated at the lung periphery and progresses 
into the lung interstitium to build up the fibrotic reticulum. The ability of fibroblastic cells to 
invade interstitial lung tissue features prominently in this pathological process.  
Aberrant activation and accumulation of fibroblasts in the diseased lung interstitium 
significantly contribute to the extensive deposition of ECM in IPF. This process is described in 
section 1.4.1 in detail.  
 
 Interstitial cell migration  1.3.2
Interstitial migration is one crucial cellular property that contributes to embryonic morphogenesis, 
disease stages such as cancer, atherosclerosis, arthritis, or mental retardation as well as tissue 
repair and remodeling. In essence, interstitial cell migration can be subclassified into two modes: 
amoeboid and mesenchymal (Ridley, Schwartz et al. 2003). While leukocytes mainly exhibit 
amoeboid mode of migration, most cancer cells and fibroblasts follow the mesenchymal mode. 
The amoeboid mode functions in a protease-independent fashion (“path-finding”), whereas the 
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mesenchymal mode depends on protease activity (“path-generating”). The multistep process of 
mesenchymal migration is highly complex and synchronized. Initially, cells polarize and 
protrusions are formed on the leading edge which forces the cell into an elongated shape. 
Subsequently, transmembrane adhesion receptors of the integrin family mediate adhesion of the 
protrusions to surrounding ECM fibers. For instance, for fibroblast adhesion to collagen fibers, 
integrin α2β1 fulfills this function (Cukierman, Pankov et al. 2002). These points of adhesion 
between protrusions and ECM provide traction for the cell, crucial for the ensuing transfer of 
mechanical forces. Crosslinking of α-actinin and myosin and its coupling to focal contacts by 
zyxin and talin results in alignment and bundling of actin filaments (Ridley, Schwartz et al. 2003). 
Increasing strengthening of cell contractility and proteolytic degradation of ECM initiates 
retraction of the trailing edge of the cell and thus forward translocation (Figure 1.3).  
As outlined in section 1.3.1, invasion of pericytes and activated fibroblasts into the lung 
interstitium is one crucial cellular function in IPF pathogenesis. Accordingly, Li and colleagues 
showed ex vivo an increased invasive capacity of fibroblasts derived from IPF lungs compared to 
control fibroblasts (Li, Jiang et al. 2011). Mechanistically, the authors identified a connection 
between increased hyaluronan synthase (HAS) expression and the reported augmented fibroblast 
invasiveness in IPF. Furthermore, α5β1 integrin was found to induce an invasive phenotype in 
lung fibroblasts. This effect could be inhibited by α4β1 integrin through increasing activity of 
phosphatase and tensin homologue deleted on chromosome 10 (Pten) (White, Thannickal et al. 
2003).  
In disease, interstitial cell invasion can further be driven by growth factor signaling. For 
example, epidermal growth factor (EGF) represents one potent inducer of cellular invasion as 
shown for cancer cells (Lu, Jiang et al. 2001) and human dermal fibroblasts (Gobin and West 
2003).  
Together, these findings indicate a pivotal role of interstitial cell migration in fibrogenesis.  
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Figure 1.3: Mode of mesenchymal migration.  
The cell starts to polarize in one direction as the cell interacts with surrounding extracellular matrix (ECM) (A). 
Protrusions are shaped in direction of the polarization, cell-ECM adhesions are formed at the leading edge and actin-
filaments align (B). While adhesion intensifies at the leading edge, contractility of actin increases and proteolysis takes 
place at the trailing edge (C). Forward translocation is accomplished by retraction of the trailing edge (D).  Figure 
template from (Pathak and Kumar 2011). 
 
 
1.4 Extracellular matrix (ECM) 
Within the extremely organized structure of the lung, functional arrangement of the cells is not 
only dependent on cell-cell contacts but also highly influenced by the ubiquitous extracellular 
matrix. Thus far, the mammalian matrisome, which comprises all proteins that contribute to 
matrices, includes ~300 proteins and thus makes up 1 - 1.5% of the whole proteome. The 
matrisome is composed of 43 collagen subunits, ~200 glycoproteins, and ~40 proteoglycans 
(Hynes and Naba 2012). These components are arranged to an interlocking meshwork structure. 
Within this structure, collagens fill a role as shaping element (Fan, Creemers et al. 2014). The 
major collagens are the interstitial types I and III (Clarke, Carruthers et al. 2013). Both types are 
characterized by their fibrillar texture and assemble from collagen subunits as homotrimers. 
Decisive for the fibrillar arrangement of these homotrimers is the repeat of the sequence Gly-X-Y, 
with X being frequently proline and Y 4-hydroxyproline (Ricard-Blum 2011). This repeat encodes 
the assembly of collagen subunits to rodlike trimers, which subsequently organize into oligomers 
and fibrils. Transglutaminase cross-linking and disulfide bonds between collagens via lysyl 
oxidases (LOX) and hydroxylases result in the fibrillous mesh-like structures of collagen-based 
ECM. 
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The ECM constitutes a pleiotropic bioactive environment for mesenchymal cells (Frantz, 
Stewart et al. 2010). Cell matrix interactions play a decisive role in guiding cellular functions such 
as migration, shape (Hakkinen, Harunaga et al. 2011), differentiation (Liu, Mih et al. 2010), and 
survival (Nho, Hergert et al. 2011). The bi-directional signal transduction between ECM and 
embedded cells is mainly accomplished by integrins, a large family of cell surface-adhesion 
receptors that assembles in heterodimers at the cell membrane (Arnaout, Mahalingam et al. 2005). 
Besides their function in cell-matrix adhesion, integrins enable the cell to mechanosense the 
surrounding environment. Thus, integrins conduct mechanotransduction to intracellular chemical 
signals (“outside-in signaling”). Activation of integrins can further be transmitted by growth factor 
or G-protein-coupled receptor signaling. These inputs can initiate a conformational change of the 
extracellular domain of the integrins, thereby regulating their affinity for extracellular ligands 
(“inside-out signaling”) (reviewed in (Harburger and Calderwood 2009)). Besides its 
biomechanical function, the ECM serves as reservoir for diverse cytokines and growth factors 
(Frantz, Stewart et al. 2010). Therefore, it may contribute to both, outside-in and inside-out 
signaling of integrins. 
As the ECM represents a highly dynamic compartment, its integrity is maintained by constant 
remodeling processes. Likewise ECM deposition, matrix degradation is mainly accomplished by 
fibroblasts as these cells not only secrete ECM molecules but also ECM degrading enzymes in a 
spatially and temporally controlled manner. In regards to ECM degradation, the zinc-dependent 
endopeptidases Matrix Metallo-proteinases (MMPs) play a decisive role. The family of MMPs, 
which comprises 25 enzymes, achieves cleavage of all ECM components (Overall 2002) and 
basement membranes (Sand, Larsen et al. 2013). Secretion of MMPs by fibroblasts represents a 
highly concerted process, which is counterbalanced by tissue inhibitors of metalloproteinases 
(TIMPs) (Willenbrock, Crabbe et al. 1993).  
 
 ECM remodeling processes in IPF 1.4.1
Balancing the dynamic processes of ECM deposition, remodeling, and resorption is highly 
complex. Precise control mechanisms assure the ECM homeostasis during morphogenesis and 
tissue repair. Disruption of the ECM homeostasis is one hallmark event of non-neoplastic and 
fibroproliferative diseases, such as IPF, systemic sclerosis, myelofibrosis, hepatic cirrhosis or 
hypertrophic scars and keloids (Huang and Ogawa 2012). Nowadays, aberrant ECM secretion and 
composition is seen not only as phenotypic response but also as active contributor of fibroblast 
activation in fibrogenesis:  
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As outlined in section 1.3.1, extensive secretion of ECM is one major phenotypic response of 
activated fibroblasts in IPF. One single fibroblast, activated by growth factors or mechanical 
stimuli, may produce up to 5,000 molecules of procollagen per minute (Lindahl, Chambers et al. 
2002), (McAnulty, Campa et al. 1991). Besides collagen, fibrotic ECM is enriched with 
glycoproteins, such as extra domain containing fibronectin, periostin, fibulin, fibrillin, vitronectin 
or versican (Booth, Hadley et al. 2012). Furthermore, increased levels of proteoglycans, such as 
hyaluronan were found in broncheoalveolar fluid of IPF patients (Bjermer, Lundgren et al. 1989).  
Extensive ECM deposition in IPF lungs might be consequence of not only increased secretion 
but also defective degradation by activated fibroblasts. Accordingly, current studies indicate 
malfunction of the ECM degrading machinery in IPF, most prominently MMPs (Pardo, Selman et 
al. 2008).   
One further aspect of fibrotic ECM is its significantly altered structure and biomechanical 
properties. According to atomic force microscopy studies, experimental fibrosis significantly 
increases stiffness of lung parenchymal tissue (Liu, Mih et al. 2010). Consistent with that, elevated 
levels of LOXL2, one enzyme responsible for covalent collagen cross-linking, were found in 
serum of IPF patients (Chien, Richards et al. 2014).  
Importantly, with doxycycline one MMP inhibitor and GS-6624 one LOXL2 antibody are 
currently being investigated in clinical trials as treatment options for IPF (compare Table 1.2). 
As bioactive compartment, the ECM can act as active contributor in fibroblast activation and thus 
fibrogenesis. Therefore, ECM and fibroblast reciprocally influence each other’s functions and 
extensively modified remodeling processes may result in a feed-forward loop of matrix deposition 
(Booth, Hadley et al. 2012), (Parker, Rossi et al. 2014). As outlined in section 1.4 the ECM serves 
both, biomechanical and biochemical roles. Accordingly, variations in the composition and 
physical properties, such as rigidity, of the ECM were found to influence cell proliferation, 
viability, spreading, differentiation, and migration (Naba, Clauser et al. 2012). Furthermore, signal 
transduction of TGFβ, Fibroblast growth factors (FGF), prostaglandine E (PGE), integrins as well 
as of mechanosensitive pathways such as Wingless/Integrase-1 (Wnt) β-catenin signaling are 
affected by the diseased ECM (Frantz, Stewart et al. 2010), (Hynes and Naba 2012).  
Taking the interdependence of ECM and mesenchymal cells into consideration, it seems 
natural that studies on fibroblast behavior, undertaken in three-dimensional matrices, elicit more 
physiologically relevant results than in the absence of ECM components (Green and Yamada 
2007).  
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 ECM model systems 1.4.2
Accumulating evidence that the ECM pivotally influences behavior of cells that physiologically 
reside in a three dimensional (3D) environment have led to the conclusion that mesenchymal cells 
should be studied in an environment that closely mimics structure and dimensionality of ECM 
(Cukierman, Pankov et al. 2002), (Abbott 2003), (Baker and Chen 2012). Therefore, to date, a 
variety of 3D cell culture systems have been established and validated. ECM-coated tissue culture 
plastic is one simplified model that is widely used. This model is applicable for studies on 
signaling pathways related to ECM adhesion. However, the planar surface does not allow 
comprehensive conclusions regarding the 3D behavior of cells (Thannickal, Henke et al. 2014). 
Models using synthetic acrylamide-, or polyethylene glycol-based matrices exhibit the same 
dimensional limitation, yet due to the potentiality of gradient formation they are the model of 
choice to study matrices of varying stiffness (Saums, Wang et al. 2014).  
In addition to acrylamide and hydrogels, native and engineered biopolymers represent 
prevailing in vitro ECM model systems. In contrast to artificially synthesized macromolecular 
structures, biopolymers more closely resemble the physiological ECM architecture (Raeber, Lutolf 
et al. 2005). Common protein components of these biopolymers are collagens (Silver and Pins 
1992), laminin (Rodin, Antonsson et al. 2014), fibrin (Hayen, Goebeler et al. 1999), elastin 
(Hafemann, Ensslen et al. 1999) as well as hybrid protein based matrices, such as Matrigel (Hall 
and Brooks 2014). Regarding the omnipresence of collagens in the lung interstitium, type I 
collagen gels harbor a high biomimetic potential for the three-dimensional texture of the 
pulmonary ECM. Type I collagen gels can be used to study cell contractility, migration and 
proteolysis in 3D. Furthermore, these gels provide multiple imaging modalities allowing studies on 
3D behavior of living cells. However, unlike acrylamide and hydrogels, the stiffness of type I 
collagen gels is not extensively adjustable (Thannickal, Henke et al. 2014).  
Two additional models that mainly benefit from their physiological composition are basement 
membrane extract gels and fibroblast-derived matrices (Goetz, Minguet et al. 2011). Although 
these models most closely mimic physiological ECM, the diversity in the composition can also be 
disadvantageous as it negatively affects robustness and reproducibility.  
Taken together, as all currently used 3D in vitro cell culture models exhibit advantages and 
disadvantages, the right choice of model system highly depends on the research question. 
Prospectively, acellular ex vivo matrices present alternative 3D model systems that circumvent 
biomimetic limitations (Booth, Hadley et al. 2012).  
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1.5 Objectives 
Fibroblast activation and invasion through stromal tissue represents one dominant 
pathomechanism in non-neoplastic fibrotic diseases such as IPF. Aberrantly activated fibroblasts in 
the disease have frequently been reported to exhibit a strong invasive capacity (Li, Jiang et al. 
2011), (White, Atrasz et al. 2006), which enables them to infiltrate the lung interstitium. To date, 
studies investigating the invasion capacity of fibroblasts have mainly focused on individual factors 
and have not implemented a systemic approach. The aim of this current study was to 
comprehensively characterize this invading fibroblast phenotype in vitro and to identify novel 
functional targets for fibroblast invasion by in-depth analysis of the invasion induced 
transcriptome signature.  
 
The first aim of this study was to establish and validate two collagen-based phenotypic assays of 
3D fibroblast invasion that enable the quantification of the cellular invasion capacity (invasion 
assay) and the effective separation of invading from non-invading fibroblasts (separation assay). 
As IPF represents a disease highly driven by growth factors, further objectives comprised 
investigations on the impact of the two pro-invasive and pro-fibrotic cytokines, EGF and TGFβ1, 
on fibroblast invasion, using the novel invasion models.   
 
The second main objective focused on unraveling the transcriptome-wide signature of fibroblast 
invasion, using the newly established separation assay. This was achieved in collaboration with 
Dr. Martin Irmler (Institute of Experimental Genetics, Helmholtz-Zentrum München). 
Subsequently, to gain insight into growth factor induced cell invasion, this signature was extended 
to TGFβ1-mediated fibroblast invasion.  
 
The final goals were to evaluate both transcriptomic invasion signatures, using detailed 
bioinformatical analysis, and to validate single identified molecules for their role in fibroblast 
invasion by in-depth analysis.  
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2. MATERIALS AND METHODS 
2.1 Materials 
 Antibodies 2.1.1
 
Table 2.1: Primary antibodies for Western blot 
Antigen name Host/Clonality Dilution Manufacturer 
Anti-αSMA (clone 1A4) Mouse/mc 1:1,000 Sigma; St. Louis, USA 
Anti-Cav1 (D46G3) XP Rabbit/mc 1:1,000 Cell Signaling; Danvers, USA 
Anti-Col 1 (600-401-103-0.1) Rabbit/pc 1:1,000 Rockland, Gilbertsville, USA 
Anti-MMP13 (ab75606) Rabbit/pc 1:333 Abcam; Cambridge, UK 
Anti-Sfrp1 (ab126613) Rabbit/mc 1:1,000 Abcam; Cambridge, UK 
Anti-β-actin peroxidase (clone 
AC-15) 
Mouse/mc 1:20,000 Cell Signaling; Danvers, USA 
 
 
Table 2.2: Secondary antibodies for Western blot 
Antigen name Host Dilution Manufacturer 
Goat anti-mouse Goat 1:10,000 Cell Signaling; Danvers, USA 
Goat anti-rabbit Goat 1:10,000 Cell Signaling; Danvers, USA 
 
 
Table 2.3: Primary antibodies for immunofluorescence stainings 
Antigen name Host/Clonality Dilution Manufacturer 
Anti-αSMA (clone 1A4) Mouse/mc 1:5,000 Sigma; St. Louis, USA 
Anti-CD29 (9EG7) Rat/mc 1:100 BD; Franklin Lakes USA 
Anti-Col 1 (600-401-103-0.1) Rabbit/pc 1:1,000 Rockland, Gilbertsville, USA 
Anti-Ki67 (M7249) Rat/mc 1:100 Dako; Hamburg, Germany 
Anti-Sfrp1 (ab126613) Rabbit/mc 1:200 Abcam; Cambridge, UK 
Anti-Vimentin (C20) Goat/pc 1:100 Santa Cruz; Dallas, USA 
 
 
Table 2.4: Secondary antibodies for immunofluorescence stainings 
Antigen name Host/Clonality Dilution Manufacturer 
Goat anti-mouse IgG DyLight™ 
649 AffinityPure  
Goat 1:500 
Jackson ImmunoResearch 
Laboratories Inc./Dianova; 
Suffolk, UK 
Goat anti-rabbit IgG Alexa Fluor 
488 
Goat 1:500 Invitrogen; Carlsbad, USA 
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Goat anti-mouse IgG Alexa 
Fluor 568 
Goat 1:500 Invitrogen; Carlsbad, USA 
Donkey anti-goat IgG Alexa 
Fluor 488 
Donkey 1:500 Invitrogen; Carlsbad, USA 
Goat anti-rat IgG Alexa Fluor 
488 
Goat 1:500 Invitrogen; Carlsbad, USA 
 
 
 Buffers and solutions 2.1.2
 
DNA loading buffer (6x) (Fermentas, Thermo Fisher Scientific): 
Substance Concentration 
Tris/HCl, pH 7.6 10 mM 
Bromophenol blue 0.03% (w/v) 
Xylene cyanol FF 0.03% (v/v) 
Glycerol 60% (v/v) 
EDTA 60 mM 
 
 
HEPES (N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid) (Sigma-Aldrich): 
Substance Concentration 
HEPES 1 M 
 
 
Lämli loading buffer (6x): 
Substance Concentration 
SDS 12% (w/v) 
Glycerol (87%) 60% (v/v) 
Bromophenol blue  0.06% (w/v) 
Tris/HCl, pH 6.8 375 mM 
DTT 600 mM 
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PBS (Phosphatate buffered saline) pH 7.4 (10x): 
Substance Concentration 
NaCl 1.37 M 
KCl 27 mM 
Na2HPO4 100 mM 
KH2PO4 20 mM 
NaCl 1.37 M 
 
 
RIPA (radio-immunoprecipitation assay) buffer: 
Substance Concentration 
Tris-Cl pH 7.4 50 mM 
NaCl 150 mM 
NP40 1% (v/v) 
Na-deoxycholate 0.25% (v/v)  
 
 
SDS (sodium dodecyl sulphate) solution (20%) (w/v): 
Substance Volume/Weight 
SDS 200 g 
Millipore-H2O 1 L 
 
 
SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) Running Buffer: 
Substance Concentration 
Tris/HCl, pH 7.4  250 mM 
Glycine 1.92 M 
SDS 1% (w/v) 
 
 
SDS-PAGE Separation Gels: 
Substance Concentration/Volume 
 7% 10% 12% 
Millipore-H2O 4.6 ml 3.7 ml 3.1 ml 
1.5 M Tris/HCl pH 8.8 2.25 ml 2.25 ml 2.25 ml 
SDS 20% 45 µl 45 µl 45 µl 
Acrylamide 2.1 ml 3 ml 3.6 ml 
APS 10% 30 µl 30 µl 30 µl 
TEMED 6 µl 6 µl 6 µl 
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SDS-PAGE Stacking Gel (4%):  
Substance Volume 
Millipore-H2O 1.8 ml 
0.5 M Tris/HCl pH 6.8 750 µl 
SDS 20% 15 µl 
Acrylamide 400 µl 
APS 10% 15 µl 
TEMED 3 µl 
 
 
TAE (Tris-acetate-EDTA) buffer (50x): 
Substance Concentration/amount 
Tris/HCl 2 M 
Glacial acetic acid  5.71% (v/v) 
EDTA, pH 8 50 mM 
 
 
TBS (Tris-buffered saline) (10x): 
Substance Concentration 
Tris/HCl pH 7.4 10 mM 
NaCl 150 mM 
 
TBS-T (TBS with TWEEN
®
20) (1x): 
Substance Concentration 
TBS (10x) 10% (v/v) 
Tween®20 0.1% (v/v) 
Millipore-H2O 89.99% (v/v) 
 
Transfer buffer (10x): 
Substance Concentration 
Tris/HCl 250 mM 
Glycine 1.92 M 
 
 
Transfer buffer (1x): 
Substance Concentration 
Transfer Buffer (10x) 10% (v/v) 
Methanol 10% (v/v) 
Millipore-H2O 80% (v/v) 
 
 Cell lines and primary cells 2.1.3
 
Table 2.5: Murine cell line 
Cell line name Description Supplier 
MLg Murine newborn lung fibroblasts 
ATCC (CCL-206), LGC Standards; 
Wesel Germany 
 
 
 
 
 
MATERIAL AND METHODS 
21 
 
 
Table 2.6: Human cell line 
Cell line name Description Supplier 
A549 
Human alveolar basal epithelial 
cells, lung carcinoma 
Leibniz-Institute DSMZ-German 
Collection of Microorganisms and 
Cell Cultures; Braunschweig 
Germany 
 
 
Table 2.7: Primary human fibroblast lines 
Identification Tissue information Supplier 
ASK013 
Non-carcinogenic lung tissue 
resection from patient with lung 
metastasis of leiomyosarcoma of 
the uterus 
Asklepios Klinik; Munich, Germany 
ASK016 
Non-carcinogenic lung tissue 
resection from patient with lung 
metastasis 
Asklepios Klinik; Munich, Germany 
A003 
Non-carcinogenic lung tissue 
resection from patient with lung 
metastasis and COPD 
Asklepios Klinik; Munich, Germany 
G20Tn 
Healthy lung tissue from patient 
after lung transplantation 
Asklepios Klinik; Munich, Germany 
ASK006 
Non-carcinogenic lung tissue 
resection from patient with 
adenocarcinoma and COPD 
Asklepios Klinik; Munich, Germany 
MLT003 Lung explant/donor lung 
Klinikum Großhadern; Munich, 
Germany 
MLT013.01 Lung explant/donor lung 
Klinikum Großhadern; Munich, 
Germany 
L0023 Fibrotic origin 
University of Michigan; USA 
(laboratory of Eric White)  
L0026 Fibrotic origin 
University of Michigan; USA 
(laboratory of Eric White) 
L0028 Fibrotic origin 
University of Michigan; USA 
(laboratory of Eric White) 
L0032 Fibrotic origin 
University of Michigan; USA 
(laboratory of Eric White) 
S86A Fibrotic origin 
University of Michigan; USA 
(laboratory of Eric White) 
S099B Fibrotic origin 
University of Michigan; USA 
(laboratory of Eric White) 
S101BA Fibrotic origin 
University of Michigan; USA 
(laboratory of Eric White) 
S121B Non-fibrotic origin 
University of Michigan; USA 
(laboratory of Eric White) 
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L0029 Non-fibrotic origin 
University of Michigan; USA 
(laboratory of Eric White) 
L0031 Non-fibrotic origin 
University of Michigan; USA 
(laboratory of Eric White) 
L0024 Non-fibrotic origin 
University of Michigan; USA 
(laboratory of Eric White) 
L0025 Non-fibrotic origin 
University of Michigan; USA 
(laboratory of Eric White) 
L0029 Non-fibrotic origin 
University of Michigan; USA 
(laboratory of Eric White) 
S126N Non-fibrotic origin 
University of Michigan; USA 
(laboratory of Eric White) 
 
 
 Laboratory equipment and software 2.1.1
 
Table 2.8: Laboratory equipment 
Product Manufacturer 
-20°C freezer MediLine LGex 410 Liebherr; Biberach, Germany 
Agarose gel running chamber Biorad; Hercules, USA 
Analytical scale XS20S Dual Range Mettler Toledo; Gießen, Germany 
Autoclave DX-45 Systec; Wettenberg, Germany 
Autoclave VX-120 Systec; Wettenberg, Germany 
Bacterial shaker Innova 42 New Brunswick; Hamburg, Germany 
Cell counter Casy Modell TT Roche Diagnostics; Mannheim, Germany 
Cell culture work bench Herasafe KS180 Thermo Fisher Scientific; Darmstadt, Germany 
Centrifuge MiniSpin plus Eppendorf; Hamburg, Germany 
Centrifuge Rotina 420R Hettich; Tuttlingen, Germany 
Centrifuge with cooling, Micro200R Hettich; Tuttlingen, Germany 
CO2 cell Incubator BBD6620 Thermo Fisher Scientific; Darmstadt, Germany 
Demineralized water Thermo Fisher Scientific; Darmstadt, Germany 
Dispenser, Ceramus 2-10 ml Hirschmann Laborgeräte; Eberstadt, Germany 
Dry ice container Forma 8600 Series, 8701 Thermo Fisher Scientific; Darmstadt, Germany 
Electronic pipet filler Eppendorf; Hamburg, Germany 
Electrophoretic Transfer Cell, Mini Protean Tetra 
Cell 
Biorad; Hercules, USA 
Film developer Curix 60 AGFA; Morsel, Belgium 
Fluorescence Mikroscope AxioImager M2  Zeiss; Jena, Germany 
Fridge MediLine LKv 3912 Liebherr; Biberach, Germany 
Gel electrophoresis chamber MINIeasy Carl Roth; Karlsruhe, Germany 
Gel imaging system ChemiDoc XRS+ Biorad; Hercules, USA 
Ice machine ZBE 110-35 Ziegra; Hannover, Germany 
Intelli-Mixer RM-2 Schubert & Weiss Omnilab; Munich, Germany 
Light Cycler LC480II Roche Diagnostics; Mannheim, Germany 
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Liquid nitrogen cell tank BioSafe 420SC Cryotherm; Kirchen/Sieg, Germany 
Liquid nitrogen tank Apollo 200 Cryotherm; Kirchen/Sieg, Germany 
Magnetic stirrer KMO 2 basic IKA; Staufen, Germany 
Mastercycler gradient Eppendorf; Hamburg, Germany 
Mastercycler Nexus Eppendorf; Hamburg, Germany 
Microbiological Incubator HERATherm IGS60 Thermo Fisher Scientific; Darmstadt, Germany 
Sartorius Micro-Dismembrator S Thermo Fisher Scientific; Darmstadt, Germany 
Microscope Axio Imager M2 (flourescence) Zeiss; Jena, Germany 
Microscope Axiovert 40  Zeiss; Jena, Germany 
Microscope LSM 710 (confocal) Zeiss; Jena, Germany 
Multipette stream Eppendorf; Hamburg, Germany 
Nalgene® Freezing Container (Mr. Frosty) Omnilab; Munich, Germany 
NanoDrop 1000 PeqLab; Erlangen, Germany 
pH meter InoLab pH 720 WTW; Weilheim, Germany 
Pipettes Research Plus Eppendorf; Hamburg, Germany 
Plate centrifuge 5430 Eppendorf; Hamburg, Germany 
Plate reader TriStar LB941 Berthold Technologies; Bad Wildbach, Germany 
Plate reader Sunrise Tecan; Crailsheim, Germany 
Roll mixer VWR International; Darmstadt, Germany 
Power Supply Power Pac HC Power Supply Biorad; Hercules, USA 
Scale XS400 2S Mettler Toledo; Gießen, Germany 
Shaker Duomax 1030 Heidolph; Schwabach, Germany 
Thermomixer compact Eppendorf; Hamburg, Germany 
Ultra pure water supply MilliQ Advantage A10 Merck Millipore; Darmstadt, Germany 
LSM Top table centrifuge MCF-2360 Schubert & Weiss Omnilab; Munich, Germany 
Vortex Mixer IKA; Staufen, Germany 
Vacuum pump NO22AN.18 with switch 2410 KNF; Freiburg, Germany 
Water bath Aqua Line AL 12 Lauda; Lauda-Königshofen, Germany 
 
 
Table 2.9: Software 
Product Manufacturer 
GraphPad Prism 5 GraphPad Software; La Jolla, USA 
Imaris Software, Version  Bitplane; Zurich, Switzerland 
Image Lab Version  Biorad; Hercules, USA 
Ingenuity® Pathway Analysis (IPA) platform Ingenuity,Systems; Redwood City, USA 
LightCycler® 480 SW 1.5 Roche Diagnostics; Mannheim, Germany 
Vector NTI Advanced 9 Invitrogen, Life Technologies; Carlsbad, USA 
Magelan Software Tecan; Crailsheim, Germany 
Tristar MicroWin 2000 Berthold Technologies; Bad Wildbach, Germany 
Axio Imager Software Zeiss; Jena, Germany 
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 Chemicals and Consumables 2.1.2
 
Table 2.10: Chemicals 
Product Manufacturer 
0.2% Trypsin - EDTA solution Sigma-Aldrich; Taufkirchen, Germany 
87% Glycerin AppliChem; Darmstadt, Germany 
Ammonium peroxodisulfate (APS) AppliChem Darmstadt, Germany 
Bovine serum albumin (BSA) Sigma-Aldrich; Taufkirchen, Germany 
Casyton Roche Diagnostics; Mannheim, Germany 
Chloroform AppliChem; Darmstadt, Germany 
Complete® Mini without EDTA (Protease-inhibitor) Roche Diagnostics; Mannheim, Germany 
Coomassie Brilliant Blue R-250 staining solution BioRad; Hercules, USA 
DAPI (4',6-diamidino-2-phenylindole) Sigma-Aldrich; Taufkirchen, Germany 
DMEM/HAM’s F12 PAA, GE Healthcare; Cölbe, Germany 
DMEM (high glucose; 4.5g/l) PAA, GE Healthcare; Cölbe, Germany 
Desoxyribonucleotides mix (dNTPs) Fermentas, Thermo Fisher Scientific;  
Dimethyl sulfoxide (DMSO) Carl Roth; Karlsruhe, Germany 
Dithiothreitol (DTT) AppliChem; Darmstadt, Germany 
ECL Plus Western Blotting Substrate Pierce, Thermo Fisher Scientific; Schwerte, Germany 
Ethanol (p.a.) AppliChem; Darmstadt, Germany 
Fetal bovine serum (FBS) "GOLD", heat inactivated PAA, GE Healthcare 
Fluorescence mounting medium Dako; Hamburg, Deutschland 
Gentamicin Invitrogen, Life Technologies; Carlsbad, USA 
HOECHST 33342 Pierce, Thermo Fisher Scientific; Schwerte, Germany 
Isopropanol, (p.a.) AppliChem; Darmstadt, Germany 
Light Cycler 480 SybrGreen l Master Mix Roche Diagnostics; Mannheim, Germany 
Lipofectamine2000 Invitrogen, Life Technologies; Carlsbad, USA 
Lipofectamine LTX with PLUS reagent Invitrogen, Life Technologies; Carlsbad, USA 
Methanol, (p.a.) AppliChem; Darmstadt, Germany 
Non-fat dried milk powder AppliChem; Darmstadt, Germany 
Nonidet P-40 AppliChem; Darmstadt, Germany 
Penicillin-Streptomycin (10,000 U/ml) Gibco, Life Technologies; Carlsbad, USA 
Peptone from Casein AppliChem; Darmstadt, Germany 
Phalloidin Invitrogen, Life Technologies; Carlsbad, USA 
Ponceau S solution  Sigma-Aldrich; Taufkirchen, Germany 
Poly-L-Lysine (0.01% solution) Sigma-Aldrich; Taufkirchen Germany 
Random hexamers 
Applied Biosystems, Life Technologies; Carlsbad, 
USA 
Recombinant human EGF protein R&D Systems; Minneapolis, USA 
Recombinant human TGFβ1 protein R&D Systems; Minneapolis, USA 
Recombinant human Sfrp1 protein R&D Systems; Minneapolis, USA 
Restore Plus Western Blot Stripping Buffer Pierce, Thermo Fisher Scientific; Schwerte, Germany 
Sfrp1-inhibitor sc-222310 (CHEMBL473916) Santa Cruz; Biotechnology; Dallas, USA 
SuperSignal West Dura Chemiluminescent Substrate  Pierce, Thermo Fisher Scientific; Schwerte, Germany 
SuperSignal West Femto Chemiluminescent 
Substrate  
Pierce, Thermo Fisher Scientific; Schwerte, Germany 
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SuperSignal West Pico Chemiluminescent Substrate  Pierce, Thermo Fisher Scientific; Schwerte, Germany 
 
 
Table 2.11: Consumables 
Product Manufacturer 
96 well MaxiSorp ELISA plate Nunc; Wiesbaden, Germany 
96 well plates, white, for luciferase assay Berthold Technologies; Bad Wildbad, Germany 
Amicon Ultra 3K-0.5 mL centrifugal filters Merck Millipore; Darmstadt, Germany 
Cell culture dishes Corning, Thermo Fisher Scientific; Schwerte 
Cell culture flasks Nunc; Wiesbaden, Germany 
Cell culture multi well plates TPP Techno Plastic Products, Switzerland 
Cell scraper/lifter Corning, Thermo Fisher Scientific; Schwerte 
Cryovials 1.5ml Greiner Bio- One; Frickenhausen, Germany 
Falcon tubes (5ml, 50ml) BD Bioscience, Heidelberg, Germany 
Filter tips Biozym Scientific, Hessisch Oldendorf Germany 
Glas Pasteur pipettes VWR International, Darmstadt Germany 
Hyperfilm® ECL™ Film Amersham, GE Healthcare; Freiburg, Germany 
Measuring pipettes sterile, single use (2ml, 5ml, 
10ml, 25ml, 50ml) 
VWR International, Darmstadt Germany 
Nylon filters, pore size 70µm BD Bioscience, Heidelberg, Germany 
PCR plates, 96-well, white Biozym Scientific, Hessisch Oldendorf Germany 
PVDF membrane (0.2 or 0.45µm) Merck Millipore; Darmstadt, Germany 
Reaction tubes (0.5ml, 1.5ml) Eppendorf; Hamburg Germany 
Sealing foil for PCR plates Kisker Biotech, Steinfurt Germany 
ThincertTM 6-well cell culture inserts (pore Ø 8µm) Greiner Bio- One; Frickenhausen, Germany 
Tips Eppendorf; Hamburg, Germany 
Whatman blotting paper 3mm GE Healthcare; Freiburg, Germany 
 
 
 Enzymes 2.1.3
 
Table 2.12: Enzymes 
Product Manufacturer 
Collagenase I Biochrom; Berlin, Germany 
DNase I AppliChem; Darmstadt, Germany 
RNase inhibitor 20U/µl Invitrogen, Life Technologies; Carlsbad, USA 
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 Oligonucleotides 2.1.4
 
Table 2.13: Oligonucleotides 
Product Manufacturer 
pEGFP-N2 vector Clonetech Laboratories Inc.; Mountain View, USA 
TOPFLASH pTA-Luc vector Addgene; Cambridge, USA 
FOPFLASH pGL3 vector Addgene; Cambridge, USA 
 
 
 Quantitative RT-PCR 2.1.4.1
Primers for quantitative PCR (qPCR), were purchased from Eurofins MWG Operon; Ebersberg, 
Germany as desalted oligonucleotide lyophilisates and dissolved in DNase/RNAse - free water to a 
concentration of 100 µM, prior use. 
 
Table 2.14: quantitative human qPCR primer.  
Gene  Sequence 5’ – 3’ 
GAPDH 
fw TGTGTCCGTCGTGGATCTGA 
rev CCTGCTTCACCACCTTCTTGA 
Sfrp1 
fw GGACCGGCCCATCTACCCGT 
rev ACACCGTTGTGCCTTGGGGC 
Cav1 
fw GGACATCTCTACACCGTTCCC 
rev CTTGACCACGTCATCGTTGAG 
MMP13 
fw AGGCTCCGAGAAATGCAGTC 
rev ATCAGGAACCCCGCATCTTG 
Pten 
fw TGGCGGAACTTGCAATCCTCAGT 
rev TCCCGTCGTGTGGGTCCTGA 
TGFβ1 
fw TTCGCCTTAGCGCCCACTGC 
rev GGCCGGTAGTGAACCCGTTG 
 
 
Table 2.15: quantitative mouse qPCR primer. 
Gene  Sequence 5’ – 3’ 
GAPDH 
fw TGACCTCAACTACATGGTTTACATG 
rev TTGATTTTGGAGGGATCTCG 
Sfrp1 
fw GTGCGAGCCGGTCATGCAGT 
rev CACACGGTTGTACCTTGGGGC 
Cav1 
fw CGACGACGTGGTCAAGATTGACTTT 
rev TGCACGGTACAACCGCCCAG 
MMP13 fw ATCCCTTGATGCCATTACCA 
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rev AAGAGCTCAGCCTCAACCTG 
Pten 
fw TCAGTGGCGGAACTTGCAATCCT 
rev CGCCGCGTGGGTCCTGAAT 
TGFβ1 
fw GTGGACCGCAACAACGCC 
rev TGGGGGTCAGCAGCCGGT 
 
 
 Standards and kits 2.1.5
 
Table 2.16: Standards 
Product Manufacturer 
1 kb DNA ladder Peqlab; Erlangen, Germany 
100 bp DNA ladder Peqlab; Erlangen, Germany 
Ultra low range DNA ladder I Peqlab; Erlangen, Germany 
Protein marker V Peqlab; Erlangen, Germany 
 
 
Table 2.17: Kits 
Product Manufacturer 
BCA Protein Assay kit Biochrom; Berlin, Germany 
Dual luciferase reporter system Promega; Mannheim, Germany 
PeqGold RNA kit Peqlab; Erlangen, Germany 
Murine Sfrp1 ELISA kit Uscn Life Science; Hubei, China 
RNase-Free DNase set Qiagen; Hilden, Germany 
RNeasy Mini kit Qiagen; Hilden, Germany 
 
 
2.2 Methods 
 Cell biological methods 2.2.1
 Isolation of primary human fibroblast 2.2.1.1
Primary human lung fibroblasts (phF) were isolated and cultured according to the two following 
protocols. At the University of Michigan, lungs were received through Gift of Life donations 
(“normal”) or explanted during transplantation (UIP or IPF). Sample tissue was taken as close to 
parenchyma as possible, avoiding major airways. Fibroblast isolations were performed in the 
laboratory of Prof. Dr. Eric White. For this, tissue pieces were placed in 150 mm tissue culture 
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dishes with DMEM media pre-warmed to 37°C. Tissue was minced with a sterile scalpel blade 
until the remaining pieces did not exceed a size of 2 mm in diameter and incubated at 37°C with 
5% CO2. The cell culture medium was changed every 2 - 3 days. When outgrowing fibroblasts 
reached approximately 50 - 60% confluence (1 - 2 weeks), remaining tissue pieces were removed. 
Prior shipping, cells were harvested and re-suspended (at 1x106 cells/ml) in freeze media and 
frozen in liquid nitrogen.  
Specimens from lung lobes or segmental lung resections, received from the Asklepios Klinik 
or Klinikum Großhadern in Munich, were dissected into pieces of 1 - 2 mm2 in size and digested 
by 5 mg of Collagenase I (Biochrom) at 37°C for 2 hours. Subsequently, samples were filtered 
through nylon filters with a pore size of 70 µm (BD Falcon). Filtrates, containing the cells, were 
centrifuged at 400 g, 4°C for 5 minutes. Pellets were resuspended in DMEM/F-12 medium 
supplemented with 20% fetal bovine serum, plated on 10 cm cell-culture dishes and cultured as 
described below (2.2.1.3). Fibroblast isolations were performed by Dr. Katharina Heinzelmann, 
Katharina Lippl, and Daniela Dietel.  
 
 Cryopreservation of mammalian cells 2.2.1.2
Cell preservation was achieved by freezing cells in liquid nitrogen in freezing medium (90% FBS 
supplemented with 10% DMSO). First, cells were washed with PBS (1x), detached with pre-
warmed trypsin/EDTA solution at 37°C for 5 min and resuspended in complete medium. 
Subsequently, cells were centrifuged (400 rpm for 5 min) and resuspended in freezing medium in 
an approximate concentration of 1 - 2x106 cells/ml. Cell suspensions were transferred to cryovials 
and frozen in a Mister Frosty (Omnilab) (-80°C, overnight) and kept for long-term storage in 
liquid nitrogen.  
 
 Culturing and sub-culturing of mammalian cells 2.2.1.3
Mouse lung fibroblasts MLg (Mlg 2908) were purchased from ATCC (CCL-206) and cultivated in 
DMEM/HAM’s F12 (PAA) medium containing 10% FBS (PAA). PhF were isolated from lung 
specimens, as described above (2.2.1.1) and subsequently cultured in DMEM/HAM’s F12 medium 
containing 20% FBS. A549 cells were cultured in DMEM (high glucose) (PAA) medium 
containing 10% FBS. All cells were cultivated and passaged under standard conditions (5% CO2 
and 37°C) to a maximal confluence of 80 - 90%. For sub-culturing, cells were washed with pre-
warmed PBS and detached with trypsin/EDTA solution (37°C, 5 min). Cells were then 
resuspended and divided in the respective medium and ratio (Table 1.1). MLg fibroblasts were not 
 
 
 
MATERIAL AND METHODS 
29 
 
 
used at passage numbers higher than 15, phF were not used at passage numbers higher than 13 and 
A549 higher than 25. 
 
Table 2.18: Cell type specific culturing conditions 
Cell type Culture medium Split ratio 
A549 DMEM (high glucose) (10% FBS) 1:2 – 1:10 
phF 
DMEM/F-12/HAM’s (20% FBS) + 
gentamicin (15 µg/ml), 
penicillin/streptomycin (1%) 
1:2 – 1:10 
MLg DMEM/F-12/HAM’s (20% FBS) 1:3 – 1:20 
 
 
 Liposome-based cell transfection 2.2.1.4
For transient cell transfection, 2.5x105 MLg cells were plated per well of a 6-well plate. Liposome-
based transfection was performed 24 hours after seeding the cells. Solution A and B were prepared 
as outlined in Table 2.19. Both solutions were first incubated separately at room temperature for 5 
minutes, mixed, and incubated for final formation of the liposomes at room temperature for 
another 20 minutes. Subsequently, 1 ml complete medium and 500 µl transfection mix were added 
onto the cells and incubated overnight. Re-seeding of the cells was accomplished 24 hours after 
transfection.  
 
Table 2.19: Transfection protocol for one well of a 6-well plate 
Solution  Reagent Volume [µl] 
A 
Optimem 246 
DNA [1µg/µl] 4 
B 
Optimem 244 
Lipofectamin 2000 6 
 
 
 Growth factor treatment of cells 2.2.1.5
Fibroblasts, cultured in a 2D cell culture system, were serum starved in DMEM/HAM’s F12 
medium containing 1% FBS, 24 hours prior cell treatment. Treatment of cells with TGFβ1was 
accomplished by culturing cells in DMEM/HAM’s F12 medium containing 1 % FBS for the 2D 
cell culture system and 1 - 5 % for the 3D cell culture assays, supplemented with 1 or 5 ng/ml 
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TGβ1. For treatment with epidermal growth factor (EGF), medium was supplemented with 10 or 
50 ng/ml EGF.  
 
 Live cell imaging in 3D 2.2.1.6
For live cell imaging in 3D, collagen matrices were prepared according to the protocol below 
(2.2.2.1), supplemented with TGFβ1 (5 ng/ml) and cast in 3.5 cm cell culture dishes. Prior seeding 
on top of the matrices, MLg fibroblasts were stained with the cell-tracker dye CMTPX (5 mM), 
(Molecular Probes), according to the manufacturer’s protocol. During the period of observation the 
cells were cultured in DMEM/HAM’s F12 medium, containing 10% FBS and 15 mM HEPES. 
Live cell imaging was performed using a PM S1 incubator chamber (Carl Zeiss) at 37°C. Upon 
seeding the cells, recordings were started within one hour, and z-stacks were acquired with an EC 
Plan-Neofluar DICI 10x/0.3 NA objective lens (Carl Zeiss) in 30 minutes intervals, operated by 
ZEN2009 software (Carl Zeiss). The settings for the LSM were as follows: zoom = 0.6, pixel 
dwell time = 3.15 ms, average =1, master gain = 899, digital gain = 1.00, digital offset = 0.00, 
pinhole = 90 mm, filters = 410–556, laser line 561 nm = 2%. The confocal 4D data sets were 
imported into Imaris 7.4.0 software (Bitplane) and processed by applying a maximum intensity 
projection volume rendering algorithm. 
 
 Live cell imaging in 2D 2.2.1.7
Time-lapse microscopy was implemented on an AxioObserver (Carl Zeiss) equipped with an 
incubator XL S1 and an AxioCam (Carl Zeiss). Nuclear staining of cells was accomplished by 
incubating the cells with HOECHST for 30 minutes. 9000 cells were seeded in each well of a 
tissue culture treated 96-well microplate with a flat bottom. Cells were kept in DMEM/HAM’s 
F12 medium containing 10% FBS and 15 mM HEPES during the whole period of observation. 
Recordings started 24 hours after seeding the cells. Images were acquired with an EC Plan-
Neofluar DICI 10x/0.3 NA objective lens (Carl Zeiss) in 20 minutes intervals for 24 hours. The 
imaging system was operated by AxioVision 4.0 software (Carl Zeiss). The acquired time-lapse 
data sets were analyzed with the Imaris 7.4.0 software. Automatic tracking of the stained cell 
nuclei was accomplished with Imaris' spot detection algorithm. Per condition 200-500 cells were 
analyzed.  
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 3D cell culture models 2.2.2
 Preparation of collagen G matrices 2.2.2.1
Collagen G matrices (Biochrom AG), produced from calf skin, were prepared according to the 
manufacturer’s protocol. In short, solution A was prepared by mixing 0.7M NaOH with 1M 
HEPES buffer (Sigma) in a 1:1 ratio. Subsequently, solution A was combined with 10x PBS, 
supplemented with 20% FCS, in a 1:1 ratio resulting in solution B (pH = 7.90 - 8.05). Solution B 
was mixed with collagen G in a 1:4 ratio for the final gelation step (Table 2.20). During the 
procedure, all reactions were kept on ice. Polymerization of the final collagen G solution was 
accomplished by incubation at 37°C for 2 hours. Visual quality control of the 3D collagen matrices 
was performed with an Axiovert 40C microscope (Zeiss). For the invasion assay, a volume of 40 
µl collagen G solution was poured in each cavity of a 96-well plate and for the separation assay, 
400 µl were used per membrane insert.   
 
Table 2.20: Preparation of collagen G matrices 
Solution  Composition Ratio 
A 0.7M NaOH + 1M HEPES 1:1 
B A + 10x PBS (20% FCS) 1:1 
C B + collagen G 1:4 
 
 
 3D collagen-based invasion assay 2.2.2.2
After gelation of the 3D collagen gel, as described in 2.2.2.1, 2x104 cells per well of a 96 well-
plate were seeded on top of the matrix and left for invasion under standard conditions (37°C, 5% 
CO2) in DMEM/HAM’s F12 medium containing 1 - 10% FBS for up to 96 hours, depending on 
the experiment (Table 2.21). The collagen gels containing the cells were washed once in PBS, 
fixed in 4% paraformaldehyde (PFA) in PBS at 37°C for 1 hour. Subsequently cells were stained 
with DAPI (1:2,000) and phalloidin (1:300) in PBS at room temperature for 1 hour. Staining with 
phalloidin was carried out in order to visually assess integrity of single cells and the cell layer, as 
well as to estimate cell confluence. Each well containing the in 3D collagen matrix embedded cells 
was imaged with a LSM710, using an EC Plan-Neofluar DICI 10x/0.3 NA objective lens (Carl 
Zeiss). The stage was automated to acquire a 5x5 tile z-stack at each well starting from its very 
center. The z-stack was set to begin 100 mm above and to end 500 mm below the surface of the 
3D collagen gel. The settings for the LSM were as follows: zoom = 0.7, pixel dwell time = 1.58 
ms, average = 1, master gain = 564, digital gain = 1.24, digital offset = 250.00, pinhole = 265 mm, 
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filters = 410–585, laser line 405 nm = 4%. Quantification of invasion capacity was accomplished 
according to 2.4.2. 
For assessment of the cellular morphology, MLg fibroblasts were transfected with a pEGFP-N2 
(Clontech) vector as described in 2.2.1.4. Subsequently, 2x104 cells were seeded on top of a 3D 
collagen matrix, prepared as described in section 2.2.2.1. For the 2D control, 2.5-5.0x103 cells 
were plated in each cavity of a 96-well plate with a flat bottom. Cells were then incubated for 72 
hours, washed with PBS and fixed in 4% paraformaldehyde (PFA) in PBS at 37°C for 1 hour. 
After fixation nuclei were stained with DAPI (1:2,000) in PBS and confocal z-stacks were 
acquired with a LSM 710 using an LD Plan-Apochromat 256/0.8 NA objective lens (Carl Zeiss) 
with the following settings: zoom = 1.0, pixel dwell time = 1.58 ms, average = 2, master gain = 
479, digital gain = 1.00, digital offset = 0.00, pinhole = 90 mm, filters = 410– 495, laser line 405 
nm = 4% and laser line 488 nm = 4%. 
 
Table 2.21: Culturing conditions for invasion assay 
Experiment  Culture medium Culturing period 
Characterization of 
invading fibroblasts 
1% FCS 72-96 hours 
Assessment of cellular 
morphology 
10% FCS 72 hours 
Assessment of invasion 
capacity 
5% FCS 72 hours 
 
 
  3D collagen-based separation assay 2.2.2.3
The separation assay is a modified setup of the invasion assay. Gelation of the 3D collagen gel was 
performed as described above (2.2.2.1). The 3D collagen matrix was directly put on the bottom 
side of tissue culture inserts for 6-well plates (ThinCertsTM, 8 mm pore size, Greiner Bio-One). 
After gelation of the 3D collagen gel, 2.5 - 5x105 cells per well were seeded on top of the insert 
membrane and left for invasion under standard conditions (37°C, 5% CO2) in DMEM/HAM’s F12 
medium containing 1 - 5% FBS for 72 - 96 hours. The tissue culture insert, containing membrane 
and 3D collagen gel, was washed twice with ice-cold PBS. Subsequently, the gel was separated 
from the membrane with a pair of tweezers and mRNA and protein were isolated from the two 
fractions as described in section 2.3.1.1 and section 2.3.2.1, respectively.  
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2.3 Molecular biological methods 
 RNA analysis 2.3.1
 mRNA isolation from 3D cell culture 2.3.1.1
For RNA isolation gel and membrane were separated as mentioned in section 2.2.2.3. Three gels 
were directly pooled in 1 ml of QIAzol Lysis Reagent (Qiagen), incubated at room temperature for 
10 minutes and mixed until the complete disintegration. For membrane samples, a minimum of 
three membranes was pooled in one well of a 6-well plate and incubated in 1 ml of QIAzol Lysis 
Reagent for 10 minutes. Subsequently, samples were transferred to 1.5 ml Eppendorf tubes and 
200 µl chloroform added. After vortexing, samples were centrifuged at 12000 g at 4°C for 15 
minutes for phase separation. The upper aqueous phase was transferred into a fresh tube and RNA 
was further purified with RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions. 
The concentration of the isolated RNA was assessed spectrophotometrically at a wavelength of 
260 nm (NanoDrop 1000). 
 
 mRNA isolation from 2D cell culture 2.3.1.2
From conventional 2D cell culture, RNA isolation was accomplished using the PeqGold RNA kit 
(Peqlab) according to the manufacturer’s instruction. The concentration of the isolated RNA was 
assessed spectrophotometrically at a wavelength of 260 nm (NanoDrop 1000). 
 
 cDNA-synthesis 2.3.1.3
cDNA was synthesized with the GeneAMP PCR kit (Applied Biosystems) utilizing random 
hexamers. For each reaction 1 µg isolated RNA diluted in 18 µl water was used and complemented 
with the required reagents according to Table 2.22. Denaturation and reverse transcription were 
performed in an Eppendorf Mastercycler with the following settings: Denaturation: lid = 45°C, 
70°C for 10 minutes and 4°C for 5 minutes. Reverse transcription: lid = 105°C, 20°C for 10 
minutes, 42°C for 60 minutes and 99°C for 5 minutes. Subsequently, cDNA was diluted to a 
concentration of  8.33 ng/µl and stored at -20°C.  
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Table 2.22: Pipet scheme for reverse transcription 
Reagent Stock concentration Volume [µl] Final concentration 
MgCl2 25 mM 8 5 mM 
10x Buffer 10x 4 1x 
dNTPs 10 mM 4 1 mM 
Random Hexamers 50 µM 2 2.5 µM 
RNase Inibitor 20 u/µl 2 1 u/µl 
Reverse Transcriptase 50 u/µl 2  2.5 u/µl 
Denat. RNA  - 18 - 
Total  40  
 
 
 Quantitative real-time Polymerase Chain reaction (qRT-PCR) 2.3.1.4
All primers for quantitative PCR were designed with NCBI’s PrimerBLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/), according to the following criteria: amplicon 
size ≤ 500 bp, TM (primer) ≈ 60°C and | | 5 , size of 
primer 18 – 24 bp, GC content ≈ 50%.  
To avoid primer hybridization, TM and ∆G for primer-dimer and hairpin formation were tested for 
all designed primerpairs using the oligoanalyzer tool from Integrated DNA Technologies 
(http://eu.idtdna.com/analyzer/applications/oligoanalyzer/#Structure%201). qRT-PCR reactions 
were performed in triplicates with SYBR Green I Master in a LightCycler® 480II (Roche) with 
standard conditions: 95°C for 5 min followed by 45 cycles of 95°C for 5 s (denaturation), 59°C for 
5 s (annealing), 72°C for 20 s (elongation), 60 – 95°C for 1 min with continuous acquisition 
(melting curve). Prior pipetting reactions according to Table 2.23, forward and reverse primers 
were diluted to a concentration of 2.5 µM in DNase/RNAse - free water. Target gene expression 
was normalized to GAPDH expression.  
 
Table 2.23: Reaction scheme qRT-PCR  
Reagent Stock concentration Volume [µl] Final concentration 
SybrGreen l Master 
Mix 
2x 5 1x 
Primer Mix 10 µM each 2 0.5 µM 
cDNA 8.33 ng/µl 3 25 ng/µl 
Total  10  
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 Verification of amplicons by agarose gel electrophoresis 2.3.1.5
Size determination and review of amplicon specificity for PCR amplified DNA fragments were 
accomplished by electrophoretic separation on 1% agarose gels. Agarose was dissolved in 1x TAE 
buffer boiled in a microwave, supplemented with SybrSafe (1x final concentration) and poured 
into a gel electrophoresis chamber. DNA samples were mixed with 6x loading dye (1x final 
concentration), loaded into the pockets and electrophoretic separated in 1% TAE buffer by 
applying 50 V/gel. For size assessment, appropriate molecular weight markers were loaded on the 
outer lanes. DNA bands were visualized using the XcitaBlue™ Conversion Screen from 
ChemiDoc at 470 nm.  
 
 Microarray 2.3.1.6
For the microarrays, total RNA was isolated with the miRNeasy mini kit® according to the 
manufacturer’s protocol (Qiagen). RNA quality was accessed by the Agilent 2100 Bioanalyzer and 
only high quality RNA (RIN > 8) was used for microarray analysis. Total RNA (150 ng) was 
amplified using the Ambion WT Expression Kit and the WT Terminal Labeling Kit (Affymetrix). 
Amplified cDNA (2.75 µg) was hybridized on Affymetrix Mouse Gene 1.0 ST arrays, containing 
about 28,000 probe sets. Staining (Fluidics script FS450_0007) and scanning was done according 
to the Affymetrix expression protocol.  
 
 Proteinbiochemistry 2.3.2
 Protein isolation from 3D cell culture 2.3.2.1
For protein isolation, gel and membrane were separated as mentioned in section 2.2.2.3. A 
minimum of three gels was pooled in one 2 ml Eppendorf tube and the remaining PBS was 
aspirated. 80 µl (2120 U) of collagenase type1 (Biochrom) was added to each tube and incubated 
while shaking at 37°C for 30 – 60 minutes until the complete disintegration of the collagen gel. 
Centrifugation for 2 minutes at 500 g at 4°C resulted in a cell pellet that was washed twice with 
ice-cold PBS. Finally, the cell pellet was lysed in 30 – 50 µl ice-cold RIPA buffer, containing 1x 
Roche complete mini protease inhibitor cocktail. For protein isolation from non-invading cells, the 
membranes were cut out with a sharp scalpel. Next, the cells were scraped off the membrane 
directly into 200 µl ice-cold RIPA buffer containing 1x Roche complete mini protease inhibitor 
cocktail. Cells of a minimum of three membranes were pooled in one 2 ml Eppendorf tube. After 
incubating the samples on ice for 30 minutes, insoluble material was removed by centrifugation at 
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14,000 g at 4°C for 15 minutes and the supernatant was further processed as described in section 
2.3.2.3 - 2.3.2.4. Protein concentrations were determined using the BCA assay described in 2.3.2.3. 
 
 Protein isolation from 2D cell culture 2.3.2.2
2.3.2.2.1 Protein isolation from cell lysates 
2.5x105 MLg fibroblasts were plated per well of a 6-well plate and cells treated according to 
section 2.2.1.5. Prior protein isolation, cell culture medium from the adherent cells was aspirated 
and cells were washed with ice-cold PBS. Cell samples, fresh or frozen (-80°C), were scratched on 
ice in 70 – 100 µl RIPA lysis buffer (complemented with 1x Roche complete mini protease 
inhibitor cocktail) per well of a 6-well plate, with a cell lifter. Cell lysates were transferred to 
microcentrifuge tubes and incubated on ice for 30 minutes. Soluble protein fractions were purified 
by centrifugation at 14,000 g at 4°C for 15 minutes. Protein concentrations were determined using 
the BCA assay described in 2.3.2.3. 
 
2.3.2.2.2 Protein isolation from cell supernatants 
For analyzing secreted Sfrp1 protein concentrations of cell culture supernatants, 2.5x105 MLg 
fibroblasts were plated in one well of a 6-well plate. Cells were treated as described under 2.2.1.5. 
For ELISAs, samples were taken 24 hours after treatment and concentrated by reducing the 
volume to one forth with Amicon® Ultra centrifugal filter units (Millipore). Briefly, 500 µl culture 
supernatant was transferred into one 3K Amicon Ultra centrifugal filter unit and subsequently 
centrifuged at 14,000 g at 4°C for 30 minutes. Subsequently, the centrifugal filter units were 
inverted and concentrated samples were recovered from the centrifugal filter units by 
centrifugation at 1,000 g at 4°C for 2 minutes.  
 
 Determination of protein concentration by bicinchoninic acid assay 2.3.2.3
(BCA) 
Protein samples were diluted 1:10 in water and protein concentration determined with the biuret 
reaction based BCA using the Pierce® BCA protein assay kit (Biochrom) according to the 
manufacturer’s instruction. Absorbance was measured at 562 nm with the Sunrise multiplate 
reader. All BCA reactions were performed in duplicates.  
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 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-2.3.2.4
PAGE) and Western blotting 
Protein samples were mixed with 6x lämli loading buffer (final concentration 1x) and proteins 
were separated using standard SDS (7-12%) PAGE (20 - 30 mA per gel). For immunoblotting, 
proteins were transferred to methanol activated PVDF (Millipore, 0.45 µm or 0.2 µm) membranes 
(350 mA for 60 minutes). Subsequently, membranes were blocked with 5% milk in 1xTBST (0.1% 
Tween®20/TBS) and incubated with primary, followed by HRP-conjugated secondary antibodies 
at 4°C over night and at room temperature for 1 hour, respectively. Upon antibody incubation, 
membranes were washed intensively. Chemiluminescence was generated by incubating the 
membranes with SuperSignal West Chemiluminescent Substrate (ECL). Finally, signals were 
documented on x-ray films.  
 
 Enzyme-linked Immunosorbent Assay (ELISA) 2.3.2.5
Sandwich enzyme immunoassay for Sfrp1 was performed using the murine Sfrp1 ELISA kit 
(E95880Mu) from Uscn Life Science, according to the manufacturer’s protocol. Cell supernatants 
were concentrated (25x) using the Amicon Ultra centrifugal as described in 2.3.2.2.2. ELISAs 
were performed by Elisabeth Hennen. Data analysis was performed using non-linear interpolation 
on standards with GraphPad Prism4 (GraphPad Software). 
 
 Luciferase reporter assay 2.3.2.6
3x104 MLg cells were plated in each cavity of a 48-well plate in DMEM/Ham’s F12 (10% FBS). 
Cells were transfected with 500 ng of TOPFLASH or FOPFLASH reporter plasmid in 
DMEM/Ham’s F12 (1% FBS), respectively (Lipofectamine® 2000, Invitrogen). Five hours after 
transfection, fibroblasts were treated with Wnt3a (R&D) (100 ng/ml), Sfrp1 inhibitor 
CHEMBL473916 (sc-222310, Santa Cruz) (10 µM, 30 µM) and rh-Sfrp1 (R&D) (1 µg/ml) over 
night. Cells were lysed and luciferase activity measured with BrightGlo reagent (Promega) 
(TriStar LB 941, Berthold Technologies).  
 
 Immunocytochemistry and immunofluorescence microscopy 2.3.2.7
phF were seeded on borosilicate glass coverslips (25 mm diameter, VWR international) in a 
density of 3x105 per well of a 12-well dish. Cells were cultured in DMEM/HAM’S F12 (20% 
FCS) at 37°C with 5% CO2for 24 hours, prior starvation in DMEM/HAM’S F12 (1% FCS) for 16 
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hours. Subsequently, fibroblasts were treated with TGFβ1 (5 ng/ml) or EGF (50 ng/ml) in 
starvation medium and incubated for 24 hours. Cells were fixed in 4% PFA in PBS at 37°C for 30 
minutes and permeabilized with 0.5% Triton-X in 4% PFA for 5 minutes. Primary antibodies were 
diluted to the appropriate concentrations in 1% bovine serum albumin (BSA, Sigma) in PBS, 
added to the samples and incubated at 4°C for 16 hours. Afterwards, samples were washed three 
times with PBS for 10 minutes each. Incubation steps for the secondary antibody were performed 
equally. Coverslips were mounted on microscope slides (Thermo Scientific) in Fluorescent 
mounting medium (DAKO). Images were acquired with a LSM 710 as z-stacks and a LD C-
Apochromat 406/1.1 NA water objective lens (Carl Zeiss).  
For the characterization of fibroblasts in 3D, MLg fibroblasts were seeded on top of the 3D 
collagen matrix, cultured as described in section 2.2.2.2, fixed in 4% paraformaldehyde (PFA) in 
PBS at 37°C for 1 hour and permeabilized in 4% PFA/0.5% Triton X-100 in PBS for 10 minutes. 
Primary and secondary antibodies were diluted in 1% BSA in PBS, incubated at 4°C for 16 hours 
and subsequently washed off by rinsing the cells three times with PBS for 20 minutes each, 
respectively. Cells were imaged in PBS with a LSM 710 as z-stacks and with an LD C-
Apochromat 406/1.1 NA water objective lens (Carl Zeiss) with the following settings: zoom = 1.7, 
pixel dwell time = 2.55 ms, average = 4, master gain = 593, digital gain = 1.00, digital offset = 
0.00, pinhole= 90 mm, filters = 410–495, laser line 488 nm = 10%, laser line 405 nm = 4% and 
laser line 561 nm = 2%. 
 
2.4 In silico analysis 
 Quantification of cell morphology 2.4.1
For assessment of cell morphology, MLg fibroblasts were transfected with an empty pEGFP-N2 
vector as described in section 2.2.1.4, cultured and imaged according to section 2.3.2.7. Confocal 
fluorescent z-stacks were volume rendered with Imaris 7.4.0 software (Bitplane) and its statistical 
analysis tool. For the numerical output of the cell shape, cell surface area ( 4 , cell volume 
	 , and sphericity (Ψ 	 ) were determined according to Imaris V6.0 Reference 
Manual (Bitplane 2007) (www.bitplane.com/download/manuals/ReferenceManual5_7_0.pdf). For 
length/width ratios two equations were utilized: 	 ∗ 1 , 
	 ∗ 1 , where a, b and c are the lengths of semi-axes of an ellipsoid. Classification in 
oblate and prolate cell shape is depicted in section 6.1. 
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 Quantification of invasion capacity 2.4.2
Acquired data sets, as described in section 2.2.2.2, were imported into Imaris 7.4.0 software 
(Bitplane) and cropped in 3D. Then the spot detection algorithm of the Imaris 7.4.0 software was 
applied to assign a spot for each fluorescent intensity of a single nucleus. The settings for the spot 
detection algorithm were as follows: [Algorithm] enable region of interest = false; enable region 
growing = false; enable tracking = false. [Source channel] source channel index = 1; estimated 
diameter = 15; background subtraction = true. [Classify spots] ‘‘quality’’ above 3.089. Thus, by 
using Imaris’ statistical analysis tool, the total number of spot objects was retrieved. Subsequently, 
the spot objects were filtered by their z-position (‘‘position z’’ below a threshold in mm), whereby 
the threshold was set at the lowest point of the collagen surface. Thus, all spot objects assigned to 
invading cells in the 3D collagen matrix were selected. This selection was duplicated to a new 
‘‘spots object’’ and the number of invading spots by using Imaris’ statistical analysis tool was 
determined. Finally, by correlating the number of spots representing the invading cells to the total 
number of spots, the percentage of invading cells in the 3D collagen matrix was defined. Invasion 
depth was ascertained by using Imaris’ statistical analysis tool. Thereby, the maximal invasion 
depth was defined as the distance between the lowest non-invading cell (on top of the matrix) and 
the deepest invading cell (within the matrix). 
 
 Bioinformatical analysis 2.4.3
For the statistical transcriptome analysis, expression console (Affymetrix) was used for quality 
control and to obtain annotated normalized robust multiarray average approach (RMA) gene-level 
data (standard settings including sketch-quantile normalisation). Heatmaps were generated with 
CARMAweb (Rainer, Sanchez-Cabo et al. 2006) and cluster dendrograms with the R script hclust.  
Molecular network analysis was conducted with the web-based software application Ingenuity® 
Pathway Analysis (IPA) by creating a custom pathway, based on the Ingenuity Knowledge Base.  
 
 Statistical analysis 2.4.4
Statistical analysis was performed using GraphPad Prism4 (GraphPad Software). Data are 
presented as mean ± standard deviation (SD). Statistical analysis was performed using unpaired 
and paired t-tests (two-tailed) or One way ANOVA with Dunnett’s multiple comparison test. For 
microarray experiments statistical analyses were performed by utilizing the statistical 
programming environment R (R Development Core Team Ref1), implemented in CARMAweb. 
Genewise testing for differential expression was done employing limma t-test and Benjamini-
 
 
 
MATERIAL AND METHODS 
40 
 
 
Hochberg (BH) multiple testing correction (FDR < 10%). Right-tailed Fisher Exact Test was 
utilized for statistical analysis on the IPA platform (Ingenuity Systems). 
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3. RESULTS 
3.1 Establishment of novel 3D collagen-based invasion assays 
Aberrant invasion through interstitial and stromal tissue is one dominant pathomechanism of 
activated fibroblasts in non-neoplastic fibrotic diseases (Li, Jiang et al. 2011) and cancer (Kalluri 
and Zeisberg 2006). The aim of this study was to extensively profile the invading fibroblast 
phenotype and to systematically investigate the molecular signatures of fibroblast invasion in order 
to identify potential regulators thereof. In a first step, a 3D collagen-based invasion assay was 
established and deployed for effective quantification of the invasive capacity of fibroblasts 
(invasion assay). Then, a modified version of the invasion assay allowed the separation of 
invading from non-invading fibroblasts (separation assay) and their subsequent molecular analysis 
and generation of transcriptome signatures of invasion.  
 
 Invasion assay 3.1.1
To assess cellular invasion in a high-content and high-throughput setting, a 96-well microplate 
collagen-based 3D cell culture model was established and validated. To establish this, fibroblasts 
of the murine lung fibroblast line MLg 2908 were utilized. 
Collagen type I was selected as ECM model system, since in vivo it represents the predominant 
structural component of the ECM of connective tissue (Vasaturo, Caserta et al. 2012), (Wolf, 
Alexander et al. 2009). In a first step, quality and thickness of the collagen microstructure was 
surveyed with a laser scanning microscope, operating in reflection mode. The polymerized 
collagen type I arranged in 200 - 300 µm thick matrices with a homogeneous microfibrillar 
structure (Figure 3.1). In the invasion model, fibroblasts were plated on top of collagen type I 
matrices and cultured under standard conditions. 
After an invasion time of 72 to 96 hours, fibroblasts were fixed and stained with phalloidin and 
DAPI. Invading fibroblasts were found to exhibit a spindle-shaped morphology, characteristic for 
fibroblasts in vivo (Kalluri and Zeisberg 2006) (Figure 3.1). Morphological changes during the 
process of invasion were analyzed in detail with a slightly different experimental set-up as 
described in section 3.1.2. 
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Figure 3.1: Confocal image of an invading MLg fibroblast, embedded in collagen matrix. 
Microfibrillar structures are visualized using a confocal laser scanning microscope operating in reflection mode. 
Maximum intensity projections (x-y) (upper panel) and (x-z) (lower panel) from a generated z-stack are shown. 
Collagen matrix (reflection mode) is displayed in grey. Nuclei and F-actin of fibroblasts were fluorescently stained with 
DAPI (blue) and phalloidin (red), respectively. Scale bar, 10 µm. (Published in (Burgstaller, Oehrle et al. 2013)). 
 
 
Visualizing the nuclei allowed subsequent assessment of the cell numbers and thus quantification 
of the invading cell fraction. With a laser scanning microscope (LSM 710) z-stacks were acquired 
from each well, thereby only scanning the DAPI channel. The scanning process was automated for 
the 96-well plate using Zen2009 (Zeiss) software and the scanning area maximized by generating a 
5x5 tile image/well. Subsequently, the collective image files of the 96 well plate were split, 
resulting in one individual file for each well. The exported imaging data were analyzed with Imaris 
software (Bitplane). To avoid false-positive counts of invading cells, caused by the meniscus of the 
matrix, the area for analysis was minimized to the planar part in the center of each well, using the 
3D-crop function. For quantification, each fluorescence signal was marked with a spot by applying 
the built-in spot detection algorithm. Thus, each spot represented one nucleus, equivalent to one 
single cell. With the built-in spot detection algorithm, the exact spatial information (x,y,z) for each 
cell can be determined. Accordingly, with the statistical analysis function for spot-objects, a 
threshold was set (red line) and invading (yellow) fibroblasts were thus distinguished from non-
invading ones (white) (Figure 3.2). 
To proof that the invasion assay enabled the assessment of an active cell invasion process 
rather than capturing matrix artifacts, the invasive fibroblast cell line MLg was compared to the 
non-invasive epithelial cell line, A549, in regards to invasion distance. The maximal invasion 
depth was defined as distance between the lowest non-invading cell (on top of the matrix) and the 
deepest invading cell (within the matrix). Upon invasion, MLg fibroblasts were traced at an 
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invasion depth of up to 136.9 ± 33.04 µm whereas A549 cells reached a maximal invasion depth of 
12.72 ± 6.35 µm (Figure 3.3).  
These data verified that MLg cells, found in deeper regions of the matrix, underwent active 
invasion.  
 
Figure 3.2: Experimental set-up and analysis of 3D collagen-based invasion assay.  
Schematic representation of the experimental set-up of the established invasion assay (A). MLg fibroblasts were cultured 
in the invasion assay for 72 hours. Maximum intensity projection (x-z) of nuclei stained with DAPI (white) (upper 
panel) and corresponding spot analysis acquired with the Imaris built-in spot algorithm (lower panel). Invading cells are 
highlighted in yellow, non-invading in white. The threshold for z-position filtering is depicted in red (B). (Published in 
(Burgstaller, Oehrle et al. 2013)). 
 
 
Figure 3.3: Quantification of the maximal invasion distance of MLg and A549 cells.  
Schematic representation of the experimental set-up and assessment of the maximal invasion depth. The maximal 
invasion depth was defined as the distance between the lowest non-invading and deepest invading cell (A). 
Quantification of the invasion depth of MLg and A549 cells (B). Data are shown as mean invasion depth (±SD) of 3 
independent experiments (n = 3). Statistical analysis: unpaired t-test. **p<0.01. (Published in (Burgstaller, Oehrle et al. 
2013)– modified). 
 
 
The dynamic process of fibroblast invasion was further analyzed by confocal 4D (z-stack over 
time) time-lapse microscopy. MLg fibroblasts were stained with a cell tracker dye (CMTPX), 
seeded on top of collagen matrices, containing 5 ng/ml TGFβ1, and live cell imaging was 
performed over a period of two days.  
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Using this method as a proof of principle, fibroblasts were traced at an invasion depth of 50 
µm (1 day 7 hours), 74 µm (1 day 22 hours) and 98 µm (2 days 14 hours) and thus observed to 
actively invade the collagen I (Figure 3.4).  
 
Figure 3.4: Live cell imaging showing fibroblast invasion over time.  
Confocal 4D time-lapse movie of MLg fibroblasts stained with the cell tracker CMTPX dye during the process of 
collagen invasion in the presence of TGFβ1 (5 ng/ml). Over the time, fibroblasts appeared in deeper regions of the 
matrix as shown in single frames at different time points (10 hours, 1 day 7 hours, 1 day 22 hours, 2 days 14 hours). 
Scale bar, 80 µm (A). Orthoview of maximum intensity projections at 10 hours and 2 days 14 hours (B). Scale bar, 50 
µm. White arrows indicate invading fibroblasts found in deeper regions of the matrix. (Published in (Burgstaller, Oehrle 
et al. 2013)– modified). 
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 Characterization of the invasive fibroblast phenotype 3.1.2
In vivo, fibroblasts reside in the 3D environment of ECM and are described as spindle-shaped 
elongated cells (Kalluri and Zeisberg 2006).  
To further validate the established collagen-based invasion model, morphological plasticity of 
fibroblasts in different culturing systems as well as during the process of invasion was assessed. 
For this, MLg fibroblasts were transiently transfected with a pEGFP-N2 (enhanced green 
fluorescent protein) vector, which effected a strong fluorescent labelling of the cells’ cytoplasm. 
Subsequently, the cells were cultured either in a conventional 2D plastic-based cell culture system 
or plated on top of a collagen matrix (3.2 mg/ml). In both conditions, cells were cultured for 72 
hours. As fibroblasts undergo spontaneous invasion, two subpopulations formed in the 3D 
collagen-based experimental set-up. Cell shape, cell surface area, cell volume and cell sphericity 
were assessed. The morphology of the different fibroblast subtypes was quantified by means of 
surface rendering of acquired confocal fluorescent z-stacks.  
For simplified mathematical modeling of the cell shape, cells were regarded as spheroids. 
Commonly, spheroids can be classified in prolate (elongated) or oblate (disk-shaped). Thereby, for 
prolate spheroids the polar radius is greater than the equatorial radius ( :  while 
for oblate spheroids the polar radius is shorter than the equatorial radius : 	 	  with 
a,b,c being the lengths of the semi-axes of an ellipsoid.  
Hence, for the numerical output of the cell shape, the prolate (eprolate) and oblate (eoblate) factor 
of a representative number of cells was estimated and a morphological shift from predominantly 
disk-shaped spheroids (eprolate = 0.36, eoblate = 0.37) of conventional 2D cultured fibroblasts (Figure 
3.5 right panel) to elongated cigar-shaped spheroids (eprolate = 0.67, eoblate = 0.15) of in 3D collagen 
cultured fibroblasts was quantified (Figure 3.5 left panel). Non-invading fibroblasts, which 
remained on the surface of the collagen matrices during culturing time, had an intermediate 
ellipsoid-like shape (eprolate = 0.51, eoblate = 0.36) (Figure 3.5 middle panel). 
 
 
 
 
RESULTS 
46 
 
 
 
Figure 3.5: Assessment of the morphological plasticity of MLg fibroblasts. 
Representative confocal images of MLg fibroblasts embedded in collagen matrix (left), on top of collagen matrix 
(middle), or cultured in 2D (right) (upper panel). Morphological evaluation of the represented fibroblast 
subpopulations (prolate and oblate factor) (lower panel). Data shown represent mean values (±SD) of randomly selected 
fibroblasts (n = 47 - 73). Statistical analysis: unpaired t-test. ***p<0.001 and ns = not significant. Scale bar, 20 µm, a.u. 
= arbitrary units. (Published in (Burgstaller, Oehrle et al. 2013)).  
 
 
Morphological plasticity of fibroblasts is furthermore reflected in the cell surface area (A), volume 
(V), and sphericity (Ψ). Significant changes in all three geometric parameters between fibroblasts 
cultured in 2D plastic dishes (A = 2956 µm2, V = 9601 µm3, Ψ = 0.73), invaded the 3D collagen I 
matrix (A = 2254 µm2, V = 5291 µm3, Ψ = 0.66), or remained on top of the collagen I matrix were 
observed (A = 1511 µm2, V = 4241 µm3, Ψ = 0.83). Fibroblasts, cultured in the 2D system, 
exhibited increased volume and surface area when compared to cells cultured on top or within the 
3D collagen I matrix. Importantly, fibroblasts embedded in the 3D collagen matrix showed lowest 
sphericity, indicating a more elongated phenotype than 2D cultured and non-invading fibroblasts 
(Figure 3.6). 
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Figure 3.6: Assessment of the geometry of MLg fibroblasts in different microenvironments.  
Geometric parameters (volume, surface area, and sphericity) were assessed from surface rendering of acquired confocal 
fluorescent z-stacks. Fibroblasts, cultured in 2D, showed highest cell volume compared to fibroblasts on top and 
embedded in collagen matrix. The cell volume significantly differed between culturing conditions (A). Accordingly, 
surface area was found highest in the 2D set-up and displayed significant differences between the three groups (B). 
Fibroblasts, remaining on top of the collagen matrix, exhibited significantly higher sphericity values compared to 
fibroblasts embedded in the matrix or cultured in 2D (C). Data shown represent mean values (±SD) of randomly selected 
fibroblasts (n = 47 - 73). Statistical analysis: unpaired t-test. *p<0.05, **p<0.01,***p<0.001. (Published in (Burgstaller, 
Oehrle et al. 2013)). 
 
 
To further characterize fibroblasts that invaded the collagen matrix, immunofluorescence stainings 
were performed. Adhesion of cells to the surrounding ECM via integrins is fundamental for the 
mesenchymal mode of migration (Cukierman, Pankov et al. 2002), (Rhee 2009). Therefore, an 
antibody against integrin β1 (CD29) was used to detect cell-ECM adhesions of invaded MLg 
fibroblasts within the 3D collagen I matrix. Thereby, fibrillar adhesion-like structures were 
visualized along F-actin fibres (Figure 3.7). 
 
 
Figure 3.7: Immunofluorescence staining for integrin β1 (CD29) in invading MLg fibroblasts. 
Representative image of invading MLg fibroblasts (invasion depth ≈ 100 - 200 µm) stained for integrin β1 (CD29), 
phalloidin, and DAPI. White boxes highlight magnification of the central part of the cells. White arrows indicate co-
localization of CD29 with F-actin (phalloidin) at elongated fibrillar adhesion-like structures. Scale bars, 20 µm. 
(Published in (Burgstaller, Oehrle et al. 2013)). 
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Further cellular functional activities such as cell cycle status, ECM production and cell polarity 
were analyzed in the invading fibroblast fraction by immunofluorescence staining.  
First, to review cellular growth of fibroblasts, embedded in the collagen matrix (invasion depth 
of 100 – 200µm), dividing cells were identified by the nuclear proliferation marker Ki67 (Figure 
3.9, upper panel).  
 
 
Figure 3.8: Immunofluorescence staining for Ki67.  
Maximum intensity projection of confocal immunofluorescence microscopy images of MLg fibroblasts stained with 
Ki67-ab, residing the collagen matrix at an invasion depth of 100 - 200 µm. F-actin was stained in red (phalloidin) and 
nuclei in blue (DAPI). Scale bar, 20 µm. (Published in (Burgstaller, Oehrle et al. 2013) - modified). 
 
 
As in vivo fibroblasts function as main ECM-producing cell type (Kendall and Feghali-
Bostwick 2014) fibroblasts, residing the collagen matrix, were stained for fibronectin. These 
fibroblasts were found to contribute, with the production of fibronectin, to the construction of a 
more complex ECM structure (Figure 3.9, upper panel).  
Additionally invading fibroblasts were found to be highly positive for vimentin, a major 
cytoskeletal component of motile mesenchymal cells (Shabbir, Cleland et al. 2014) (Figure 3.9, 
lower panel).  
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Figure 3.9: Immunofluorescence staining fibronectin and vimentin in invading MLg fibroblasts.  
Maximum intensity projection of confocal immunofluorescence microscopy images of MLg fibroblasts, residing the 
collagen matrix at an invasion depth of 100 – 200 µm. Fibronectin (middle panel) and vimentin (lower panel) were 
stained in green. F-actin (phalloidin) was stained in red and DAPI in blue. Scale bar 10 µm. (Published in (Burgstaller, 
Oehrle et al. 2013) - modified). 
 
 
 Separation assay 3.1.3
To analyze the molecular properties of the invading fibroblast phenotype, a 3D collagen-based 
separation assay was established. Porous Polyethylenterephthalat (PET) membrane inserts (Ø of 
pore = 8 µm) were coated with collagen matrix on the underside. Fibroblasts were plated onto the 
membrane, opposite to the collagen matrix plug and cultured for 72 hours and 96 hours. Invading 
fibroblasts migrated through the pores of the membrane into the collagen matrix.  
To physically split the two fractions, the membranes, which were colonized with the non-
invading cells, were detached from the collagen matrices, which contained the invading cells. 
Subsequently, RNA and protein were extracted from the fractions and subjected to detailed 
molecular analysis (Figure 3.10).  
 
 
 
 
RESULTS 
50 
 
 
 
Figure 3.10: Experimental set-up of 3D collagen-based separation assay. 
Schematic representation of the experimental set-up of the separation assay, indicating the application range of the assay. 
Fibroblasts are initially plated on top of the membrane inserts and invade over a period of 72 to 96 hours through the 
pores of the membrane into the collagen matrix. Subsequently, invading fibroblasts (collagen matrix fraction) are 
separated from non-invading fibroblasts (membrane fraction). Either RNA or protein is extracted from both fractions and 
finally used for various molecular and biochemical analysis.  
 
 
3.2 Growth factor induced fibroblast invasion 
Growth factor signaling, eminently TGFβ1 (Santibanez, Quintanilla et al. 2011) and EGF 
(Baughman, Lower et al. 1999), are profoundly altered in fibrotic lung diseases. Hence, the impact 
of TGFβ1 and EGF on fibroblast invasion was evaluated with the 3D collagen invasion assay.  
MLg fibroblasts were cultured on top of collagen matrices for 24 hours and subsequently 
stimulated with TGFβ1 (1 and 5 ng/ml) or EGF (10 and 50 ng/ml). 48 hours after stimulation with 
the growth factors, the invasion capacity was assessed. Figure 3.11 A and B represent 3D 
reconstructions of the acquired z-stacks with a spot analysis and z-position dependent color coding 
(A-B). TGFβ1 significantly induced invasion into the 3D collagen matrices from 11.52 ± 4.56% to 
16.26 ± 7.00% (1 ng/ml) and 15.63 ± 5.93% (5 ng/ml) (Figure 3.11 C). Treatment with EGF 
resulted in 19.15 ± 4.71 (10 ng/ml) and 21.36 ± 5.62% (50 ng/ml) (Figure 3.11 D).  
Of note, for further experiments TGFβ1 and EGF were used in a concentration of 5 ng/ml and 
50 ng/ml, respectively. 
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Figure 3.11: TGFβ1 and EGF induce MLg fibroblast invasion. 
Software-based quantification of fibroblast nuclei (stained with DAPI) within and on top of collagen matrices by means 
of 3D reconstructed confocal z-stacks allowed the assessment of the invasion capacity of MLg fibroblasts. TGFβ1 (1 
ng/ml and 5 ng/ml) significantly induced fibroblast invasion as assessed 48 hours after treatment (A). By applying the 
same conditions, treatment of the cells with EGF resulted in a strong pro-invasive effect (10 ng/ml and 50 ng/ml) (B). 
Data are shown in five technical replicates per each of the five independent experiments (n = 5) (±SD). Statistical 
analysis: One way ANOVA with Dunnett’s multiple comparison test. (n.t. = non-treated). *p<0.05, **p<0.01, 
***p<0.001. Scale bar, 300 µm. (Published in (Oehrle, Burgstaller et al. 2015) (in press) - modified). 
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3.3 Molecular characterization of the invading fibroblast phenotype 
 Gene profile of the invasive fibroblast phenotype 3.3.1
To comprehensively characterize the invading fibroblast phenotype, not only by morphology but 
also on molecular levels, invading and non-invading MLg fibroblasts were separated by utilizing 
the established 3D collagen-based separation system described in section 3.1.2. Subsequently, 
differences in the gene profile were uncovered applying whole transcriptome analysis (Affymetrix 
Mouse Gene 1.0 ST arrays). Microarrays, gene clustering and initial data processing, and statistical 
analyses were performed by Dr. Martin Irmler (Institute of Experimental Genetics, Helmholtz-
Zentrum München). Initially, microarrays were conducted after 72 and 96 hours of invasion. For 
quality control of the microarray performance, the ratio of the area under the curve (AUC) for a 
receiver operating characteristic curve (ROC) of detection of positive versus negative controls was 
determined. AUC ratios of all samples ranged between 0.91 and 0.95 and thus meet the required 
standard criteria. Data were normalized with RMA in standard settings including sketch quantile 
normalization. Genewise testing for differential expression was done employing the (limma) t-test 
and Benjamini-Hochberg multiple testing correction. Transcripts with a false discovery rate (FDR) 
lower than 10% were considered as statistically significant and thus used for analysis. The 
comparison of invading to non-invading fibroblast fractions, after 72 hours of invasion, revealed a 
signature of 1086 targets with expression ratios > 1.5-fold and 163 targets with differential 
expression ratios > 2-fold. After 96 hours of invasion, 1049 probes with a differential regulation 
of > 1.5-fold and 182 > 2-fold were found in the invading subpopulation (Figure 3.12 A).  
To test for similarities between groups of the whole transcriptome replicate analysis, 
hierarchical clustering was performed with R scripts (hclust) and illustrated in a dendrogram. 
Effective clustering was validated for the arrays of non-treated (n.t.) MLg fibroblasts, conducted 
after 72 hours and 96 hours of invasion (72 h n.t. inv., 72 h n.t. non-inv., 96 h n.t. inv., 96 h n.t. 
non-inv.). 
The two main clusters separated into invading and non-invading fibroblasts, while sub-
clustering into the two different time-points (72 hours and 96 hours) (Figure 3.12B). 
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Figure 3.12: Differential gene expression numbers of conducted microarrays and hierarchical clustering.  
Graphical representation of differentially expressed genes with a FDR < 10%. Genes that had an expression ratio of 
1 <> 1.5 between invading (inv.) and non-invading (non-inv.) phenotypes are depicted in light grey. Probesets with a 
ratio of > 1.5 and > 2 are represented in dark grey and black, respectively (A). Cluster dendrogram, conducted with R 
using the script hclust, on RMA data filtered for expression values higher than 100 in at least one sample reveals 
effective clustering of invading and non-invading fibroblasts at 72 and 96 hours (B). Inv. = invading, non-inv. = non-
invading. (Published in (Oehrle, Burgstaller et al. 2015) (in press) - modified). 
 
 
For visualization of differentially regulated transcripts with expression ratio  > 2-fold, heatmaps 
were generated with CARMAweb. Heatmaps of invasion signatures at 72 and 96 hours are 
depicted in Figure 3.13 A and B, respectively.  
Probesets with transcript variations of > 1.5-fold upon invasion were further graphically 
represented by means of volcano plots (Figure 3.13 C and D). Of note, regulation of transcripts in 
both, up- and down-regulated groups, increased over time, with a concomitant rising statistical 
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significance. By literature research, both signatures were found to comprise transcripts, which are 
highly interesting in the context of fibroblast invasion and/or ILD and are described in detail in the 
text below (For complete gene expression lists see section 6.2 and GEO (GSE55322)). 
For a more systematic approach on target selection, the invasion signatures at 72 and 96 hours 
were analyzed for correlating gene regulation. The invasion induced transcriptome signature was 
enriched for commonly regulated genes at 72 and 96 hours of invasion. In this comparative 
analysis approach, targets with a fold induction of > 1.5 fold were included. With a total number of 
621 overlapping genes, 166 of which in the up- and 455 in the down-regulated group, the 
expression profiles of the invading fibroblasts at 72 hours and 96 hours were highly equal (Figure 
3.14 A). This result verified reproducibility and robustness of the 3D collagen separation system 
and substantiated the invasion induced gene expression profile. By plotting logarithmical 
expression values of the gene profiles at 96 hours against 72 hours, overlapping genes were 
assigned. Of note, no target was found to be up-regulated in one and down-regulated in the other 
group, demonstrating a consistency between time-points (Figure 3.14 B).  
Of interest, several proteins, involved in matrix degradation were differently regulated upon 
invasion. Overlapping up-regulated genes included Matrix metalloprotease (MMP) 13, which was 
the highest up-regulated transcript after 72 (4.5-fold) and 96 hours (9.4-fold) of invasion. 
Interestingly, besides MMP13, with MMP3 (4.0-fold / 72 hours; 7.6-fold / 96 hours) and MMP10 
(2.8-fold / 72 hours; 3.4-fold / 96 hours), two further MMPs were found up-regulated in the 
invasion induced transcriptome signatures. In addition, the MMP inhibitor tissue inhibitor of 
metalloproteinases (Timp) 3 was significantly down-regulated in the invading fibroblast phenotype 
at 72 hours (1.7-fold) and 96 hours (1.6-fold). This finding indicates a pivotal role of matrix 
degradation in the profile of the invading fibroblast phenotype. Thus, likely ECM degradation 
assists in the process of fibroblast invasion. 
Furthermore, Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (Enpp2), also named 
autotaxin, an enzyme recently reported as pathogenic contributor of IPF (Oikonomou, Mouratis et 
al. 2012), (Tager, LaCamera et al. 2008) was significantly up-regulated upon 72 (2.9-fold) and 96 
hours (5.1-fold) of invasion.  
Importantly, TGFβ1 was found to be significantly up-regulated in the invasion signature at 96 
hours (3.3-fold). At 72 hours of invasion the up-regulation accounted 2.4-fold. With TGFβ1, the 
invasion induced transcriptome signature included one key mediator of fibrogenesis. Within this 
study, TGFβ1 was found to significantly induce fibroblast invasion in the established 3D collagen 
invasion assay (Figure 3.11 A). 
With bone morphogenic protein 4 (BMP4), one further member of the TGFβ-superfamily was 
significantly differentially regulated upon invasion with a down-regulation of 3.7-fold (72 hours) 
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and 3.5-fold (96 hours). Strikingly, the inhibitor of BMP4 signaling, Gremlin 2 (Grem2), was 
found to be upregulated upon invasion with 1.6-fold at 72 hours and 2.4-fold at 96 hours.  
Osteoglycin (Ogn), also called mimican, is one further TGFβ associated small proteoglycan 
that was consistently down-regulated at 72 and 96 hours of invasion with 4.5-fold and 3.7-fold, 
respectively.  
Collagen invasion also affected, by a significant down-regulation of CTGF (connective tissue 
growth factor or CCN2) (2.0-fold at 72 hours and 2.4-fold at 96 hours), WISP1 (WNT1 inducible 
signaling pathway protein (WISP) 1) (1.6-fold / 72 hours and 1.6-fold / 96 hours), Cyr61 (cysteine-
rich angiogenic protein 61 or CCN1) (2.0-fold / 72 hours and 1.9-fold / 96 hours) and an up-
regulation of NOV (nephroblastoma overexpressed or CCN3) (1.7-fold / 72 hours and 2.7-fold / 96 
hours) members of the matricellular protein cluster of CCN proteins, which in part has been 
recognized in fibrogenesis (Konigshoff, Kramer et al. 2009), (Kono, Nakamura et al. 2011), 
(Zhang, Li et al. 2014).   
Intriguingly, Pten was significantly decreased by 2.9-fold in the invasion induced 
transcriptome signature at 72 hours and 3.3-fold at 96 hours. These reduced expression levels of 
Pten were considered as an important corroborative finding for the invasion signature, as a loss of 
function for Pten is widely associated with fibrosis, cancer, and cellular invasion (White, 
Thannickal et al. 2003), (Tamura, Gu et al. 1998). 
Secreted frizzled-related protein 1 (Sfrp1) is one further remarkable target found in the present 
study on the invading fibroblast phenotype in lung disease. Sfrp1, which acts mainly as inhibitor of 
canonical and non-canonical Wnt-signaling pathways, was found to be strongly down-regulated 
upon invasion with 2.7-fold at 72 hours and 2.1-fold at 96 hours.  
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Figure 3.13: Heatmaps and Volcano plots for transcript expression of the invasion signatures at 72 and 96 hours. 
Separation and RNA extraction of invading (inv.) and non-invading (non-inv.) cell fractions was accomplished 72 (A) 
and 96 hours (B) after initial plating. The presented heatmaps depict the top > 2-fold differentially regulated targets 
found in the microarray analyses (Affymetrix Mouse Gene 1.0 ST array). High and low expressed targets of the inv. 
compared to non-inv. cell fraction are illustrated in the heatmaps in red and blue, respectively. Each column represents 
one independent experiment. Expression profile of fibroblast invasion at 72 hours (C) and 96 hours of > 1.5-fold 
regulated targets (D). P-values are plotted against fold-difference (FD) values in a logarithmic scale. n.t. = non-treated, 
inv. = invading, non-inv. = non-invading. (Published in (Oehrle, Burgstaller et al. 2015) (in press) - modified). 
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Figure 3.14: Overlap of gene expression in the conducted transcriptome analyses at 72 and 96 hours.  
The expression overlap is depicted in Venn diagrams comparing expression ratios of invading (inv.) and non-invading 
(non-inv.) fibroblasts at 72 and 96 hours of invasion. The overlap accounted 621 probesets; 166 in the up-, and 455 in 
the down-regulated group (A). Dotplot, representing gene expression ratios at 96 hours against 72 hours in a logarithmic 
scale (B). Targets, associated with invasion/ILD are highlighted in the dotplot by their name. Inv. = invading, non-inv. = 
non-invading. (Figure A published in (Oehrle, Burgstaller et al. 2015) (in press) - modified). 
 
 
To narrow down promising targets, the overlapping signature of fibroblast invasion was analyzed 
in detail with the Ingenuity® Pathway Analysis (IPA) software. Heatmaps were generated for the 
ten most significantly over-represented “disease processes” and “biological function” by using the 
transcript profiles with fold induction of > 1.5 for both time-points. Strikingly, the clusters 
“invasion of cells”, “idiopathic pulmonary fibrosis”, and “metastasis” were most significantly 
affected upon 72 and 96 hours of invasion. This finding once more validated the significance of 
the generated transcriptome signature and implied a role of the invasion profile in disease.  
From the top three enriched clusters, “invasion of cells”, “idiopathic pulmonary fibrosis”, and 
“metastasis” underlying molecular networks were generated. Importantly, from the most 
significantly regulated transcripts, described in Figure 3.14 B, TGFβ1, MMP13, MMP3, Grem2, 
Enpp2, Bmp4, Pten, and Sfrp1 appeared in the generated network. TGFβ1 was identified as being 
connected with all three clusters. Additionally, MMP3, MMP9, Pten, BMP4, and ENPP2 were 
associated with both “invasion of cells” and “metastasis”. A cluster of micro RNA precursors, 
including miR-10, miR-130, miR-143, miR-145, miR-181*, and let-7 was found to be down-
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regulated in the invasion signature. These miRNAs were either linked to “metastasis”, “invasion of 
cells”, and/or “idiopathic pulmonary fibrosis” (Figure 3.15). 
 
 
Figure 3.15: Analysis of functional gene cluster enrichment in the invasion induced transcriptome signature with 
the Ingenuity® pathway analysis platform (IPA).  
The ten most significantly over-represented “disease processes” and “biological function” are represented in a heatmap. 
Of note, the clusters “invasion of cells”, “idiopathic pulmonary fibrosis”, and “metastasis” were found to be most 
significantly enriched in the invasion induced transcriptome signature (A). From the top three enriched clusters, 
“invasion of cells”, “idiopathic pulmonary fibrosis” and “metastasis” underlying molecular networks were generated. 
Targets, significantly up-, or down-regulated in the invading fibroblast phenotype are represented in green and red, 
respectively. Dashed orange lines illustrate activating relationships, yellow lines findings that are inconsistent with the 
state of downstream molecules, and grey lines that the mode of effect is not defined (B). (Published in (Oehrle, 
Burgstaller et al. 2015) (in press). 
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 Identification of TGFβ1-mediated transcriptomic invasion signature 3.3.2
With TGFβ1, one pro-invasive regulator was identified in the overlapping fibroblast invasion 
transcriptome signature. As this target is of particular interest in the context of ILD and was linked 
to the clusters “invasion of cells”, “idiopathic pulmonary fibrosis”, and “metastasis” in the 
generated networks presented in section 3.3.1 (Figure 3.15), the gene expression pattern of 
TGFβ1-modulated fibroblast invasion was profiled next.  
Invasion of MLg lung fibroblasts was induced by TGFβ1 (5 ng/ml) stimulation in the 3D 
separation system, 24 hours after plating. After 72 hours, the invading fibroblast subpopulations 
were separated from the non-invading and RNA probed by whole transcriptome analysis. 
Microarrays and data processing were performed under equal terms as described in 3.3.1 
(collaboration with Dr. Martin Irmler from the Institute of Experimental Genetics, Helmholtz-
Zentrum München).  
Within the invading and non-invading fibroblast fractions, gene expression induced by TGFβ1 
treatment was revealed by comparing the gene profile of TGFβ1-treated to non-treated controls. In 
the non-invading fraction 1013 probesets were significantly regulated upon TGFβ1 treatment with 
a fold-change of > 1.5 and 310 with a fold-change of > 2. In the invading fibroblast fraction, 679 
probesets with expression ratios of >1.5-fold and 202 with expression ratios of > 2-fold, were 
differentially expressed between treatment groups (Figure 3.16 A). Hierarchical clustering, as 
illustrated in a dedrogram generated with R scripts (hclust), revealed that array data mainly 
clustered in invading and non-invading groups and subdivided into non-treated and TGFβ1-treated 
on the second hierarchical level. Of note, two samples (96 h TGFβ1 non-inv. 5 and 96 h TGFβ1 
inv. 5) were identified as outliers and excluded from further analyses (Figure 3.16 B). 
The TGFβ1-induced gene expression profile in the invading fibroblast fraction was of 
particular interest and was used in the subsequent experiments to more precisely define the 
molecular basis of fibroblast invasion in the context of ILD.  
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Figure 3.16: Differential gene expression numbers of conducted microarrays (TGFβ1-treated groups) and 
hierarchical clustering.  
Graphical representation of differentially expressed genes with a FDR < 10%. Genes that had an expression ratio of 1 -
 1.5 between invading (inv.) and non-invading (non-inv.) or non-treated (n.t.) and TGFβ1-treated are depicted in light 
grey. Probesets with a ratio of > 1.5 and > 2 are represented in dark grey and black, respectively (A). Cluster 
dendrogram, conducted with R using the script hclust, on RMA data filtered for expression values higher than 100 in at 
least one sample. Two samples (96 h TGFβ1 non-inv. 5 and 96 h TGFβ1 inv. 5) were identified as outliers and excluded 
from further analyses (B). n.t. = non-treated; inv. = invading, non-inv. = non-invading. 
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For a complete description of TGFβ1-induced transcript variations two heatmaps were created for 
differentially regulated transcripts with expression ratio > 2-fold. First, for the non-invading group, 
the TGFβ1-induced gene profile was compared to the gene profile of the non-treated control group 
(Figure 3.17 A). Secondly, for the invading fibroblast fraction, TGFβ1 and non-treated groups 
were compared (Figure 3.17 B). 
Comparing microarrays of non-invading TGFβ1-stimulated (5 ng/ml) with non-invading untreated 
fibroblasts, C1q and tumor necrosis factor related protein 3 (C1qtnf3) was found to be the highest 
up-regulated transcript (34.7-fold), as shown in the heatmap of Figure 3.17 A. Focusing on the 
group of genes associated with matrix degradation, Disintegrin and Metalloproteinase domain-
containing protein 12 (Adam12) and Metallopeptidase with Thrombospondin Type 1 Motif, 16 
(Adamts16) were significantly up-regulated upon TGFβ1 treatment with 5.4-, and 4.3-fold, 
respectively. In the group of significantly down-regulated targets, with Bmp4 (8.3-fold), Ogn (6.7-
fold), and Sfrp1 (2.0-fold) targets associated with the invasion signature were identified. 
Of interest, in line with the generated heatmap of non-invading TGFβ1-stimulated versus non-
invading untreated fibroblasts, comparison of invading TGFβ1-stimulated with invading untreated 
fibroblasts revealed C1qtnf3 as most highly up-regulated target (12.0-fold) (Figure 3.17 B). 
Mmp12 was furthermore significantly up-regulated (3.3-fold) and Ogn down-regulated (4.4-fold) 
in the invading fibroblast fraction upon TGFβ1 stimulation. Unexpectedly, Enpp2, one target 
found to be significantly up-regulated in the invasion signature, was highly down-regulated in the 
TGFβ1-treated invading cells (7.1-fold). 
For an extended analysis on TGFβ1-induced gene regulation in invading and non-invading 
fibroblast phenotypes, volcano plots were generated for transcription profiles with > 1.5-fold 
induction. In the invading compared to non-invading TGFβ1-treated transcript profile, TGFβ1 
(1.9-fold), Enpp2 (1.8-fold), and Ogn (2.4-fold) were identified (Figure 3.18 A).  
In the analysis of invading TGFβ1-treated compared to non-treated fibroblasts, Sfrp1 was one 
target identified to be significantly down-regulated in the invading fibroblast phenotype upon 
stimulation (1.5-fold).  
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Figure 3.17: Heatmaps visualizing differential gene expression of TGFβ1-treated compared to non-treated non-
invading and invading fibroblasts.  
Heatmap representing differential gene expression (> 2-fold) of non-invading (non-inv.) and non-treated compared to 
non-inv. TGFβ1-treated fibroblasts at 96 hours of invasion and 72 hours of treatment, respectively (A). Differential 
TGFβ1-induced gene expression (> 2-fold) in invading (inv.) fibroblast subpopulation (B). High and low expressed 
probesets of the inv. compared to non-inv. cell fraction are illustrated in the heatmaps in red and blue, respectively. Each 
column represents one independent experiment. Inv. = invading, non-inv. = non-invading. 
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Figure 3.18: Volcano plots for TGFβ1-induced variation in transcript expression levels.  
Volcano plots representing logarithmic gene expression ratios of TGFβ1-treated compared to n.t. fibroblasts at 96 hours. 
P-values are plotted against fold-difference (FD) values in a logarithmic scale. TGFβ1-induced (5 ng/ml) changes in 
expression levels in non-invading (non-inv) (A) and invading (inv) (B) MLg fibroblast. Inv. = invading, non-inv. = non-
invading. 
 
 
Subsequently, in order to further enrich the invasion transcriptome signature, the expression profile 
of invading fibroblasts was compared with the identified signature of TGFβ1-induced invasion. 
With that, the focus was set on genes that were both, regulated by TGFβ1 and related to the 
invading capacity of the cells. In total, 193 targets were found in the overlap of invading compared 
to non-invading and invading TGFβ1-treated compared to untreated profiles with > 1.5-fold 
induction. This overlap itemized in 27 consistently up-, and 40 down-regulated transcripts (Figure 
3.19 A). Thus 129 probesets were inversely regulated between groups, as depicted in clear circles 
in Figure 3.19 B. As targets of interest in the context of fibroblast invasion were considered those, 
which showed aligned regulation between groups, as depicted in grey circles in Figure 3.19 B. 
Consequently, these targets were represented in the heatmap shown in Figure 3.21 B. 
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Figure 3.19 Overlap of gene expression in the conducted transcriptome analyses at 96 hours invading/non-
invading with invading TGFβ1/non-treated.  
The expression overlap is depicted in Venn diagrams comparing expression ratios of invading (inv.) and non-invading 
(non-inv.) fibroblasts at 96 hours with TGFβ1-treated and non-treated (n.t.) inv. fibroblasts. The overlap accounted 193 
probesets; 27 equally regulated in the up-, and 40 in the down-regulated group (A). Dotplot representing logarithmic 
gene expression ratios of inv. compared to non-inv. fibroblasts against TGFβ1-treated/ n.t. fibroblasts at 96 hours (B). 
Clear circles: targets, with opposing regulation between groups. Grey circles: Targets, consistently up-, or down-
regulated in both groups. Inv. = invading, non-inv. = non-invading. 
 
 
The overlapping signature of targets, regulated upon invasion and in the invading subpopulation by 
TGFβ1 stimulation, was designated as TGFβ1-mediated transcriptomic invasion signature. IPA 
analysis revealed that both groups showed gene cluster enrichments in invasion, morphogenesis, 
and carcinogenesis-related pathways (Figure 3.20). The heatmap of the TGFβ1-mediated 
transcriptomic invasion signature revealed among others, Grem2 (2.4-, 1.7-fold up-regulated), 
Bmp4 (3.5-, 2.6-fold down-regulated), Ogn (3.7-, 4.4-fold down-regulated), Pten (3.3-, 1.6-fold 
down-regulated), and Sfrp1 (2.1-, 1.5-fold down-regulated) as invasion critical targets (Figure 
3.20).  
Taken together these data provide for the first time a detailed description of invasion induced 
gene regulation in fibroblasts with the extension to TGFβ1-mediated invasion.  
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Figure 3.20: Heatmaps of the TGFβ1-mediated transcriptomic invasion signature. 
The 10 most significantly over-represented “disease processes” and “biological functions” in inv. compared to non-inv. 
fibroblasts, and inv. TGFβ1-treated (5 ng/ml) compared to non-treated (n.t.) fibroblasts at 96 hours are represented in a 
heatmap. These “disease processes” and “biological functions” include “invasion of cells”, “migration of cells”, and 
“metastasis” (A). TGFβ1-mediated transcriptomic invasion signature depicted as heatmap of the consistently up- and 
down-regulated genes in the analyzed overlap of inv. compared to non-inv. fibroblasts, and inv. TGFβ1-treated (5 ng/ml) 
compared to n.t. fibroblasts. Low and high expressed targets in the heatmap are depicted in blue and red, respectively 
(B). Inv. = invading, non-inv. = non-invading. 
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 Gene array verification 3.3.3
The gene expression profiling approach, presented in section 3.3.1, was validated by confirmative 
expression analysis using qRT-PCR, surveying expression changes of several invasion-associated 
target genes: MMP13 (Lederle, Hartenstein et al. 2010), (Sabeh, Li et al. 2009), TGFβ1 (Zolak, 
Jagirdar et al. 2013), Caveolin 1 (Cav1) (Lino Cardenas, Henaoui et al. 2013), and Phosphatase 
and Tensin Homolog (Pten) (White, Thannickal et al. 2003). Control qRT-PCR analysis was 
performed for all microarrays and is exemplified for the 96 hour samples in Figure 3.21. Whole 
transcriptome analysis revealed an induction of 9.4-fold for MMP13 (p = 8.2x10-8), 3.3-fold for 
TGFβ1 (p = 8.2x10-8), and a reduction of 1.3-fold for Cav1 (p = 2.3x10-2) and Pten 3.3-fold (p = 
1.1x10-5) in the invading fibroblasts 96 hours after plating (Figure 3.21 A). Accordingly, in the 
qRT-PCR data MMP13 and TGFβ1 were found significantly higher expressed in the invading 
fibroblast subpopulation with 6.02- and 1.85-fold induction, respectively. Furthermore, Cav1 was 
significantly down-regulated by 3.48-fold and Pten by 2.61-fold (Figure 3.21 B), corroborating the 
microarray data. Thus, the qRT-PCR data confirmed the robustness of the applied microarray 
analysis and validated the described fibroblast invasion transcriptome signature.  
 
 
Figure 3.21: Validation of transcriptome analysis for selected invasion-associated genes. 
Separation of MLg fibroblasts was accomplished at 96 hours of invasion and selected invasion-associated genes 
(MMP13, TGFβ1, Cav1, and Pten) were probed. Original microarray data for five independent experiments. Data are 
represented with Benjamini-Hochberg (BH)-adjusted p-values. Genewise testing for differential expression was done 
employing the limma t-test and Benjamini-Hochberg multiple testing correction (FDR < 10%) (A). Confirmative qRT-
PCR analysis (B) of the selected group of genes (n = 4). Data are represented with p-values. Inv. = invading, non-inv. = 
non-invading. Statistical analysis: paired t-test *p<0.05 and ***p<0.001. (Published in (Oehrle, Burgstaller et al. 2015) 
(in press) - modified).    
 
 
In a next step, regulation of two of the chosen invasion-associated transcripts, MMP13 and Cav1 
in the invading fibroblasts was analyzed on protein level. Protein samples extracted from invading 
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and non-invading fibroblasts after physical separation were probed by immunoblotting. While 
MMP13 was strongly up-regulated in the invading fibroblast phenotype, Cav1 expression was 
negatively affected as shown in Figure 3.22. Consequently, protein expression data went in line 
with mRNA expression as revealed by microarray and qRT-PCR analysis (Figure 3.21). 
 
Figure 3.22: MMP13 and Cav1 protein expression in invading MLg fibroblasts. 
Representative immunoblots illustrating up-regulation of MMP13 (A) and down-regulation of Cav1 (B) in invading 
mouse lung fibroblasts. Inv. = invading, non-inv. = non-invading. (Figure A published in (Burgstaller, Oehrle et al. 
2013)- modified), Figure B published in (Oehrle, Burgstaller et al. 2015) (in press)). 
 
 
To rule out any cell line (MLg) restricted effects and to validate the results from murine in human 
cells, separation and subsequent analysis of the chosen targets on mRNA level was performed for 
primary human lung fibroblasts (phF). Corroborating the findings in MLg fibroblasts, MMP13 and 
TGFβ1 were up-regulated on mRNA level upon invasion, with 2.26-fold and 1.14-fold, 
respectively (Figure 3.20). Additionally, Cav1 was 2.42-fold and Pten 3.17-fold down-regulated in 
invading phF. In conclusion, selected invasion relevant target genes were uniformly differentially 
regulated in murine and human fibroblasts upon invasion.  
 
 
Figure 3.23: Expression of invasion-associated target genes in invading phF.  
qRT-PCR analysis of invading (inv.) compared to non-invading (non-inv.) fibroblasts after 96 hours of invasion. Data 
are represented as mean values from four independent experiments (n = 4). Inv. = invading, non-inv. = non-invading. 
Statistical analysis: paired t-test *p<0.05 and **p<0.01. published in (Oehrle, Burgstaller et al. 2015) (in press) - 
modified). 
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3.4 Secreted frizzled-related protein 1 (Sfrp1) 
In search of novel potential regulators of fibroblasts invasion, by applying a systematic 
comparative analysis of invasion of transcriptomic profiles (section 3.3.1 - 3.3.2) Sfrp1 emerged as 
an interesting target for in-depth functional analysis. Sfrp1 belongs to a family of secreted 
glycoproteins that triggers Wnt-signaling cascades by binding to Wnt ligands or Frizzled receptors 
(Esteve and Bovolenta 2010). Thereby, Sfrps act inhibitory on the Wnt-signaling pathways that 
potentially play an important role in IPF pathogenesis (Konigshoff, Kramer et al. 2009) (Vuga, 
Ben-Yehudah et al. 2009).  
As part of the present study, the role of Sfrp1 expression in the context of fibroblast invasion 
and interstitial lung disease was investigated.   
 
 Sfrp1 within the molecular signature of invading fibroblasts 3.4.1
The resulting invasion-related expression signature (section 3.3.2) was screened for functional 
targets and novel regulators of fibroblast invasion. In this process, Sfrp1 was identified to be 
uniformly down-regulated after both, 72 and 96 hours of invasion as well as in the TGFβ1-induced 
invasion signature. Down-regulation of Sfrp1 in invading MLg fibroblasts was first verified on 
mRNA and protein level. With a mean ddCt-value of 1.23 (≡ 2.35-fold) between invading and 
non-invading cells, Sfrp1 mRNA expression was significantly reduced upon invasion (Figure 3.24 
A). To verify this on protein level, immunoblot analysis demonstrated a strong Sfrp1 protein 
down-regulation in the invading MLg fibroblasts (Figure 3.24 B). Thereupon, together with the 
microarray data reduced Sfrp1 levels were considered as a consistent feature of the molecular 
signature of invading lung fibroblasts.    
 
 
 
Figure 3.24: Sfrp1 expression in invading MLg fibroblasts.  
Sfrp1 transcript levels are significantly reduced in invading compared to non-invading MLg fibroblasts, as revealed by 
qRT-PCR of four independent experiments (n = 4) (A). Data are shown as dCt-values in relation to GAPDH. Down-
regulation of Sfrp1 on protein level was confirmed by immunoblotting (B). Inv = invading, non-inv. = non-invading. 
Statistical analysis: paired t-test *p<0.05. Published in (Oehrle, Burgstaller et al. 2015) (in press) - modified). 
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Sfrp1 belongs to the family of secreted frizzled-related proteins that consist of five members 
namely Sfrp1, Sfrp2, Frzb (Sfrp3), Sfrp4, and Sfrp5. To investigate specificity of Sfrp1 down-
regulation, gene expression data sets were scanned for all members of the Sfrp family. In the 
microarray data at 96 hours, Sfrp1 showed a significant decrease during invasion from 1268.0 ± 
239.1 relative fluorescence units (RFU) in non-invading to 592.0 ± 125.7 RFU in invading MLg 
fibroblasts. Expression levels of Sfrp2 thru Sfrp5 however, were near the lower detection limit and 
with exception of Frzb not substantially affected by invasion. Expression of Frzb was significantly 
increased in the process of invasion from 31.80 ± 2.05 RFU to 34.60 ± 0.89 RFU (Figure 3.25). 
 
 
Figure 3.25: Transcript levels of Sfrp isoforms.  
Various expression levels of the Sfrp isoforms Sfrp1-5 in Affymetrix Mouse Gene 1.0 ST array data set at 96 hours. Data 
are represented as mean linear relative fluorescence units (RFU) from five independent experiments (n = 5). Inv. = 
invading, non-inv. = non-invading. Statistical analysis: paired t-test. *p<0.05. 
 
 
To verify down-regulation of Sfrp1 in a disease-related context, differential expression of Sfrp1 in 
response to invasion was further investigated in patient-derived fibroblasts. On transcript levels, 
Sfrp1 was significantly down-regulated in the invading fraction of fibroblast lines isolated from 
eight different patient-derived lung biopsy samples, with a mean ddCt value of 2.44 (≡ 5.43-fold) 
(Figure 3.26 A). Sfrp1 expression on protein level was investigated in three different patient lines 
(P1, P2, P3) by immunoblot analysis (Figure 3.26 B). These data confirmed the differential 
expression of Sfrp1 upon 3D collagen invasion found in MLg fibroblasts.  
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Figure 3.26: Differential expression of Sfrp1 in phF upon invasion.  
phF show a significant down-regulation of Sfrp1 transcript levels upon invasion (96 hours), as detected in eight 
different fibroblast lines derived from lung biopsies/explants (n = 8) (A). Three phF lines were probed with Western 
blot analysis (n = 3) and a strong reduction of Sfrp1 expression was detected in the invading (inv.) compared to non-
invading (non-inv.) subpopulation (B). (P = patient). Statistical analysis: paired t-test. ***p<0.001. 
 
 
 Growth factor induced regulation of Sfrp1 3.4.2
Due to the fact that Sfrp1 was identified in the inherent and the TGFβ1-induced transcriptomic 
invasion signature, it was hypothesized that Sfrp1 might function as an initial trigger for fibroblast 
invasion. To address this hypothesis, the regulation of Sfrp1 expression by TGFβ1 was analyzed in 
more detail. Besides TGFβ1, EGF was identified as a pro-invasive growth factor (Figure 3.11) and 
therefore included in the studies on growth factor regulated Sfrp1 expression dynamics. MLg 
fibroblasts were cultured for 4, 8 and 24 hours in conventional 2D plastic dishes in the presence or 
absence of TGFβ1 (5 ng/ml) or EGF (50 ng/ml). The Sfrp1 expression was monitored on mRNA 
level by qRT-PCR. Sfrp1 transcripts were significantly down-regulated 24 hours after treatment 
with TGFβ1 (ddCt value of -1.79 ≡ 3.45-fold) and EGF (ddCt value of -2.43 ≡ 5.38-fold) (Figure 
3.27). 
As Sfrp1 transcript levels were gradually reduced over time in MLg fibroblasts after 
stimulation with TGFβ1 (5 ng/ml) and EGF (50 ng/ml), the correlation on protein level was 
analyzed next. Using Enzyme-linked immunosorbent assays (ELISAs), the amount of secreted 
Sfrp1 was determined in the fibroblasts’ supernatants. Baseline secretion ranged at 326.13 ± 
133.48 pg/ml and was significantly lowered to 44.81 ± 27.88% and 34.24 ± 22.89% 24 hours after 
TGFβ1 and EGF stimulation, respectively. In the total cell lysate, Sfrp1 expression was 
substantially reduced. Coinciding with the mRNA data, down-regulation of Sfrp1 on protein level 
occurred earlier in response to EGF than to TGFβ1. Three independent experiments demonstrated 
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that Sfrp1 expression in the EGF-treated fibroblasts was reduced 8 hours after stimulation, whereas 
TGFβ1-treated fibroblasts lagged behind showing first signs of reduced protein expression after 48 
hours of treatment (Figure 3.28 B). The more efficient Sfrp1 down-regulation upon EGF than 
TGFβ1 treatment might be reflected in the higher pro-invasive efficiency of EGF compared to 
TGFβ1 as shown in Figure 3.11 
 
 
Figure 3.27: Down-regulation of Sfrp1 transcript upon TGFβ1 and EGF stimulation.  
Dynamics of TGFβ1-, (5 ng/ml) (A) and EGF (50 ng/ml) -induced (B) Sfrp1 down-regulation on mRNA level. Data are 
shown as ddCt-values of three independent (n =3) experiments at the indicated time-points. Statistical analysis: One way 
ANOVA with Dunnett’s multiple comparison test. (n.t. = non-treated). *p<0.05, ***p<0.001. 
 
 
 
Figure 3.28: TGFβ1 and EGF induced reduction of Sfrp1 protein expression.  
Significant reduction of secreted Sfrp1 was detected by ELISA 24 hours after stimulation with TGFβ1 (5 ng/ml) or EGF 
(50 ng/ml) (A). In MLg cell lysates, EGF (50 ng/ml) induced a strong reduction of Sfrp1 protein expression already 8 
hours and TGFβ1 (5 ng/ml) 48 hours after treatment (B). Data are shown as relative expression (±SD) of 4 independent 
experiments Statistical analysis: One way ANOVA with Dunnett’s multiple comparison test. (n.t. = non-treated). 
*p<0.05, **p<0.01.  
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 Sfrp1 expression in interstitial lung disease (ILD) 3.4.3
Sfrp1 is significantly down-regulated in invading lung fibroblasts as observed in the 3D cell 
culture invasion assay. Moreover, growth factors like TGFβ1 and EGF that play a major role in 
interstitial lung diseases down-regulated Sfrp1 expression in a conventional 2D cell culture 
system. After this extensive characterization of Sfrp1 expression in MLg fibroblasts, the aim was 
to investigate the relevance of Sfrp1 down-regulation in ILD. Therefore, Sfrp1 mRNA expression 
was investigated in fibroblast lines of ILD patients compared to controls. While no significant 
difference was identified between groups, a trend to lower expression levels in ILD-lines was 
apparent (mean ddCT 1.7 ≡ 3.25-fold).  
 
 
Figure 3.29: Sfrp1 mRNA expression in phF derived from ILD patients.  
Seven control and eight ILD lines were probed for Sfrp1 mRNA expression with qRT-PCR. ILD lines showed a trend to 
lower Sfrp1 transcript levels (n = 7-8). Data are shown as relative expression (±SD). 
 
 
Subsequently, Western blot analysis of in total eight different ILD lung fibroblast lines and seven 
control lines, isolated from lung transplant donors, was performed. Figure 3.30 A depicts a 
representative immunoblot of four control and five ILD lines and Figure 3.30 B densitometric 
quantification, normalized to β-actin, of all eight ILD and seven control lines tested. Importantly, 
Sfrp1 showed overall a trend to be lower expressed in fibroblasts derived from ILD patients 
compared to controls. As control for the degree of fibrosis, the well accepted fibrotic markers 
Col1a1 (Eickelberg and Laurent 2010) and αSMA (Fernandez and Eickelberg 2012a) were probed 
and a slight overall induction of both markers was found in the diseased cells.  
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Figure 3.30: Sfrp1 protein expression in phF derived from ILD patients.  
Representative Western blot of four control and five ILD-derived fibroblast lines. Samples were probed for Sfrp1, 
αSMA and Col1a1 (A). Densitometric quantification of Sfrp1 (B), Col1a1 (C), and αSMA (D), normalized to β-actin 
expression of all phF lines tested (control: n = 7, ILD: n = 8).  
 
 
Next, differences in the invasion capacity of ILD-derived compared to control fibroblasts were 
investigated. Seven ILD (red) and seven control fibroblast lines (grey) were subjected to the 3D 
collagen invasion assay (72 hours) in the absence and presence of EGF (50 ng/ml) for 48 hours. In 
both groups, EGF significantly induced invasion. However, fibrotic and control lines did not differ 
in the invasion capacity. Of note, invasion capacity of single lines within the different groups was 
highly variable (Figure 3.31).  
 
 
Figure 3.31: Induction of phF invasion upon EGF stimulation.  
Software-based quantification of fibroblast invasion by means of 3D reconstructed confocal z-stacks. EGF (50 ng/ml) 
significantly induced fibroblast invasion as assessed 48 hours after treatment. Data-points derived from fibroblasts of 
interstitial lung disease (ILD) patients are highlighted in red circles, control lines in grey circles. Statistical analysis: 
Paired t-test. (n.t. = non-treated). ***p<0.001. 
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Due to these two major observations, first, that Sfrp1 was down-regulated in some, but not all 
ILD-derived fibroblast lines and second, that the invasion capacity between different fibroblast 
lines varied strongly, it was further investigated whether Sfrp1 expression affected the invasion 
capacity of the different lines. Therefore, a correlation analysis of Sfrp1 expression and the 
invasion capacity was performed. Interestingly, Sfrp1 expression negatively correlated with the 
invasion capacity of the different lines only for EGF-induced invasion. This observation was made 
for Sfrp1 mRNA expression, as revealed by qRT-PCR (linear regression; F-value = 5.51 and p-
value = 0.0369 of slope; R2 = 0.316) (Figure 3.32 A) and on protein level, from normalized 
Western blot signals (linear regression; F-value = 13.72 and p-value = 0.0035 of slope; R2 = 0.555) 
(Figure 3.32 B). In conclusion, reduced Sfrp1 expression levels went in line with increased EGF-
induced invasion. Thus, down-regulation of Sfrp1 may be a central event in the process of 
fibroblast invasion.  
 
 
Figure 3.32: Correlation of Sfrp1 expression and EGF-induced fibroblast invasion.  
PhF lines from 14 individual patients were analyzed for Sfrp1 expression and EGF-induced invasion capacity. A strong 
negative correlation between Sfrp1 expression was found on mRNA level (Statistical analysis: linear regression; F-value 
= 5.51 and p-value =0.0369 of slope; R2 = 0.316) (A) and protein level (Statistical analysis: linear regression; F-value = 
13.72 and p-value =0.0035 of slope; R2 = 0.555) (B). Dashed lines represent the linear regression and a confidence 
interval of 95%, respectively. Data points for ILD-derived lines are represented in red. 
 
 
In conventional 2D cell culture systems, MLg fibroblasts showed a significant reduction in Sfrp1 
expression upon TGFβ1 and EGF treatment (Figure 3.27 and Figure 3.28). To verify this 
regulation in phF, Sfrp1 immunofluorescence stainings were performed. Both growth factors, EGF 
(50 ng/ml) and TGFβ1 (5 ng/ml), induced a strong reduction of Sfrp1 expression 24 hours after 
treatment (Figure 3.33). Of note, co-staining with the fibrotic marker αSMA revealed a mutual 
exclusion of Sfrp1 and αSMA positive cells (Figure 3.33 B). This result indicates that Sfrp1 
expression may prevent fibroblast activation in vitro. Expectedly, the content of αSMA positive 
cells in TGFβ1-treated samples was strongly higher than in the non-treated controls.  
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Figure 3.33: TGFβ1 and EGF reduced Sfrp1 protein expression in phF.  
Representative immunofluorescence stainings for Sfrp1 (green) in phF revealed a strong reduction of Sfrp1 expression 
24 hours after treatment with EGF (50 ng/ml) (middle panel) and TGFβ1 (5 ng/ml) (right panel) compared to non-
treated (n.t.) control (left panel). Content of αSMA positive fibroblasts was increased in TGFβ1-treated samples (right 
panel) (A). Co-staining with αSMA (red) discloses a mutual exclusion of Sfrp1 and αSMA, as visualized in the higher 
magnified image (B). Nuclei are stained with DAPI (blue). Scale bar, 100 µm. 
 
 
Subsequently, phF, which were left untreated or stimulated with either EGF (50 ng/ml) or TGFβ1 
(5 ng/ml) were stained for Sfrp1 and for the fibrotic marker Col1a1. For the assessment of cell 
density and morphology, F-actin was visualized with phalloidin. In contrast to the myofibroblast 
marker αSMA, staining of Col1a1 did not reveal a clear exclusion with the Sfrp1 signal in neither 
of the treatment groups (Figure 3.34).  
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Figure 3.34: Co-staining of Sfrp1 and col1a1 in phF.  
Representative images of immunofluorescence stainings for Sfrp1 (green) and Col1a1 (white), phalloidin (red) in non-
treated (n.t.) (upper panel), EGF-, (50 ng/ml) (middle panel) or TGFβ1-treated (5 ng/ml) phF samples (lower panel). 
Nuclei are stained with DAPI (blue). Scale bar, 20 µm. 
 
 
As Sfrp1 is a secreted glycoprotein, it mainly acts extracellular. Thus, besides regulation of Sfrp1, 
localization of the protein in human lung fibroblasts was further assessed. Therefore, fibroblasts 
were stained for Sfrp1 and F-actin in a 2D cell culture system. Z-stacks were acquired by means of 
confocal immunofluorescence microscopy 48 hours after plating the cells. Thereupon, signals for 
Sfrp1 in images of each plane from the upper to the lower side of the cell were evaluated. A 
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maximum intensity projection of a x-z orthoview indicated that phF secreted Sfrp1 on the side of 
the cell contact with the culture dish.  
 
Figure 3.35: Localization of Sfrp1 in phF. 
Confocal immunofluorescence microscopy showed a deposition of secreted Sfrp1 (green) on the basal side of fibroblasts. 
Five images of a z-stack are depicted starting from the basal (0 µm) to the apical (4.9 µm) side of the cell (upper panel). 
The maximum intensity projection of a x-z orthoview is shown in the lower panel. F-actin was stained with phalloidin 
(red) and nuclei with DAPI (blue). Scale bars, 20 µm. 
 
 
  Functional characterization of Sfrp1 in invading fibroblasts  
For the functional characterization of Sfrp1 in the context of fibroblast invasion, a specific Sfrp1 
inhibitor, the diarylsulfone sulfonamide derivate 5-(benzenesulfonyl)-N-[3-
(dimethylamino)propyl]-2-ethylbenzenesulfonamide, (CHEMBL473916) (EC50 = 1.27 µm 
(Gopalsamy, Shi et al. 2008)) was utilized. First, activation of the canonical Wnt-signaling 
pathway by the inhibitor was monitored and thus the working concentration of the inhibitor titrated 
in the presence of recombinant Wnt3a by means of a TCF luciferase reporter (TOP/FOP) assay. 
For the assay, MLg fibroblasts were transfected with TOPFLASH or FOPFLASH reporter 
plasmids. Cells were treated with Wnt3a (100 ng/ml), recombinant human (rh) Sfrp1 (1 µg/ml), or 
CHEMBL473916 (10 µM, 30 µM) five hours after transfection and subsequently luminescence as 
read-out for luciferase activity was measured. A significant reporter activity induction was 
detected after Wnt3a (100 ng/ml) stimulation, which was counteracted by the co-treatment with rh-
Sfrp1. Co-stimulation with the Sfrp1-inhibitor CHEMBL473916 potentiated the Wnt3a induced 
luciferase activity. Thereby, CHEMBL473916 showed highest effects when used in a 
concentration of 30 µM. Consequently, CHEMBL473916 was used in a dose of 30 µM in all 
further experiments (Figure 3.36).  
3.4.4
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Figure 3.36: Titration of the Sfrp1-inhibitor CHEMBL473916 with TCF luciferase (TOP/FOP) assay.  
MLg fibroblasts were transfected with TOP/FOPFLASH reporter constructs and treated with Wnt3a (100 ng/ml), rh-
Sfrp1 (1 µg/ml) and/or Sfrp1-inhibitor (10 µM, 30 µM). Luciferase activity was assessed by means of luminescence 
measurement of TOP-transfected cells and normalized to the respective FOP-transfected counterparts. Data are shown in 
relation to Wnt3a treated group for three independent (n = 3) experiments (±SD). Statistical analysis: One way ANOVA 
with Dunnett’s multiple comparison test. (n.t. = non-treated). *p<0.05, **p<0.01, ***p<0.001. 
 
 
To study whether the inhibition of Sfrp1 by CHEMBL473916 induces fibroblast invasion, MLg 
cells were treated with the inhibitor (30 µM) in the 3D collagen invasion system. Invasion capacity 
was assessed 48 hours after treatment. Inhibition of Sfrp1 significantly augmented invasion from 
10.78 ± 3.20% to 16.41 ± 3.46%. In combination with the pro-invasive growth factor EGF (50 
ng/ml) this effect was further enhanced to 26.41 ± 5.29%, which might be explained by a 
synergistic effect of Sfrp1 down-regulation by EGF and functional inhibition of Sfrp1 with 
CHEMBL473916 (Figure 3.37 A). Of note, CHEMBL473916 (30 µM) did not induce cell toxicity 
in the MLg cells, as assessed by total cell counts (Figure 3.37 B).   
To assess whether Sfrp1 inhibition specifically modified 3D invasion or whether the effects 
seen resulted from increased cell motility in general, 2D migration assays were performed. 
Fibroblasts were treated with CHEMBL473916 (10 µM, 30 µM) in a conventional 2D cell culture 
system. Live cell imaging was conducted 24 hours after stimulation for 48 hours. The assay did not 
reveal an impact of Sfrp1 inhibition on 2D motility with a mean baseline motility rate of 0.29 ± 
0.04 µm/min and 0.27 ± 0.04 µm/min (10 µm), 0.26 ± 0.01 µm/min (30 µM) after Sfrp1 inhibition 
(Figure 3.38). Therefore, inhibition of Sfrp1 might exclusively alter fibroblast invading migration 
behavior in a 3D environment, as mimicked by the collagen-based invasion assay but not 
migration on 2D surfaces.  
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Figure 3.37: Induction of fibroblast invasion by Sfrp1 inhibition.  
Sfrp1 was specifically inhibited by CHEMBL473916 (30 µM) in MLg fibroblasts (red circle) and invasion capacity 
measured in the 3D collagen invasion assay compared to control (open circles). The inhibitor significantly enhanced 
invasion to 16.41 ± 3.46% compared to 10.78 ± 3.20% in the non-treated control. Invasion was monitored 72 hours after 
plating and 48 hours after treatment. In addition cells were either only treated with EGF (50 ng/ml) (grey triangles) or a 
combination of EGF and the inhibitor (red triangle). Total relative cell counts, normalized to the mean of the untreated 
control (B). Data are shown in five technical replicates per each of eight independent experiment (n = 8) (±SD). 
Statistical analysis: One way ANOVA with Dunnett’s multiple comparison test. (n.t. = non-treated). *p<0.05, 
***p<0.001. 
 
 
Figure 3.38: Assessment of 2D motility of MLg fibroblasts after Sfrp1 inhibition CHEMBL473916.  
Inhibition of Sfrp1 with CHEMBL473916 (10 µM, 30 µM) did not significantly alter 2D motility of MLg fibroblasts 24 
hours after treatment. Data are shown as mean motility (±SD) of 3 independent experiments (n = 3).   
 
 
In summary, within this study, 3D collagen-based invasion assays were established and validated. 
On hand of these 3D cell culturing models, the whole transcriptome profile of fibroblast invasion 
was unraveled. This signature was furthermore extended to TGFβ1-mediated cell invasion. In 
search of novel target genes associated with fibroblast invasion, Sfrp1 was identified in the 
inherent and TGFβ1-mediated transcriptomic signature. Subsequently, a connection between ILD 
and fibrogenic growth factor signaling with low Sfrp1 expression levels in phF was established. 
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Thereupon, Sfrp1 was validated as a protective functional target for fibroblast invasion in the 
established 3D collagen-based invasion assay.  
These data provide strong evidence that Sfrp1 acts as modifier of fibroblast invasion in 
general and in the context of fatal lung diseases, such as ILD.   
 
 
 
 
DISCUSSION 
81 
 
 
4. DISCUSSION 
Tissue repair that takes place as a physiological dynamic response to lung injury is highly 
dependent on a versatile and active fibroblast phenotype that eventually restores the lung 
architecture. When fibroblasts become aberrantly activated, tissue repair processes cumulate in 
excessive lung remodeling, as seen in IPF. In the fibrotic lung, activated fibroblasts infiltrate the 
lung interstitium, form fibroblastic foci, and deposit high amounts of ECM.  
The current study concentrated on one essential feature of activated fibroblasts, their tissue 
invasion capacity. Although, this invasive fibroblast phenotype in IPF has frequently been reported 
in scientific literature (Suganuma, Sato et al. 1995), (Li, Jiang et al. 2011), (White, Thannickal et 
al. 2003), it has not comprehensively been characterized thus far.  
Using the herein established 3D invasion models, invading fibroblasts were extensively 
profiled. Microarray analysis of invading and non-invading fibroblast phenotypes resulted in a 
transcriptome signature of cellular invasion. Confirmative for the model approach, this invasion 
signature included several markers reported to be involved in cellular invasion and/or fibrosis i.e. 
TGFβ1, MMP13, Caveolin 1 (Cav1), and Phosphatase and tensin homologue deleted on 
chromosome 10 (Pten). Applying the invasion signature to system biological analysis with the help 
of Ingenuity® Pathway Analysis (IPA) software, a significant enrichment of the biological 
processes “invasion of cells”, “IPF”, and “metastasis” was further unraveled.  
In order to specify fibroblast invasion in the context of IPF, effects of profibrotic growth 
factors, in particular TGFβ1, were analyzed with the 3D invasion model. In line with the literature, 
TGFβ1 was identified as a pro-invasive cytokine (Zolak, Jagirdar et al. 2013). Thereupon, the gene 
expression profile of invading fibroblasts was extended to TGFβ1-mediated invasion. The 
overlapping signature of base-line and TGFβ1-mediated invasion comprised 193 genes, including 
Sfrp1. Sfrp1 was significantly down-regulated upon invasion and growth factor treatment, as 
assessed on mRNA and protein level. A connection of Sfrp1 expression levels and invasion was 
not only elaborated for TGFβ1 but moreover Sfrp1 expression and EGF induced invasion 
correlated negatively in primary human fibroblasts from different patients.  
These data delineate for the first time a comprehensive description of the whole transcriptome 
profile of fibroblast invasion assessed by means of a novel collagen-based 3D high-throughput 
invasion assay.  
 
4.1 3D ECM model systems for extensive profiling of invasive cell types 
The first goal of this current thesis was to establish valid 3D cell culture models, enabling the 
extensive characterization of fibroblast invasion. The first model, termed invasion assay, a 
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collagen-based 3D cell culture model in 96-well format, was developed using MLg fibroblasts. 
This model allowed an assessment of cellular invasion capacity in a high-throughput manner. 
Collagen type I matrices were chosen as model ECM structure as collagen is one of the most 
abundant ECM proteins and collagen type I is heavily deposited in fibrotic diseases such as 
pulmonary fibrosis (Vasaturo, Caserta et al. 2012), (Wolf, Alexander et al. 2009), (Chien, Richards 
et al. 2014). Furthermore, according to the literature, polymerized collagen type I used in a 
concentration of 3.2 mg/ml was expected to give rise to an environment of comparable stiffness to 
healthy lung parenchymal tissue (Liu, Mih et al. 2010), (Harjanto, Maffei et al. 2011).  
To date, cell motility has widely been studied in 2D cell culture systems. Prevailing 2D 
migration assays are wound healing or scratch assays, transwell migration assays, capillary 
chamber or tube assays or time-lapse cell tracking (reviewed in (Kramer, Walzl et al. 2013)). 
However, there is a fast-growing body of literature indicating that the migratory behavior of 
mesenchymal cells, which physiologically reside in the ECM, should be studied in a 
physiologically more relevant 3D environment rather than on 2D plastic surfaces (Cukierman, 
Pankov et al. 2002). Moreover, dimensionality and structure of the cell culture system were 
reported to influence signaling of mechanoregulatory growth factors, such as TGFβ1 (Grinnell and 
Ho 2002), (Brown, Sethi et al. 2002) and the mode of cellular adhesion (Cukierman, Pankov et al. 
2001). Based on this knowledge, several 3D invasion assays have been developed in the past. 
These assays range from 3D cell tracking assays using time-lapse microscopy to spheroid gel 
invasion assays. Spheroid-based assays have mainly been used to assess tumor outgrowth and 
metastasis behavior of neoplastic epithelial cells. Another invasion assay, commercialized by 
Platypus (Oris™) works with assessment of cellular infiltration into a cell exclusion zone (Joy, 
Vollmer et al. 2014).  
The invasion assay, established here, can be seen as a variant form of organotypic skin models 
or vertical gel invasion assays. Vertical invasion assays have been used over a long period of time 
to assess for example lymphocyte migration (Schor, Allen et al. 1983) or behavior of carcinoma 
cells in a 3D co-culture system in the presence of stromal fibroblasts (Timpson, McGhee et al. 
2011). In those studies, evaluation of invasion behavior was accomplished by counting extracted 
cells, scintillation counting of radioactive labeled cells, or immunohistochemical stainings 
(Kramer, Walzl et al. 2013). This current study extended the applicability of the vertical invasion 
assay by implementing an automated analysis method resulting in, to my knowledge, an 
unprecedented modified high-throughput invasion assay.  
Resulting from the high-throughput format of the established invasion assay, this model 
potentially enables also the screening for compounds interfering with the invasion capacity of 
cells. In the course of this study, compounds resulting from a bioinformatical approach on the 
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identified invasion signature (see section 3.3.1) and the proteasome inhibitor oprozomib (ONX 
0912) were tested. Selected compounds investigated in the course of this study did not include 
effective candidates and were therefore not further elaborated in this thesis.  
The second 3D cell culture model, termed separation assay, that was established, allowed the 
physical separation of invading and non-invading fibroblasts by the combination of a porous 
polyethyleneterephthalate (PET) membrane and a collagen I matrix. This setup enabled the 
systematic identification of the molecular signature of fibroblast invasion by whole transcriptome 
analysis of invading and non-invading cell fractions following their physical separation. Thus far, 
conventional invasion assays described before were solely deployed to assess cellular invasion, but 
were not used for a detailed molecular profiling of the invading cellular phenotype.   
Altogether, the two newly established assays may be superior to former published assays, as 
they are easily performed and most importantly can be applied for measuring the invasion capacity 
in combination with a concomitant extensive molecular and biochemical profiling. 
 
4.2 Growth factor mediated fibroblast invasion 
The parenchymal invasion of activated lung fibroblasts is a central event in IPF, a disease highly 
driven by growth factors. Therefore, the relation between growth factor signaling and fibroblast 
invasion was of particular interest. TGFβ1 and EGF were found to significantly induce fibroblast 
invasion in vitro, suggesting a pivotal role of these growth factors in fibroblast activation. 
As reported, the pleiotropic fibrogenic cytokine TGFβ1 is a key regulator of IPF (Fernandez 
and Eickelberg 2012a). With respect to mesenchymal activation, TGFβ1 was found to induce 
proliferation, as well as synthesis and deposition of ECM, specifically collagen type I (Cutroneo, 
White et al. 2007). Furthermore, TGFβ1 was shown to elicit the transformation of several cell 
types into activated fibroblasts, including epithelial, endothelial cells and pleural mesothelial cells 
(PMCs) (Gao, Yan et al. 2015), (Nasreen, Mohammed et al. 2009), (Montorfano, Becerra et al. 
2014).  
The role of TGFβ1 for PMC-mesenchymal transition, as well as dissemination of fibrotic 
lesions in the lung interstitium was recently demonstrated by Zolak et al.. By tracking PMCs after 
intratracheal TGFβ1 instillation in mice, expressing green fluorescence protein exclusively in 
PMCs through the control of the Wilms tumor-1 promoter, the authors could verify TGFβ1-
induced infiltration of PMCs into the lung interstitium with a concomitant mesenchymal transition 
(Zolak, Jagirdar et al. 2013). These data highlight the importance of TGFβ1-induced interstitial 
invasion of mesenchymal cells in IPF pathogenesis.  
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Moreover, in cancerous diseases, TGFβ has been linked to tumor invasiveness and dissemination 
(Massague 2008). In this context, paracrine crosstalk between cancer cells and cancer associated 
fibroblasts (CAF) from the neoplastic stroma by TGFβ1 has recently been recognized as an 
important contributor for an aggressive phenotype of breast cancer (Yu, Xiao et al. 2014). 
In addition to TGFβ1, a second growth factor, EGF; was tested for its capacity to induce 
fibroblast invasion. EGF was chosen as it represents a noted pro-invasive cytokine for cancer cells 
(Lu, Jiang et al. 2001) and dermal fibroblasts (Gobin and West 2003). In the established 3D 
invasion assay, EGF was found to strongly increase fibroblast invasion, thus verifying the model 
approach and providing a potent positive control for cellular invasion.  
In summary, in the present study TGFβ1 and EGF were successfully demonstrated to be 
positive effectors of fibroblastic invasion in the newly established 3D cell culture model. 
 
4.3 Phenotypic characterization of fibroblasts cultured in 3D  
For mesenchymal cells that physiologically reside in the lung interstitium, adaptive and reciprocal 
interactions between cells and surrounding matrix are well recognized (Cukierman, Pankov et al. 
2002). The 3D environment may trigger cellular responses, such as adhesion or migration status of 
the cells. These changes may be reflected in the cellular morphology. Accordingly, Hakkinen and 
colleagues compared effects of different environments on the cell morphology and could identify 
matrix-dependent influences (Hakkinen, Harunaga et al. 2011), (Rhee 2009). Here, we used the 
assessment of fibroblast morphology as a measure to describe the invading fibroblast phenotype in 
the established 3D invasion assay. Fibroblasts that spontaneously invaded the collagen matrix had 
a distinct morphology compared to fibroblasts that remained on top of the matrix in the course of 
the culturing period. The invading fraction had a highly elongated or cylindrical phenotype as 
determined by length/width ratios and their significant low sphericity values. Invading fibroblasts 
further seemed to exhibit fewer lateral protrusions, which may indicate persistent directionality of 
cell orientation. Thus, fibroblasts within the 3D collagen matrix were found elongated and 
polarized, indicating that the cell is in the active process of 3D invasion (Friedl and Wolf 2003). 
Additionally, both cell fractions, invading and non-invading, outlined against fibroblasts cultured 
in 2D, which had a highly spread morphology. These findings are in line with previous studies, 
where comparable significant changes in cell morphology between fibroblasts cultured in 2D and 
3D were reported (Hakkinen, Harunaga et al. 2011). As integrins are the main adhesion receptors 
responsible for the bi-directional signal transduction between ECM and embedded cells (Arnaout, 
Mahalingam et al. 2005), integrin assembly and activation status for cells cultured in the invasion 
model remain intriguing open questions. In the course of to current study, thin fibrillar adhesion-
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like structures, which stained positive for integrin β1 (CD29) were visualized along F-actin fibres 
of fibroblast embedded in the collagen matrix. 
In order to exclude effects of the collagen type I matrix on cell viability as stated previously 
(Xia, Diebold et al. 2008), intact cell cycle turnover for collagen-embedded fibroblasts was 
verified by nuclear Ki67 staining. Subsequently, completing the characterization of fibroblasts 
cultured in the invasion assay, fibroblasts embedded in collagen were found to secrete high 
amounts of fibronectin. Accordingly, embedded fibroblasts maintained their function as ECM 
producing cells and may refine the composition of the surrounding ECM structure. Furthermore, 
substantial expression of vimentin, a major intermediate filament and important component of 
motile mesenchymal cells, provided evidence for intact cellular mechanical integrity of fibroblasts 
in the 3D collagen-based cell culture system (Mendez, Restle et al. 2014), (Shabbir, Cleland et al. 
2014).  
In conclusion, fibroblasts embedded in collagen matrix exhibit a distinct morphological 
phenotype, are proliferative, and express characteristic mesenchymal markers.  
 
4.4 Analysis of the gene profile of fibroblast invasion 
To date, studies investigating invasion capacity of cells have mainly focused on single factors 
(White, Thannickal et al. 2003), (Li, Jiang et al. 2011), (Goetz, Minguet et al. 2011), (Sabeh, Li et 
al. 2009) and have not implemented a systems biology approach. Here, using the established 3D 
separation assay, the whole transcriptome signature of the invading fibroblast phenotype was 
unraveled by microarray analysis.  
Initially, arrays were conducted at two different time-points of invasion. A systematic 
comparative analysis (IPA) was performed to substantiate the fibroblast invasion signature and 
narrow down the number of promising targets. The pathway analysis of the overlapping invasion 
signature of both time-points identified a significant enrichment for the biological processes 
“invasion of cells”, “idiopathic pulmonary fibrosis”, and “metastasis”. As outlined in section 3.3.1, 
the underlying molecular networks of these functional clusters revealed that the invasion signature 
featured a profile of matrix degradation, several prevailing IPF-associated transcripts, as well as 
members of the CCN and TGFβ-superfamilies. 
Regarding the functional cluster of matrix degradation, the Matrix Metallo-proteinases 
(MMPs), MMP13, MMP3, and MMP10 were found to be up-regulated in the invading cellular 
subpopulation at both time-points. These zinc-dependent endopeptidases may assist in the protease 
dependent process of interstitial migration. However, as in a very recent study MMPs were found 
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to also regulate cancer amoeboid migration (Orgaz, Pandya et al. 2014), these findings do not 
implicitly imply a mesenchymal rather than amoeboid mode of migration in the invasion model.  
Interestingly, in the context of pulmonary fibrosis, an up-regulation of MMP13 along with 
MMP1 and MMP7 in IPF lung homogenates, was reported in the past (Rosas, Richards et al. 
2008), (Bauer, Tedrow et al. 2015), whereby the lung epithelium and interstitial space featured as 
their main source (Nkyimbeng, Ruppert et al. 2013). Furthermore, as reasoned from studies 
showing an increased MMP13 expression in subsets of cancer associated fibroblasts (CAFs), 
MMP13 expression in invading fibroblasts may not solely trigger their own invasion capacity but 
also induce invasion of carcinoma cells (Lederle, Hartenstein et al. 2010), (Lecomte, Masset et al. 
2012). Recently, MMP3 has been reported as a potential systemic biomarker for IPF as disease 
severity was found to be reflected in augmented serum MMP3 levels (DePianto, Chandriani et al. 
2015). In addition, MMP10 was found to be increased in IPF lung tissue (Bauer, Tedrow et al. 
2015). Apart from its role in cellular invasion, MMP overexpression in the disease might further 
indicate ongoing ECM remodeling processes, accomplished by activated fibroblasts. An 
association of this profile of matrix degradation to the clusters “metastasis” and/or “invasion of 
cells” was predicted by IPA.  
Importantly, confirming literature reports, the invasion signature comprised Phosphatase and 
tensin homologue deleted on chromosome 10 (Pten) as down-regulated target at both time-points 
analyzed. As dual protein/lipid phosphatase, Pten dephosphorylates phosphatidylinositol (3,4,5)-
trisphosphate, which leads to an inhibition of the AKT/mTOR pathway (Maehama and Dixon 
1998). Pten has widely been studied in the context of cellular invasion, cancer and fibrosis. 
Accordingly, activated fibroblasts in IPF exhibit decreased Pten expression which correlates with 
increased αSMA expression (White, Atrasz et al. 2006). Moreover, reactivation of Pten activity by 
α4β1 integrin was reported to interfere with an α5β1 integrin-induced invasive phenotype of lung 
fibroblasts (White, Thannickal et al. 2003). In epithelial kidney cells, Pten was described as a 
stabilizer of junctional complexes, thereby preventing transformation to an invasive phenotype 
(Kotelevets, van Hengel et al. 2005). In addition, in the context of IPF, Xia et al. identified that the 
down-regulation of Pten in fibroblastic foci is accompanied by decreased Caveolin 1 (Cav1) levels. 
They postulated that depletion of the integral membrane protein Cav1 reduces membrane-
associated Pten, which in turn favors the activation of PI3K/Akt signal pathway (Xia, Khalil et al. 
2010). The scaffolding protein Cav1 is an important component of the plasma membranes’ 
caveolae, which can assist in triggering a large number of signaling pathways, such as TGFβ, EGF, 
Src, Rho GTPases, and β integrins (reviewed in (Gvaramia, Blaauboer et al. 2013) and (Okamoto, 
Schlegel et al. 1998). Although not included in the list of strongest down-regulated transcripts 
upon invasion, Cav1 showed consistently lower expression in invading fibroblasts. Despite the fact 
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that down-regulation of Cav1 has repeatedly been reported in IPF (Xia, Khalil et al. 2010), (Wang, 
Zhang et al. 2006), literature survey reveals a double-edged role of differential expressed Cav1 in 
the context of cellular invasion and pulmonary fibrosis. Thus, in CAFs elevated levels of Cav1 
favor tumor invasion and metastasis (Goetz, Minguet et al. 2011). In pulmonary fibrosis activation 
of fibroblasts was demonstrated to go along with a decreased Cav1 expression mediated by TGFβ1 
(Shivshankar, Brampton et al. 2012), however Cav1 deficiency has a protective impact in 
experimental fibrosis (Shivshankar, Brampton et al. 2012).  
In addition to Pten and Cav1, the invasion signature featured with autotaxin (ENPP2) one 
further target that has recently been described in pulmonary fibrosis (Oikonomou, Mouratis et al. 
2012), (Tager, LaCamera et al. 2008). This enzyme is mostly responsible for extracellular 
lysophosphatidic acid (LPA) production, which is a potent mitogen. In IPF patients increased LPA 
levels were detected in the alveolar space, with a direct link to pathogenesis. Subsequently, 
increased LPA concentrations could be traced back to elevated autotaxin expression and 
pharmacological inhibition of autotaxin attenuated bleomycin induced fibrosis. In the invasion 
signature, autotaxin ranked among the most significantly up-regulated transcripts and an 
association to the clusters “metastasis” and “invasion of cells” was predicted.  
Collagen invasion also affected members of the CCN protein family which comprises Cyr61, 
CTGF, NOV, and WISP 1-3 (CCN 4-6) (Holbourn, Acharya et al. 2008). While NOV was found 
to be up-regulated upon invasion, expression of CTGF, Cyr61, and WISP1 was negatively 
affected. Thus, collagen invasion significantly regulated the expression of four out of six members 
of this matricellular protein cluster. Considering that CCN proteins play a crucial role in cellular 
processes, such as proliferation, apoptosis, cell adhesion, ECM production and migration (Leask 
and Abraham 2006) as well as in pulmonary fibrosis (Konigshoff, Kramer et al. 2009), collective 
regulation of this cluster upon cellular invasion may pose an interesting finding in the generated 
invasion signature. 
Of interest, TGFβ1 was found differentially regulated in the invading fibroblasts, hence the 
invasion induced transcriptome signature included the key mediator of fibrogenesis. Considering 
the pro-invasive property of TGFβ1, up-regulation of this growth factor in the invading fibroblast 
phenotype might be of particular interest as increased TGFβ1 levels potentially induce a feed-
forward loop of fibroblast activation. TGFβ1 was associated with all three enriched clusters 
“invasion of cells”, “idiopathic pulmonary fibrosis”, and “metastasis”. Notably, two further 
members of the TGFβ-superfamily, bone morphogenic protein 4 (BMP4) and osteoglycin (Ogn) 
were found to be differentially regulated in the invading fibroblasts. BMP4 mainly functions in 
skeletal repair, regeneration and kidney formation and was identified to be involved in the 
pathogenesis of pulmonary hypertension (Bragdon, Moseychuk et al. 2011) (Frank, Johnson et al. 
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2005). Strikingly, while BMP4 was significantly down-regulated, the inhibitor of BMP4 signaling, 
gremlin 2 (Grem2), was found to be upregulated upon invasion. Moreover, Gremlin is known to be 
overexpressed in IPF (Koli, Myllarniemi et al. 2006). Most recently, BMP4 was identified in a 
genomic IPF signature albeit an up-regulation was reported here (Bauer, Tedrow et al. 2015).  
In summary, these molecular changes highlight the potential relevance of the generated 
invasion signature in IPF pathogenesis.  
 
4.5 TGFβ1-induced invasion gene profile and strategy for target selection 
In the course of this thesis, the key fibrogenic cytokine TGFβ1 was verified as a pro-invasive 
mediator. Remarkably, expression of TGFβ1 was found to be increased in fibroblasts upon 
collagen invasion at both time-points tested. As outlined in section 4.4, this might indicate that via 
TGFβ1 invading fibroblasts initiate a feed-forward loop of fibroblast activation. Therefore, we 
sought to profile the TGFβ1-mediated invasion signature. Interestingly, overall expression data 
clustered on the first hierarchical level in invading and non-invading groups, which subdivided 
into non-treated and TGFβ1-treated on the second hierarchical level, indicating a very distinct 
invasion dependent gene profile.  
In the TGFβ1-induced gene profiles, differential expression between 1) non-invading treated 
and untreated, as well as 2) invading treated and untreated was monitored. A proof for effective 
stimulation by TGFβ1 was found in both signatures, as for example TGFβ1 strongly induced 
expression of C1q and tumor necrosis factor related protein 3 (C1qtnf3), which is in line with the 
literature. Accordingly, Hoyles et al. reported an TGFβ1 dependent induction of C1qtnf3 in 
primary mouse fibroblasts which was less pronounced in fibroblasts of TGFRII knockout animals 
(Hoyles, Derrett-Smith et al. 2011).  
As in the context of IPF pathogenesis TGFβ1-mediated cellular invasion might be of specific 
interest, congruently regulated genes in the baseline invasion signature and TGFβ1-mediated 
invasion signature were considered in particular for subsequent functional investigations. In order 
to filter relevant candidates for TGFβ1-regulated invasion, the overlap of the baseline invasion 
signature and the TGFβ1-induced signature in invading fibroblasts was revealed by systematic 
comparative analysis. IPA analysis showed that both gene profiles integrated in functional clusters 
of invasion, morphogenesis, and carcinogenesis-related pathways. The molecular basis of the 
overlapping signature comprised among others Grem2, BMP4, Ogn, Pten, and Sfrp1. This strategy 
not only allowed for enrichment of invasion relevant targets but also for the exclusion of targets 
found with reversed regulation. Thus, TGFβ1 for example strongly down-regulated Enpp2, one 
target found to be highly up-regulated upon invasion. Additionally, members of the CCN protein 
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family (CTGF, WISP1, Cyr61), which were found repressed in the invasion signature, were 
induced by TGFβ1.  
Of note, aligning the invasion signature to TGFβ1-induced invasion was one approach used to 
screen for targets of interest. Nevertheless, since TGFβ1 is not considered as the exclusive 
regulator of fibroblast invasion, the baseline invasion signature harbors numerous further targets of 
interest in the context of fibroblast invasion as described in section 3.3.1.  
 
4.6 Sfrp1 as functional target for fibroblast invasion 
With the strategy on target selection described above, several potential invasion critical candidates 
were extracted from the invasion signature including Sfrp1. Sfrps belong with the Dickkopf 
protein family (DKK), Wnt inhibitory factor-1 (WIF-1), Nemo-like kinase (NLK), and β-catenin 
binding inhibitors to a group of endogenously expressed Wnt-signaling modulators. Thereby, Sfrps 
antagonize Wnt-signaling by preventing binding of Wnt ligands to their receptors, Frizzled (FZD), 
either by direct binding of Wnt or the formation of non-functional complexes with FZD (Baarsma, 
Konigshoff et al. 2013). In mammals, the Sfrp family of secreted glycoproteins comprises five 
members: Sfrp1 thru Sfrp5 (Surana, Sikka et al. 2014). Of these members, Sfrp1 was exclusively 
found to be down-regulated in the invasion signature. In the current study, Sfrp1 attracted 
particular interest as in the context of ILD, Wnt-signaling pathways have widely been shown to be 
up-regulated. (Konigshoff, Kramer et al. 2009), (Vuga, Ben-Yehudah et al. 2009). However, the 
potential role of Sfrp1 in this context is not known in detail. In regards to Wnt pathway 
involvement in pulmonary fibrosis, Königshoff et al. revealed an activation of the canonical 
Wnt/β-catenin pathway in experimental fibrosis (Konigshoff, Balsara et al. 2008). In addition, 
Vuga et al. identified an induction of the non-canonical Wnt pathway ligand Wnt5a in fibroblasts 
derived from UIP compared to healthy lungs in a gene expression study (Vuga, Ben-Yehudah et al. 
2009).  
Corroborative incidence for Wnt-signaling in IPF currently arose from further large gene 
expression studies. Accordingly, Bauer and colleagues reported a regulation of Wnt/β-catenin 
pathway associated molecules in the genomic signature of IPF lungs. Interestingly, this signature 
included an up-regulation of Sfrp2 (Bauer, Tedrow et al. 2015), which was not observed in the 
present study.  
Here, not only was a significant down-regulation of Sfrp1 on mRNA and protein levels in 
invading MLg and phF demonstrated, but correlation studies also manifested a significant 
association of Sfrp1 expression and the invasion capacity of phF. Accordingly, low Sfrp1 levels in 
phF indicated a high EGF-induced invasion capacity and vice versa. However, the baseline 
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invasion capacity of phF lines could not be predicted by Sfrp1 expression levels. This might 
indicate that low Sfrp1 expression levels in phF provide a pro-invasive environment on which a 
second trigger may act.  
In various cancerous diseases, including lung cancer, silencing of Sfrp1 has frequently been 
reported, thus assigning Sfrp1 to well established tumor suppressor genes. In the context of 
carcinogenesis, a tumor-suppressive role through mediation of apoptosis by p53 has been ascribed 
to Sfrp1 (Gauger and Schneider 2014). Furthermore, Sfrp1 was suggested as a potential marker for 
breast cancer progression, as silencing of Sfrp1 was found to be associated with adverse tumor 
progression (Veeck, Niederacher et al. 2006). Interestingly, regarding cellular invasion, ectopic 
expression of Sfrp1 in invasive human derived MDA-MB-231 adenocarcinoma cells attenuated 
tumor outgrowth and lung metastases by reducing the migratory potential of the cells (Matsuda, 
Schlange et al. 2009). Additionally, Sfrp1 along with Sfrp2 was reported to prevent transition of 
cervical cancer cells and concomitant invasion through Wnt-signaling (Chung, Lai et al. 2009). In 
the established invasion model, inhibition of Sfrp1 by a diarylsulfone sulfonamide derivate 
significantly increased invasion of MLg fibroblasts. The concentration of the Sfrp1 inhibitor was 
titrated by means of the TCF/LEF luciferase reporter assay and thus adjusted to the canonical Wnt-
signaling pathway. Invasion, induced by Sfrp1 inhibition was further enhanced by EGF 
stimulation, which may be explained by a synergistic effect of functional inhibition of Sfrp1 and 
pro-invasive EGF activity. Due to limitations in cell viability upon lipotransfection of small 
interfering RNAs in the 3D cell culture models, effects of Sfrp1 knock-down on the invasion 
capacity could not be studied.  
Interestingly 2D migration, as assessed by automatic cell tracking, was not affected by 
functional inhibition of Sfrp1. Altogether, Sfrp1 was found to be more highly expressed in non-
invading fibroblasts on the collagen surface than in invading fibroblast within the matrix and 
functional inhibition of Sfrp1 induced an invading fibroblast phenotype without affecting lateral 
2D migration (Figure 4.1).  
One could speculate that Sfrp1 might particularly affect cellular processes exclusively 
important for cell invasion, such as matrix degradation and reciprocal cell matrix effects. 
Remarkably, in silico analysis (IPA) revealed an interaction of Sfrp1 and MMPs, which is detailed 
below.  
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Figure 4.1: Schematical illustration of Sfrp1 expression in fibroblasts upon collagen invasion. 
In vitro, fibroblasts that remained on the collagen surface exhibit high Sfrp1 expression levels (green) (1). Down-
regulation of Sfrp1 induces fibroblast invasion (2). Invading fibroblasts exhibit low Sfrp1 levels (yellow) (3). Lateral 
migration might not be affected by Sfrp1 expression. 
 
 
Although, a detailed analysis of downstream effects of Sfrp1 was beyond the scope of this 
thesis the transcriptome invasion signature was used to create a Sfrp1-referred molecular network 
to delineate future research directions around Sfrp1 in the context of fibroblast invasion (Figure 
4.2). Based on the IPA knowledgebase, low expression levels of Pten, as found in the invasion 
signature, may favor low Sfrp1 expression (Bronisz, Godlewski et al. 2012). Furthermore, down-
regulation of Sfrp1 is predicted to contribute to higher expression and activation of MMP9 and 
MMP3. Based on this prediction, it might be highly promising to investigate expression and 
activity of MMPs in light of the fact that the inhibition of Sfrp1 increases cellular invasion without 
affecting 2D motility (Figure 4.1).  
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Figure 4.2: Prediction on up- and down-stream effects of Sfrp1 in the conducted invasion signature. 
A molecular network around the invasion transcriptome signature (> 1.5-fold, 96 hours) was generated using the up- and 
down-stream function algorithm (IPA). Hepatocyte growth factor (HGF), TGFβ1 and Epidermal growth factor receptor 
(EGFR), histone H4, and Pten were found upstream of Sfrp1. Predicted downstream targets of Sfrp1 were MMP10, 
MMP3, MMP9, and SRY (sex determining region Y)-box 9 (SOX9).  
 
 
4.7 Regulation of Sfrp1 in interstitial lung disease (ILD)-related 
environments 
In the course of the current study, the pro-invasive cytokines TGFβ1 and EGF were found to 
significantly diminish Sfrp1 expression in fibroblasts while functional inhibition of Sfrp1 induced 
an invading phenotype. This might indicate that pro-invasive effects of these growth factors might 
in part be mediated by down-regulation of Sfrp1 although further studies, including for example 
overexpression of Sfrp1, are needed to prove this hypothesis.  
As outlined in the previous section, Sfrp1 acts as a tumor suppressor gene. Accordingly, 
aberrantly low expression of Sfrps has frequently been observed in cancer, such as lung, kidney, 
ovarian or breast tumors (Surana, Sikka et al. 2014). Additional, studies furthermore provided 
evidence that this down-regulation is caused by epigenetic silencing, primarily promoter 
hypermethylation. Accordingly, Sfrp1, Sfrp2, and Sfrp4 promoter hypermethylation were reported 
in cervical cancer (Chung, Lai et al. 2009). Notably, Zhu et al. could demonstrate a negative 
correlation of Sfrp1 and Sfrp5 promoter methylation with EGFR mutation (Zhu, Wang et al. 
2012), indicating EGF-induced Sfrp promoter hyper-methylation. In human A549 lung 
adenocarcinoma cell line, diminished Sfrp1 expression has recently been reported upon TGFβ1 
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stimulation with a concomitant induction of cell migration and invasion (Ren, Wang et al. 2013). 
However, in the context of mesenchymal invasion in ILD, the mode of Sfrp1 silencing still 
remains elusive.  
As highlighted above, Sfrp1 represents a secreted inhibitor of canonical and non-canonical 
Wnt-signaling pathways, which are involved in pathogenesis of several cancers and 
fibroproliferative diseases in different organs (Clevers 2006), (Yeang, McCormick et al. 2008). 
Taking into consideration that TGFβ1 potentially activates both Wnt-signaling pathways (Carre, 
James et al. 2010), (Kumawat, Menzen et al. 2013), down-regulation of Sfrp1 by TGFβ1 might 
represent a link for cross-activation of Wnt-signaling by TGFβ1. Interestingly, an interchanged 
relationship has also been reported by Gauger et al. as they identified an increased sensitivity to 
TGFβ1 signaling upon Sfrp1 reduction in mammary epithelial cells (Gauger, Chenausky et al. 
2011). Therefore, it might be worth to further investigate the role of Sfrp1 in TGFβ1 Wnt-
signaling crosstalk especially in the background of pulmonary fibrosis.  
In summary, TGFβ1 and EGF were found to diminish Sfrp1 expression and secretion in MLg 
fibroblasts as well as Sfrp1 deposition by primary human fibroblasts. Cytokine-induced Sfrp1 
depletion in fibroblasts may represent an initiating event for invasion. Additionally, invading 
fibroblasts were found to express higher levels of TGFβ1, which might in turn initiate activation of 
adjacent cells (Figure 4.3).   
 
 
Figure 4.3: Suppression of Sfrp1 expression by TGFβ1 and EGF. 
TGFβ1 and EGF inhibit expression and secretion of Sfrp1 whereupon fibroblasts acquire an invading phenotpye. 
Activated, invading fibroblasts in turn secrete higher levels of TGFβ1 thus theoretically activating adjacent fibroblasts.   
 
 
The final part of this thesis aimed to establish a link between Sfrp1 expression and interstitial lung 
disease (ILD). For this purpose, fibroblasts derived from ILD patients were probed for Sfrp1 
expression. Although no significant down-regulation of Sfrp1 in ILD compared to non-ILD 
fibroblasts could be proven, a clear trend towards lower Sfrp1 levels in diseased fibroblasts 
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emerged. However, as discussed above, an overall significant correlation between Sfrp1 
expression and EGF-induced invasion capacity was found in phF.    
Interestingly, transcriptional silencing was recently discovered in fibroblasts derived from 
keloid lesions (Russell, Russell et al. 2010), Systemic Sclerosis (Dees, Schlottmann et al. 2014), 
and IPF fibrotic lungs (Hsu, Shi et al. 2011). Further, Sfrps were reported to inhibit collagen 
synthesis and improve tissue function in experimental tissue injury models. Thus, Sfrp4 
administration following unilateral ureteral obstruction ameliorated experimental renal fibrosis 
(Surendran, Schiavi et al. 2005). Along with these findings, exogenously administered Sfrp2 
prevented right ventricle fibrosis in an experimental myocardial infarction model with a significant 
reduction in collagen type 1 deposition (He, Zhang et al. 2010). Hence, Sfrp silencing in fibrotic 
fibroblasts was predominantly linked to increased ECM deposition and not to the invasive 
behavior of the cells, as elaborated in the current study. Regarding this perspective of the disease, 
increased invasion capacity of fibroblasts, derived from fibrotic lungs has frequently been reported 
in the literature (Suganuma, Sato et al. 1995), (Li, Jiang et al. 2011), (White, Thannickal et al. 
2003). Although, this coherence could not be verified in the current study, which might be due to 
limitations in patient numbers, a significant correlation of low Sfrp1 expression levels in ILD-
derived fibroblasts with an elevated invasion capacity was found.  
Therefore in conclusion, our findings may add a new aspect of the impact of Sfrp1 silencing in 
fibrotic diseases, especially ILD.  
 
4.8 Conclusion and future directions 
Two novel 3D collagen-based invasion models emerged from this study. Using these 3D models, a 
transcriptome-wide signature of fibroblast invasion was elaborated that delineates this complex 
cellular phenotype to unprecedented detail. The relevance of this signature was validated by an in 
silico (IPA) systemic analysis. With Sfrp1, one invasion relevant target was extracted from the 
invasion signature and analyzed in the context of fibrotic lung disease. A significant down-
regulation of Sfrp1 in response to the cytokines TGFβ1 and EGF was demonstrated. Expression of 
Sfrp1 was further substantially diminished in ILD compared to control derived fibroblasts. 
Importantly, a strong negative correlation between Sfrp1 expression and EGF-induced invasion 
capacity could be shown. In summary, strong evidence was provided for a significant role of the 
established invasion signature in the course of fibrogenesis in ILD. Furthermore Sfrp1 was 
validated as a functional target within the invasion signature and further in vitro studies strongly 
indicated a substantial role of Sfrp1 silencing in fibrogenesis.  
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In the course of the current study, several potential future research directions emerged with regards 
to the invasion signature and Sfrp1 function in pulmonary fibrosis.  
As stated above, besides Sfrp1 the invasion signature harbors several further potential targets 
worth elaborating in the context of fibroblast invasion. These targets include several MMPs, 
Enpp2, BMP4, Ogn and the CCN protein family. Furthermore, a different strategy for target 
selection might be chosen to enrich the invasion signature for targets of interest. For example 
enrichment of the signature by comparative analysis with reported gene profiles of experimental or 
clinical pulmonary fibrosis might reveal further invasion and disease relevant targets (e.g. (Bauer, 
Tedrow et al. 2015)).  
Regarding Sfrp1, the mode of down-regulation was not investigated in the current study. 
Considering frequent reports on promoter hypermethylation as the underlying mechanism for 
aberrant Sfrp silencing in cancer and fibrotic diseases, the methylation status of Sfrp1 upon 
invasion in the 3D collagen matrix might be of further interest.  
As outlined above, detailed analyses on downstream effects of Sfrp1 were beyond the scope of 
this thesis. Nevertheless, the Sfrp1-referred molecular network (Figure 4.2), described in section 
4.6 might assist to delineate future research directions around Sfrp1 in the context of fibroblast 
invasion that include Pten, MMP9, and MMP3.  
Furthermore, it remains an intriguing open question, whether downstream effects of Sfrp1 are 
primarily mediated by the canonical or non-canonical Wnt-signaling pathway. In particular, non-
canonical Wnt-signaling, comprising among others the Wnt/planar cell polarity (PCP), the Wnt-
cGMP/Ca2+, and the Wnt/receptor tyrosine kinase-like orphan receptor 2 (ROR2), is highly 
associated with cell adhesion, formation of filopodia, and migration (Gomez-Orte, Saenz-Narciso 
et al. 2013). These signaling cascades interact with cell division cycle 42 protein (Cdc42), Ras-
related C3 botulinum toxin substrate 1 (Rac1), and Ras homologous A (RhoA) members of the 
small GTPases Rho family, as down-stream effectors, which regulate actin cytoskeleton 
rearrangement. Therefore, one can speculate that the effect of Sfrp1 might potentially be triggered 
by the non-canonical Wnt pathways.  
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6. APPENDIX 
6.1 Scheme for cell morphology quantification 
 
 
Figure 6.1: Overview on prolate and oblate Spheroids.  
Decision criteria for prolate and oblate cell shape. Imaris V6.0 Reference Manual (Bitplane 2007), (Reprinted with 
permission of Bitplane (Bitplane AG, Zurich; Switzerland)).  
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6.2 Gene expression lists 
Up-regulated probesets in invading/non-invading fibroblasts 
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Table 6.1: Up-regulated probesets in invading/non-invading fibroblasts.  
Gene expression lists for microarrays conducted at 72 and 96 hours of MLg fibroblast invasion. Data are shown for up-
regulated probesets with  > 1.5-fold regulation. Data are sorted by 72 h n.t. (inv/non-inv). Statistical analysis: limma t-
test and Benjamini-Hochberg multiple testing correction.( n.t. = non-treated, BH = Benjamini-Hochberg, FDR = False 
discovery rate, inv. = invading, non-inv. = non-invading).   
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Down-regulated probesets in invading/non-invading fibroblasts 
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Table 6.2: Down-regulated probesets in invading/non-invading fibroblasts.  
Gene expression lists for microarrays conducted at 72 and 96 hours of MLg fibroblast invasion. Data are shown for 
down-regulated probesets with  > 1.5-fold regulation. Data are sorted by 72 h n.t. (inv/non-inv). Statistical analysis: 
limma t-test and Benjamini-Hochberg multiple testing correction.( n.t. = non-treated, BH = Benjamini-Hochberg, FDR = 
False discovery rate, inv. = invading, non-inv. = non-invading). 
 
 
  
 
 
 
APPENDIX 
134 
 
 
Up-regulated probesets in TGFβ1/untreated
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Table 6.3: Up-regulated probesets in invading and non-invading TGFβ1-treated fibroblasts.  
Gene expression lists for microarrays conducted at 96 hours of MLg fibroblast invasion in the presence or absence of 
TGFβ1 (5 ng/ml). Data are shown for up-regulated probesets with  > 1.5-fold regulation. Data are sorted by 96 h inv. 
(TGFβ1/n.t.). Statistical analysis: limma t-test and Benjamini-Hochberg multiple testing correction.( n.t. = non-treated, 
BH = Benjamini-Hochberg, FDR = False discovery rate, inv. = invading, non-inv. = non-invading, T = TGFβ1, C = 
Control). 
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Down-regulated probesets in TGFβ1/untreated 
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Table 6.4: Down-regulated probesets in invading and non-invading TGFβ1-treated fibroblasts.  
Gene expression lists for microarrays conducted at 96 hours of MLg fibroblast invasion in the presence or absence of 
TGFβ1 (5 ng/ml). Data are shown for down-regulated probesets with  > 1.5-fold regulation. Data are sorted by 96 h inv. 
(TGFβ1/n.t.). Statistical analysis: limma t-test and Benjamini-Hochberg multiple testing correction.( n.t. = non-treated, 
BH = Benjamini-Hochberg, FDR = False discovery rate, inv. = invading, non-inv. = non-invading, T = TGFβ1, C = 
Control). 
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